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1. INTRODUCTION 
Polymorphonuclear neutrophils (PMN) represent a large percentage of the 
circulating leukocytes population and are the most abundant type of white 
blood cells in human blood. They are also known as granulocytes since they 
contain numerous granules within the cytoplasm and are characterized by a 
particular morphology of the nucleus, which is segmented into three or five 
lobes joined together by a thin membrane. These cells play a fundamental role 
in immune defense against pathogen organisms and are the first mediators in 
the inflammatory response (Korkmaz, B. et al. 2010). In particular, they 
perform the antimicrobial activity through two main mechanisms: oxidative and 
non-oxidative. The first one consists in the production through NADPH-
oxidase of the phagolysosomes of many reactive oxygen species, which are 
extremely toxic for bacteria. Instead, in the non-oxidative mechanism the 
fusion of cellular phagolysosomes with the primary granules of neutrophils is 
followed by the release of proteases and peptidases in the same 
phagolysosome (Faurschou, M. et al. 2003). Recently, in addition to this type 
of activity, it was discovered a further extracellular defense mechanism 
through the formation of the so-called NETs, or neutrophil extracellular traps. 
The main NETs components are DNA, histones, antibacterial granular 
proteins, and other nuclear and cytoplasmatic proteins, which together play 
an important role not only for their ability to trap bacteria and fungi but also in 
immune response, recruiting a large number of neutrophils in the damaged 
site so increasing the harmful effect on bacteria (Agraz-Cibriana, J. M. et al. 
2017) (Fig. 1).  
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Fig. 1: Neutrophil component involved in the immune response 
 
Coming back to the non-oxidative intracellular mechanism, the PMN granules 
involved in this process can be classified into four different classes according 
to their protein content and the different ability to be released after pro-
inflammatory stimuli by external microorganisms. The granules are divided 
into primary or azurophil, secondary or specific, tertiary or gelatinase and 
secretory (Pham, C. T. 2006) (Fig. 2).  
 
 
Fig. 2: PMN cytoplasmatic granules 
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The azurophil granules contain myeloperoxidase, some bactericidal proteins 
and three serine proteases: Proteinase 3 (PR3), Cathepsin G (CG) and 
Neutrophil Elastase (NE). 
 
1.1 HUMAN NEUTROPHIL SERINE PROTEASES (NSP) 
 
Human Neutrophil Serine Proteases (NSP) are enzymes with high homology 
belonging to the chymotrypsin family. NSP are stored in azurophil granules as 
zymogens associated with proteoglycans, which are activated after 
inflammatory stimuli by the hydrolysis of the N-terminal extremity by the 
enzyme Dipeptidyl Peptidase 1, also known as Cathepsin C.  
The main enzymes belonging to the NSP class, in addition to the Human 
Neutrophil Elastase, which will be discussed in detail in the next paragraph, 
are: 
 Cathepsin G, a protein of 28.5 kDa consisting of 235 amino acids 
residues and belonging to a family of cysteine cathepsins and aspartic 
acid proteases. The gene responsible for encoding this enzyme is 
CTSG, located in the chromosome 14q. Its main function is the 
degradation of the structural components of the extracellular matrix of 
pathogens (Turk, V. et al. 2012).  
 Proteinase 3, an enzyme of 29 kDa consisting of 222 amino acids 
residues and expressed by PRTN3, a gene located in the chromosome 
19. It contributes to the degradation of the chemokine resulting in a 
truncated form with more potent neutrophil chemoattraction activity 
(Van den Sten, P. E. et al. 2000). 
 Neutrophil Serine Protease 4, recently discovered and sharing 30% of 
identity for other proteases. The peculiarity of this enzyme is its ability 
to hydrolyze a particular peptide bond involving an arginine residue 
(Perera, C. N. et al. 2013). 
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1.2 HUMAN NEUTROPHIL ELASTASE (HNE) 
 
HNE is an enzyme belonging to the chymotrypsin super-family and it is stored 
in the azurophil granules of polymorphonuclear neutrophils. It is a globular 
glycoprotein with a molecular weight of 29-33 kDa, consisting of a single 
polypeptide chain of 218 amino acids and two asparagine-linked carbohydrate 
side chains at Asn95 and Asn144 (Lucas, S. D. et al. 2011). It is stabilized by 
four disulfide bridges and it shows basic properties due to the presence of 19 
arginine residues affording a value of the isoelectric point around 10-11. HNE 
is encoded by the ELA2 gene, located in the chromosome 19 and consisting 
of 5 exons and 4 introns; it is synthetized as inactive zymogen of 267 amino 
acids representing the so-called pre-proform (Korkmaz, B. et al. 2008). This 
pre-proform undergoes various consecutive steps that lead to the mature 
enzyme. The signal peptide, consisting of 29 amino acids, is removed to yield 
the proform, which is glycosylated on the amino acids Asn109 and Asn159. 
Subsequently, the cleavage by Cathepsin C of the N-terminal fragment affords 
a structural rearrangement of the N-terminal region, which inserted into the 
protein core, leads to the enzyme catalytically active (Hajjar, E. et al. 2010) 
(Fig. 3). 
 
Fig. 3: Enzyme activation 
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The X-ray crystallographic analysis shows the tridimensional HNE structure, 
that adopts a fold consisting of two β-barrels made each of six anti-parallel β-
sheets, analogously to all chymotrypsin-like serine proteases. There are also 
two α-helix structures and one of this shows a C-terminal extremity (Fig. 4 
yellow cylinders);  it is also possible to identify the two asparagine residues 
(Asn109 and Asn159) corresponding to the two N-glycosylation sites (Fig. 4 
yellow stars). Finally, it is possible to highlight the three amino acid residues 
indispensable for the proteolytic activity and constituting the active site of the 
enzyme (Fig. 4 green stars) (Hajjar, E. et al. 2010).  
 
 
Fig. 4: HNE structure 
 
This last one represents the so-called catalytic triad consisting of Ser195, 
Asp102 and His57 (Fujinaga, M. et al. 1996). The HNE proteolytic activity 
occurs through three fundamental steps: interaction with the substrate, 
acylation of Ser195 and deacetylation. The OH group of the Ser195 is a potent 
nucleophile and activated by the transfer of an electron from the carboxylic 
group of the Asp102 and able to attack a specific carbonyl group of the 
substrate. Once the nucleophilic attack occurred, the generated tetrahedral 
intermediate evolves in the formation of the acyl-enzyme complex through the 
cleavage of the peptide bond. The acyl-enzyme complex is then attacked by 
a water molecule to generate a new tetrahedral intermediate that collapses, 
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assisted by general acid catalysis from His57. This results in the release of 
the substrate as acid (COOH form) and in the regeneration of the enzyme 
(Fig. 5) (Kelly, E. et al. 2008) (Korkmaz, B. et al. 2008). 
 
 
Fig. 5: HNE action mechanism 
 
1.3 HNE PHYSIOLOGICAL ROLE 
 
Analogously to other NSPs, HNE plays an important role in physiological 
condition and it is considered a multifunctional enzyme able to operate in 
pathogens killing, inflammatory processes and maintenance of tissue 
homeostasis (Pham, C. T. 2006). Furthermore, it is implicated in the 
chemotaxis and migration of inflammation mediators by the hydrolysis of 
adhesion molecules (Fig. 6) (Cepinskas, G. et al. 1999) (Hermant, B. et al. 
2003).  
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Fig. 6: HNE physiological role 
 
HNE release occurs through a series of intracytoplasmatic reactions, which 
afford the entry of calcium ions into the granules. This event entails the 
beginning of the degranulation process in which all the contents of the various 
granules are released in the neutrophils. In particular, the increase of the 
intracellular calcium ions concentration allows the interaction of the protein (t)-
SNARE of the membrane with the granules protein (v)-SNARE; this interaction 
leads to their fusion resulting in the release of HNE into the extracellular 
environment. However, although the most part of HNE is released externally, 
a certain percentage remains bound to the plasma membrane surface so 
increasing the catalytic activity and resistance to inactivation by endogenous 
inhibitors (Lee, W. L. et al. 2001). 
 
1.3.1 Antimicrobial activity 
This function can be performed by HNE both intracellularly and extracellularly. 
As regard HNE intracellular antimicrobial activity, it is synergic with the oxygen 
reactive species, ROS, and takes place after the pathogen phagocytosis by 
azurophil granules. In particular, the fusion of the plasma membrane with the 
phagosome membrane triggers the reduction of molecular oxygen to 
superoxide anion by the enzyme NADPH-oxidase. This phenomenon leads to 
the formation of a gradient inducing the entry of H+ and K+ ions, which mediate 
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the NSPs release from their matrix. Additionally, intraphagous 
myeloperoxidase (MPO) allows the oxidation of the Cl- to ClO-, a potent 
antimicrobial agent (Fig. 7) (Pham, C. T. 2006) (Nauseef, W. M. 2007). These 
phenomena, together with HNE proteolytic activity, produce a synergistic 
effect for the pathogen kill.  
 
 
Fig. 7: Intracellular antimicrobial activity 
 
Instead, the extracellular antimicrobial activity can be both indirect and direct. 
In the first case, HNE produces antimicrobial proteins by hydrolysis of serum 
proteins, as well as breaking the bacterial virulence factors (Weinrauch, Y. et 
al. 2002). About the direct action, HNE is able to trap and destroy pathogens 
through the formation of the neutrophil extracellular traps (NETs). These 
particular structures are mainly composed by chromatin and cationic 
proteases that are released into the extracellular environment after the 
activation of the neutrophils by specific stimuli such as bacterial endotoxins or 
other pathogenic factors. Following activation, ROS accumulation generates 
a cellular response that destroys the structural components of the ECM, 
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resulting in cell flattening that allows the translocation of NSPs in the nucleus 
with subsequent proteolytic action against histones which leads to the DNA 
decondensation (Fig. 8) (Briukmann, V. et al. 2004).  
 
 
Fig. 8: NETs formation 
 
1.3.2 Anti-inflammatory activity 
In addition to its bactericidal properties, HNE is also an important regulator of 
the local inflammatory response. The role that HNE plays in the inflammatory 
processes is very complex and still not entirely clear. It plays a double role 
that leads to modulate the chemokine action. Chemokines are a family of 
small peptides involved in the recruitment of leukocytes to the inflammatory 
sites; they are released by various inflammatory cells and they bind to their 
receptors on the leukocyte surface (Pham, C. T. 2006). Removal of peptide 
fragments by NSPs of certain chemokines produces an increase in the 
receptor affinity. In particular, the hydrolysis of the N-terminal portion of 
Interleukin-8 (IL-8) by HNE leads to a species with higher chemotactic activity 
(Padrines, M. et al. 1994). Likewise, the hydrolysis of the C-terminal portion 
by HNE allows a greater recall of macrophages and dendritic cells (APC cells), 
which possess receptors similar to this peptide (Wittamer, V. et al. 2005). In 
contrast, not all modifications of these proteins by HNE lead to an increase in 
their anti-inflammatory activity. For example, the hydrolysis by HNE of 
CXCL12 and CCl3 proteins, also known as SDF1α and MEP1α respectively, 
leads to a loss of their chemotactic activity (Ryu, O. H. et al. 2005) (Rao, R. 
M. et al. 2004).  
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Recent studies highlight a correlation between HNE and Tumor Necrosis 
Factor alpha (TNFα), even if the nature of this correlation is still unclear. Some 
studies affirm that there is a loss of activity after the interaction between the 
enzyme and TNFα; others show that there is the formation of biologically 
active small soluble peptides (Kormaz, B. et al. 2010). A further physiological 
role in the inflammatory processes is related to the interaction with the Tool-
Like Receptor 4 (TLR-4), a transmembrane glycoprotein that contributes to 
the defense against pathogens and participates in the innate immune 
response (Walsh, D. E. et al. 2001).  
 
1.3.3 HNE and tissue homeostasis  
HNE is able to maintain tissue homeostasis in our body since it repairs 
damaged tissues as well as it degrades the structural proteins (Bieth, J. G. 
1986). On the Extracellular Matrix (ECM), HNE performs a proteolytic action 
degrading elastin, collagen, fibronectin, laminin and proteoglycans (Barret, A. 
J. et al. 1986). Finally, HNE is able to activate the complement cascade in 
plasma, as well as it degrades some coagulation factors and it interacts with 
the immunoglobulins IgG, IgA and IgM (Havemann, K. et al. 1978).   
 
1.4 HNE ENDOGENOUS INHIBITORS 
 
The proteolytic activity of serine proteases, essential for the maintenance of 
important functions in our organism, can be dangerous if not properly 
maintained under control (Von Nussbaum, F. et al. 2016). The first 
fundamental regulatory mechanism is the inactivation of these enzymes 
through the storage into specialized compartments, such as azurophil 
granules for serine proteases. However, only this mechanism is insufficient to 
regulate their proteolytic activity, so the presence of endogenous inhibitors 
that completely inhibit the activity of proteases (Von Nussbaum, F. et al. 
2015a) is of great importance. These inhibitors can be grouped into three main 
classes: serpins (serine protease inhibitors) (Ekeowa, U. I. et al. 2009), TIMPS 
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(tissue proteins of metalloproteases) (Gipson, T. S. et al. 1999) and cystatin 
(cysteine protease inhibitors) (Turk, V. et al. 2008). In particular, HNE activity 
is mainly regulated by α1-antitrypsin (AAT) (also known as α1-proteinase 
inhibitor, α1-PI), monocyte and neutrophil elastase inhibitor (MNEI) (also 
called Serpine B1), belonging to the family of canonical inhibitors including 
also the leukoprotease secretion inhibitor, SLPI and elafin, and finally α2-
macroglobulin. Several studies demonstrated that these inhibitors, in 
addition to the regulation of the inflammatory processes by controlling the 
proteolytic activity of enzymes, could directly affect other processes such as 
leukocyte chemotaxis and release of pro-inflammatory mediators, contributing 
to defending the organism against pathogens attack (Groutas, W. C. et al. 
2011). 
 
α1-Antitrypsin is a water-soluble glycoprotein with a molecular weight of 53 
kDa, mainly produced by the liver, but in small quantities also by monocytes, 
macrophages, pulmonary alveolar cells and intestinal and corneal epithelium. 
It is released into the bloodstream, where it has a concentration of 0.9-1.75 
g/L, and through this reaches the lungs. At the level of the lower airway, it 
regulates not only the activity of HNE, the main substrate of this inhibitor, but 
it is also active against other targets such as PR3 (Janciauskiene, S. M. et al. 
2011). It has a three-dimensional structure consisting of three β sheets and a 
reactive mobile central ring (RCL) in which there is a particular amino acid 
sequence that acts as a binding site for target proteases (Lomas, D. A. et al. 
2004). Its blood concentration increases considerably in response to 
inflammatory stimuli or infections, allowing to maintain the correct proteolytic 
activity of elastase (Janciauskiene, S. M. et al. 2011). A deficiency of α1-PI 
can significantly increase the risk of COPD (Chronic Obstructive Pulmonary 
Disease) in the lower airway and may cause liver disease, including cirrhosis 
and hepatocellular carcinoma (Heutinck, K. M. et al. 2010) (Fig. 9). 
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Fig. 9: Physiological and pathological roles of α1-PI 
 
MNEI, or Serpin B1, contained within the neutrophil granules, acts not only 
on elastase, but also on PR3 and CG, performing a similar function, as above 
reported. In particular, it is involved in the regulation of lung inflammatory 
processes, such as cystic fibrosis and chronic pathologies due to excessive 
protease activity of neutrophils (Benarafa, C. et al. 2002). 
 
SLPI, or inhibitor of leukoprotease secretion, is another important serine 
protease inhibitor, which, unlike MNEI, does not inhibit PR3 activity 
(Thompson, R. C. et al. 1986). It belongs to the family of chelonianin and it is 
present in all body fluids, including tears, saliva, seminal fluid, bronchial 
secretions and intestinal mucus. It is a non-glycosylated protein with a 
molecular weight of 11.7 kDa and with strong basic characteristics (pI = 11) 
(Quabius, E. S. et al. 2015). It is produced in the lungs by epithelial tracheal 
and bronchial cells and by the alveolar cells of type II (Sallenave, J. M. 2002) 
and its concentration is superior in the higher airways with respect to the 
deepest ones. Although its role is not yet fully understood, it has recently been 
shown to have an important function in the regulation of the immune response 
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and in the control of inflammatory and septic shock processes (Zhong, Q. Q. 
et al. 2017). 
 
Elafin, or elastase specific inhibitor (ESI), is a non-glycosylated protein of 6 
kDa, originally isolated from the skin of patients with psoriasis but also present 
in pulmonary secretions (Wiedow, O. et al. 1990). Unlike α1-PI, classified as 
a "systemic" inhibitor because it is synthesized in the liver and then spilled into 
the bloodstream, elafin and SLPI too are called "alarm" inhibitors because 
they are directly produced and released into the epithelium of the airways in 
response to the release of cytokines such as interleukin IL-1β and the tumor 
necrosis factor (TNFα), together with the HNE (Zhong, Q. Q. et al. 2017) 
(Pfundt, R. et al. 2000). As SLPI, elafin has tracheo-bronchial origins and it is 
synthesized by pneumocytes of type II (Sallenave, J. M. 2000). It is a basic 
protein (pI = 9.7), stable at acid medium and its amino acid sequence as well 
as its active site share 40% of identity for SLPI (Wiedow, O. et al. 1990). It is 
a powerful inhibitor of HNE and PR3, while it has no activity against CG (Zani, 
M. Z. et al. 2004). It shows similar functions to SLPI because it performs anti-
inflammatory, immunomodulatory and antibacterial activities. This last one is 
due to its positive charge, which causes destabilization of the pathogen 
membrane (Scott, A. et al. 2011). Consequently, an altered expression of this 
protein seems to be crucial for the development of inflammatory airways 
disease, but also skin diseases such as psoriasis (Wiedow, O. et al. 1990). 
 
Finally, α2-macroglobulin is a polyvalent homotetramer protein with a 
molecular weight of 725 kDa present in high concentration in human blood 
(2mg/L) (Petersen, C. M. 1993). It inhibits plasma serine, cysteine and metal 
proteases (Janciauskiene, S. M. et al., 2011) through a mechanism of action 
completely different from those previously described for other inhibitors. In fact 
it traps the enzyme, causing loss of its proteolytic activity only towards the 
macromolecules but not for small peptides, which can be hydrolyzed in the 
catalytic site (Travis, J. et al. 1983). In addition, due to its high molecular 
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weight, α2-macroglobulin is not able to spread outwardly to the endothelium, 
so it has been hypothesized that its main role is to control the proteases 
activity only at the level of the blood circulation (Sottrup-Jensen, L. 1989). 
 
All the enzymes above reported may lose their activity due to oxidative agents 
or to the same proteases. Primarily, HNE is able to hydrolyze some of these 
inhibitors, such as elafin. Moreover, other proteases, such as MMPs (Taggart, 
C. C. et al. 2001) or cytyl cathepsin (Geraghty, P. et al. 2007), are able to 
inactivate endogenous inhibitors. In other cases, it may also occur that the 
adhesion of the neutrophils to the extracellular matrix relegates proteases, 
released from the granules, into the periplasmic space. So that endogenous 
inhibitors are no longer able to reach and hydrolyze the enzymes that continue 
to carry out its proteolytic activity (Pham, C. T. 2006). 
 
1.5 PATHOLOGIES RELATED TO HNE 
 
Neutrophils represent the first indispensable line of defense during the 
inflammatory processes. However, as described in the previous paragraph, 
HNE activity needs to be strictly controlled, as its imbalance can contribute to 
the development of very serious diseases with a very negative impact on 
tissue integrity (Heutinck, K. M. et al. 2010). The involvement of HNE and 
other NSPs in the development of chronic pulmonary inflammatory diseases 
is widely documented and correlated with an imbalance between HNE and 
endogenous inhibitor activity, which causes  an increase of the proteolytic 
activity and an infiltration of neutrophils following a massive inflammatory 
response (Korkmaz, B. et al. 2010) (Fig. 10). 
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Fig. 10: HNE-anti-proteases balance 
 
There are numerous chronic inflammatory pathologies affecting the 
respiratory system caused by this type of imbalance: chronic obstructive 
pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress 
syndrome (ARDS) and cystic fibrosis (CF) (Korkmaz, B. et al. 2010). 
 
COPD, or chronic obstructive pulmonary disease, is a pathology characterized 
by chronic bronchitis and emphysema, responsible for the alteration of normal 
respiratory activity, since they are characterized by a limited inflow of air into 
the pulmonary tree (Barnes, P. J. et al. 2005). The World Health Organization 
(WHO) estimates that 210 million people are affected by COPD and in 2020 
it will become the fourth leading cause of death. The primary cause of COPD 
is tobacco smoke but other risk factors include indoor and outdoor air 
pollution, occupational dusts, and chemicals or frequent lower respiratory 
infections during childhood, as well as genetic α1-PI deficiency (Lucas, S. D. 
et al. 2011). The α1-PI absence affects about 2% of cases and it is due to a 
genetic mutation that makes the individual not able to synthetize a sufficient 
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amount of α1-PI, resulting in an uncontrolled HNE proteolytic activity in the 
pulmonary tissue and thus increasing the risk of premature pulmonary 
emphysema (Wewers, M. D. et al. 1987). As regards the tobacco smoke, an 
epidemiologic study conducted on smokers affected by COPD found an 
enlargement of the air space caused by the breakdown of the alveolar cells in 
10% of patients (American Thoracic Society, 2003). Tobacco smoke activates 
macrophages of the airways, which in turn stimulate the release of 
chemotactic factors such as IL-8 and leukotriene B4, inducing pulmonary 
neutrophil accumulation and subsequent secretion of their proteases, HNE 
and MMPs (Barnes, P. J. et al. 2005). Therefore, there is a strong imbalance 
between proteases and anti-proteases, followed by an increase of the release 
of TNF-α and other pro-inflammatory mediators that cause the destruction of 
pulmonary parenchyma and extracellular matrix (Houghton, A. M. et al. 2006). 
All these factors cause an epithelial damage, increased microvascular 
permeability, mucus hypersecretion and mucosal dysfunction (Hoenderdos, 
K. et al. 2013) (Fig. 11). 
 
 
Fig. 11: Neutrophils role in healthy conditions and in COPD disease 
 
However, the available COPD therapeutics are limited to a few classes of 
agents such as glucocorticosteroids, bronchodilators, anticholinergics, 
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phosphodiesterase inhibitors and supplemental oxygen. These therapeutics 
only help to control its symptoms and increase quality of life for the patients, 
as no currently available treatment reduces the progression of COPD or 
suppresses the inflammation in small airways and lung parenchyma (Matera, 
M. G. et al. 2012).  
 
ARDS, acute respiratory distress syndrome, and ALI, acute lung injury, are 
two pulmonary inflammatory pathologies caused by trauma and sepsis 
(Tsushima, K. et al. 2009). ARDS and ALI are characterized by an increase in 
hypoxemia and alveolar-capillary permeability, whose severity, greater in 
ARDS, is the main element distinguishing these two pathologies (Korkmaz, B. 
et al., 2010). 
 ARDS is characterized by the inflammation of the lung parenchyma, 
which causes an alteration of normal gaseous exchanges with 
concomitant release of pro-inflammatory mediators. Various studies 
showed that this pathology is caused by a strong increase in oxidative 
stress levels, but especially by an alteration in the balance between 
proteases and anti-proteases, in particular a down regulation of 
synthesis of elafin, a specific and potent HNE inhibitor (Wang, Z. et al. 
2009). 
 ALI is a pathology caused by a variety of factors including Gram-
negative bacterial infection and it is characterized by interstitial and 
alveolar edema, associated with an increase in neutrophil infiltration at 
this level. Also in this case, the overproduction of HNE in the plasma 
and the absence of a sufficient amount of inhibitors is the main cause 
of this disorder (Kawabata, K. et al. 2002). 
Generally, during the initial phase of both pathologies, neutrophils are 
massively accumulated in vascular tissue and they are responsible for 
microvascular damage, which in turn results in epithelial damage, increased 
capillary permeability, and interstitial edema. After the formation of the edema, 
HNE also generates powerful chemiotactic peptides, which increase 
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inflammatory response in the lungs and favor mucus production (Leavell, K. 
J. et al. 1996). 
 
Cystic fibrosis (CF) is an inherited condition with an incidence rate of 
approximately 1 in 2500 new born babies (Tizzano, E. F. et al. 1992); it is 
prevalent in Europe and in the United States and it is the most common fatal 
genetic disease in Caucasian populations till now (Wagner, C. J. et al. 2016). 
CF is an autosomal recessive genetic disorder caused by loss of expression 
or functional mutations of the cystic fibrosis transmembrane conductance 
regulator (CFTR), which encodes for an ionic channel involved in the flow of 
chloride and sodium ions across epithelial membranes leading to increased 
and dehydrated mucus secretions in the lungs. Consequently, a mutation of 
this gene has significant abnormalities in the function of the exocrine glands, 
resulting in alteration of ionic composition and increased viscosity of epithelial 
secretions. In particular, mucus becomes dense and sticky, preventing the 
proper passage of air through the respiratory airways (Buchanan, P. J. et al. 
2009). The sweat glands and salivary glands, the small intestine glands, the 
pancreatic glands and the bile ducts, the mammary glands and the deferent 
duct  can be also affected by this pathology (Voynow, J. A. et al. 2008) (Fig. 
12). 
 
 
Fig. 12: Organs affected by CF 
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The alteration of the normal characteristics of the respiratory airways surface 
results in an increase in susceptibility to the attack of bacterial agents and the 
activation of a vigorous inflammatory response as a result of increased mucus 
production which, in healthy individuals, is released during an infection 
(Nichols, D. P. et al. 2015). However, in patients affected by cystic fibrosis the 
fundamental problem lies in the high concentration of lung neutrophils, which 
rises up to 70% compared with 1% in healthy individuals (Buchanan, P. J. et 
al 2009). Neutrophil are recruited to these sites of infection by increased 
expression of chemoattractants such as IL-8 by lung epithelial tissue. The 
increase of IL-8 promotes a further increase in HNE levels released by the 
same neutrophils, thereby creating a state of chronic infection (Devaney, J. 
M. et al. 2003). The damage can result in the destruction of the cellular 
epithelium, in the alteration of the ciliary beat and increased mucus secretion, 
affording decreased mucus clearance, alteration of the characteristics of the 
same mucosal secretion and particularly dangerous, the failure to protect the 
organism against the action of pathogens (Nichols, D. P. et al. 2015) (Fig. 13). 
 
 
Fig. 13: Neutrophils role in Cystic Fibrosis 
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In addition to all these pathologies, it has been observed that HNE is also 
involved in the development and progression of breast and lung cancer. In 
fact, it was demonstrated that many types of cancer originate from bodily 
districts affected by chronic inflammatory conditions (Coussens, L. M. et al. 
2002) and that PMN neutrophils and their proteases are greatly involved in 
the progression of the diseases (Demaria, S. et al. 2010). It has been 
observed that tumor cells form metastases through a series of consecutive 
events that recall those whereby neutrophils act at the level of inflammation 
sites or fight an infection (Sato, T. et al. 2006).  The tumor cells are also able 
to release proteases to favor their invasion process in host tissues, because 
they need to overcome a variety of elastin, collagen and proteoglycan tissue 
barriers (Lu, P. et al. 2012). In addition, it was also demonstrated that the 
deterioration of elastic fibers caused by HNE could favor the diffusion of other 
cancer cells or the generation of elastin fragments with cytokine-like 
properties, such as elastokines (Antonicelli, F. et al. 2007). These last ones 
favor the tumor progression in different ways:  
o they increase the phlogistic phenomenon and therefore the 
chemotactic activity of monocytes and neutrophils; 
o they increase the expression of some MMPs in fibroblasts; 
o they act as potent angiogenic agents and stimulate the production of 
IL-8 by endothelial cells; 
o they amplify the expression of tumor cell growth factors (Hornebeck, 
W. et al. 2005). 
Among the other pathologies not related to the respiratory system where HNE 
seems to be involved, we can mention rheumatoid arthritis (Capsoni, F. et al. 
2005), dermatitis and psoriasis (Wetzel, A. et al. 2006) and atherosclerosis 
(Henriksen, P. A. et al. 2008).  
 
Rheumatoid arthritis is characterized by the articular infiltration of 
neutrophils and monocytes, which contribute to the degradation of cartilage 
tissue by the production of reactive oxygen species (Capsoni, F. et al. 2005) 
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and enzymes with proteolytic activity. In particular, HNE is able to destroy 
important proteins constitutive of cartilage tissue, such as type II collagen and 
proteoglycans (Wiedow, O. et al. 1992). 
 
Psoriasis and some types of dermatitis, such as contact dermatitis and 
atopic dermatitis, are skin infections caused by a defect in skin cohesion, 
resulting in formation of micro-abscesses, papules and erythematous plaques 
(Dhanrajani, P. J. 2009). The loss of contact of keratinocytes seems to be due 
to the lysis of the adhesion proteins normally forming the desmosome 
junctions, suggesting a possible role of HNE in this pathology (Brown, R. S. 
et al. 1993) (Wiedow, O. et al. 1992). 
 
Finally, atherosclerosis is a chronic inflammatory disease of the arteries 
characterized by the progressive formation of atherosclerotic plaques, which 
can cause obstruction of the vessels due to their breakup or detachment and 
their transport to the plasma (Garcia-Touchard, A. et al. 2005). This 
multifactorial inflammatory process results in cerebral and cardiovascular 
complications associated with an increase in the morbidity and mortality and 
its major clinical manifestations are acute heart attack, stroke and peripheral 
artery damage (Hartwig, H. et al. 2015). Several studies confirmed that HNE 
is involved in plaque formation (Dollery, C. M. et al. 2003) since endothelial 
cells, after activation, synthesize adhesion molecules and chemotactic factors 
of neutrophils such as cytokines and IL- 8 (Naruko, T. et al. 2002) (Fig. 14). 
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Fig. 14: Atherosclerosis and HNE 
 
1.6 HNE INHIBITORS 
 
In the last three decades, many stakeholders in academia and the 
pharmaceutical company have discovered a variety of innovative elastase 
inhibitors. We will briefly summarize this evolution of HNE inhibitors along five 
generations: 1st generation, 2nd generation, 3rd and 4th generation, 5th 
generation (Von Nussbaum, F. et al. 2015a).  
 
1.6.1 1st generation 
 
Peptide inhibitors 
Peptide inhibitors are high molecular weight proteins, consisting of a variable 
number of amino acid residues (350-500) and they are able to work as highly 
specific suicidal substrates against HNE. An important class of the peptide 
inhibitors is represented by the serpins, endogenous HNE inhibitors already 
described, which can be obtained either by purification of natural compounds 
or by genetic engineering techniques. However, despite being characterized 
by a highly specific activity, these types of inhibitors have two major 
disadvantages. The first one concerns the route of administration, since they 
can be administered only intravenously or by inhalation. The second one is 
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due to low stability, which increases in particular pathophysiological conditions 
or oxidative stress. Pathogenic agents and/or microbial proteases may 
partially degrade these inhibitors and thus block their function (Sallenave, J. 
M. 2010) (Guyot, N. et al. 2008), or the inhibitor may be inactivated due to the 
oxidation of its methionine residues (Nobar, S. M. et al. 2005). 
 
1.6.2 2nd generation 
 
In contrast to the first generation, these small molecules (SMOLs) are also 
able to reach and inhibit membrane-bound elastase. Of further importance, 
such inhibitors might be able to enter neutrophils cells and thereby interfere 
with the host defense function of elastase (Von Nussbaum, F. et al. 2015a). 
Compounds belonging to the 2nd generation can function as acyl-enzymes or 
the transition state analogues.  
 
Acyl-enzyme inhibitors 
The acylating inhibitors afford a tetrahedral transition state analog, which 
collapses with the displacement of a leaving group to afford a very stable acyl-
enzyme complex that can also irreversibly inactivate the enzyme (Fig. 15). 
The main concern related to acyl-enzyme inhibitors is its hydrolysis to 
regenerate the free enzyme and this phenomenon depends upon the acylating 
power of the inhibitor. This ability is evaluated by its acylating and deacylating 
power rates, Kon and koff, respectively, and the main goal has been to develop 
acylating agents which generate a stable acyl-enzymes complex (Lucas, S. 
D. et al. 2011).  
 
 
Fig. 15: Interaction acyl-enzyme inhibitors-HNE 
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N-benzoyl pyrazoles, identified by Prof. Quinn's group using high-throughput 
chemolibrary screening, represent a series of potent and specific HNE 
inhibitors and the most active terms show a Ki in the nanomolar range (Fig. 
16).  
 
 
 
 
 
 
 
 
 
 
 
Fig: 16: N-benzoyl pyrazoles 
 
They act as pseudo-irreversible HNE inhibitors and molecular modeling 
studies showed how the active derivatives effectively bind to the active site of 
HNE by blocking the enzyme (Schepetkin, I. A. et al. 2007). For this purpose, 
the substituted phenyl ring proved to be fundamental, but the ortho 
substitution is not favorable for the activity, since it prevents the free rotation 
of the phenyl rings locking the molecule in a position not suited for the 
interaction with the active site. (Khlebnikov, A. I. et al. 2008). 
 
In 1982 Teshima et al. reported a series of 4H-3,1-benzoxazin-4-ones as 
serine protease inhibitors with a low selectivity for HNE. Ser195 attacks the 
carbonyl of the benzoxazinone leading to the ring opening to form a stable 
acyl-enzyme complex (Radhakrishnan, R. et al. 1987) (Fig. 17). 
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Fig. 17: benzoxazinones mechanism of action 
 
Further studies were carried out to improve the inhibitory activity and 
selectivity of these compounds, till 2009 a class of 2-pyridine-benzoxazinone 
derivative having an IC50 = 61 nM (Fig. 18, compound D) was discovered 
(Shreder, K. R. et al. 2009). Structure activity relationship studies indicate that 
pyridine-3-yl at position 2 of benzoxazinone is preferred over a phenyl ring. 
Electron-donating groups at 7-position improves the chemical stability of 
benzoxazinones and the disubstitution at 5- and 7-position is particularly 
favorable for HNE inhibitory activity. Among the 5,7-disubstituted 
benzoxazinones examined, the 5-ethyl-7-methoxy derivatives, bearing a 
piperazine or a piperidine at pyridine ring (Fig. 18, compounds E and F), were 
found to have the best balance of chemical stability and potency (Lucas, S. D. 
et al. 2011).  
 
 
 
 
 
 
 
Fig. 18: 2-Pyridin benzoxazinone derivatives 
 
β-lactam derivatives represent another important class of inhibitors. The first 
report of β-lactam-based HNE inhibitors by Merck back in 1986 led to major 
efforts to obtain β-lactams as promising candidates for further development 
as HNE inhibitors. Various modifications were performed on the β-lactam 
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nucleus and recently the group of Prof. Moreira came to the synthesis of 4-
oxo-β-lactams, which are potent and selective HNE inhibitors. Some docking 
studies have also shown that the presence of two ethyl groups on C3 of the 
β-lactam allows a good anchoring of the molecule into the hydrophobic pocket 
S1. It is due to the correct orientation of Ser195 oxygen atom versus at least 
one of the carbon atoms of the carbonyl groups of the β-lactam ring 
(Mulchande, J. et al. 2010). An example is compound G (kon= 3.24 x 106 M-1 
s-1). 
 
 
 
 
 
 
Transition state analogues 
Compounds acting as transition-state analogues are attacked by Ser195, 
forming a stable tetrahedron intermediate which inhibits irreversibly HNE. The 
bond is also stabilized by the formation of hydrogen bridges between the 
functional groups of the molecule and NH groups of the amino acid residues 
present in the active site.  The older inhibitors of this type were molecules 
showing a formyl group. However, due to pharmacokinetic problems, the 
research was subsequently focused on the replacement of aldehyde hydrogen 
atom with electron-withdrawing groups to improve the stability and the 
electrophilicity of the carbonyl carbon atom (Lucas, S. D. et al. 2011). 
 
The first inhibitors of this class working with this mechanism of action were 
peptidyl trifluoromethyl ketone derivatives (TFMKs). These molecules, 
synthesized by AstraZeneca, initially appeared as promising compounds for 
the treatment of respiratory diseases. One of interesting compound was ICI 
200,880 which showed a good inhibitory potency (Ki = 0.2 nM), but a high 
metabolic instability due to the peptide backbone (Edwards, P. D. et al. 1996).  
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Another potent compound, identified during the course of a screening program 
carried out by Ono Pharmaceutical to find orally active inhibitors is ONO-6818. 
This compound is a potent HNE inhibitor (ki = 12.6 nM) and exhibit a potent 
oral activity (ED50 = 1.4 mg/kg). For all these reasons, it was selected as a 
promising therapeutic agent for the treatment of HNE-related chronic 
inflammatory diseases, such as COPD, ALI and ARDS. It reached Phase II 
clinical trials in 2002, however, the development was discontinued when data 
from Japanese Phase IIa study in COPD patients revealed an abnormal 
elevation in liver functions related to the treatment (Ohbayashi, H. 2005). 
 
 
 
 
 
 
 
 
1.6.3 3rd and 4th generation 
 
Compounds with pyridone and dihydropyrimidone scaffold are the most 
representative terms of non-reactive, reversible inhibitors belonging to the 3rd 
and 4th generation of neutrophil elastase inhibitors. An unique binding mode 
in the active center of the enzyme (S1 pocket) triggers a conformational 
change in the protease creating a de novo formed deep S2 pocket enabling 
further unprecedented target interaction (Hansen, G. et al. 2011). This 
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interaction does not followed the linear topology of the substrate binding cleft 
as it is the case with 1st and 2nd generation inhibitors. On the contrary, the 
orientation of 3rd and 4th generation inhibitors is almost perpendicular to the 
natural substrate-binding cleft. Whereas 3rd generation inhibitors, binding S1 
pocket are able only to create the de novo S2 pocket, while 4th generation 
inhibitors are also able to bind the new deepened S2 pocket  (Fig. 19 e 20) 
(Von Nussbaum, F. et al. 2015a). 
 
 
Fig. 19: HNE-3rd generation inhibitor complex 
 
 
Fig. 20: HNE-4th generation inhibitor complex 
 
The drug-like properties of these compounds are very interesting and the two 
most significant candidates are Alvelestat (AZD9668) and BAY-678. 
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Both clinical candidates, Alvelestat and BAY-678 contain an identical S1 
binding motif, m-(trifluoromethyl)-phenyl group. X-ray studies of the complex 
HNE-inhibitor have surprisingly revealed that S1 binding motif in conjunction 
with the central pyridone scaffold widens the remote S2 pocket significantly.  
These modern inhibitors have displayed an outstanding selectivity versus 
similar serine proteases and a very high target specificity with no significant 
interactions with other pharmaceutically relevant targets, in contrast to the 2nd 
generation inhibitors.  
AZD9668 and BAY-678 have revealed significant efficacy in pre-clinical 
models of ALI and lung emphysema, demonstrating their anti-inflammatory 
and anti-remodeling activity. Additionally, BAY-678 has shown significant 
beneficial pulmonary hemodynamic and vascular effects in models of PAH 
(Pulmonary Arterial Hypertension) in rats and mice. The safety and efficacy of 
both compounds have been initially assessed in clinical Phase I trials with 
healthy volunteers and with COPD patients (Stevens, T. et al. 2011) 
(Gunawardena, K. et al. 2010); all these trials have confirmed a very good 
safety and tolerability of these two 3rd and 4th generation elastase inhibitors. 
But at the moment only AZD9668 is in Phase II of clinical trials for the 
treatment of cystic fibrosis and bronchiectasis; for these pathologies it has 
proved to be particularly effective as it results in an increase in lung function 
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and a reduction in inflammatory biomarkers in the expectorate (Stockley, R. 
et al. 2013). 
 
1.6.4 5th generation 
 
The 5th generation of neutrophil elastase inhibitors are structurally closely 
related to that of 4th generation. However, in this case, an additional 
substituent results in an unprecedented improvement in potency though it 
does not directly interact with the target. In fact, the additional substituent 
raises the rotational barrier at the crucial pyrimidone-cyanophenyl axis and 
thereby freezes the structure in an ideal bioactive conformation thus pre-
organizing the inhibitor for the forthcoming binding event. Among these 
compounds are significant BAY 85-8501, BAY-8040 produced by Bayer and 
a derivative developed by Chiesi Farmaceutici with triazole-pyrimidone (H) 
scaffold. 
 
 
 
BAY 85-8501 displays an extraordinary potency (ki = 0.08 nM) comparable to 
the endogenous anti-proteases and remarkably two orders of magnitude 
higher when compared with corresponding 4th generation inhibitors. It also has 
high selectivity, excellent metabolic stability which results in low clearance and 
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increased half-life without going to inhibit CYP isoforms. In the preclinical 
phase, this compound confirmed anti-inflammatory effect, when tested in 
emphysema and ALIanimal model. In all studies, this compound proved to be 
safe and well tolerated without evidence of acute side effects; currently the 
compound is in Phase II clinical trials (Von Nussbaum, F. et al. 2015b). 
Compound BAY-8040, with pyrimido-pyridazinic structure is a promising 
inhibitor with IC50 = 28 nM (Von Nussbaum, F. et al. 2016). The X-ray structure 
of the compound complexed with the protease showed a unique but highly 
stable hydrogen bond between carbonyl group of the pyrimidone and the 
amino-group of Val216 (Fig. 21). 
 
 
Fig. 21: HNE-BAY-8040 complex 
 
Finally, another promising compound of this class is compound H, developed 
by Chiesi Farmaceutici, which exhibits an IC50 < 20 nM. The interest of this 
compound is due not only to the potency, but also to its possible administration 
via aerosol, therefore dismissing the side effects of the systemic route 
(Armani, E. et al. 2015).  
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1.7 PROLASTIN® AND SIVELESTAT® 
 
Despite the large number of molecules previously described, at present only 
two drugs are commercially available for clinical use.  
 
Prolastin® (purified α1-PI) is a peptide drug, analog to the natural α1-PI, 
which can be obtained by recombinant DNA techniques or it can be isolated 
from human serum by various methods of purification (Tebbutt, S. J. 2000). It 
is currently used for the treatment of α1-PI deficiency, a genetic disorder 
characterized by a low level of HNE endogenous inhibitor in the blood that 
may cause the development of a severe form of emphysema (Kohnlein, T. et 
al. 2008) (Fregonese, L. et al. 2008). This drug represents the most direct 
therapeutic approach for the α1-PI deficiency and it is administered by venous 
infusion in order to maintain plasma levels above 11 μM, the minimal 
concentration needed to protect the respiratory system from excessive HNE 
activities (American Thoracic Society, 2003). To maintain these levels, the 
drug should be administered weekly, with doses ranging from 60 to 120 
mg/kg. After a few days of discontinuation of treatment, HNE activity again 
occurs on the surface of the respiratory epithelium (Wewers, M. D. et al. 1987). 
Some non-randomized observation studies also showed a slower decline in 
pulmonary function in subjects receiving Prolastin® compared to the patients 
who did not receive enhancement therapy. At present, the formulation of 
Prolastin for aerosol is undergoing clinical testing; it will be significantly more 
beneficial than the endovenous administration, as it would dramatically reduce 
the dosage and drive the drug directly to the site of action (Griese, M. et al. 
2008). In 2003, the FDA also approved two new α1-PI intravenous 
formulations, Aralast (Baxter) and Zemaira (CSL Boehring), but they were 
introduced in therapy only in the USA. Additionally, in May 2007, the FDA 
announced the validation of Aralast NP® (Baxter Heathcare), with features 
similar to Aralast (Stoller, J. K. et al., 2002) (Alpha Therapeutic Corp. 2003). 
Some modifications to the drug production process also allowed Prolastin®-
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C that have a higher purity compared to simple Prolastin (Stocks, J. M. et al. 
2010). 
 
Sivelestat by Ono Pharma (ONO-5046) is the second drug, approved in 2002, 
but only in Japan and Korea. In the same year, Eli Lilly started a clinical study 
of the same drug for the western market but the FDA stopped the project due 
to unsatisfactory results originating from the clinical trials (Bayer Healthcare, 
2004). It is a selective HNE non-peptide and low molecular weight inhibitor 
(M.W. 528.51). 
 
 
 
 
 
 
 
 
 
Sivelestat works as an acyl-enzyme inhibitor and it shows an IC50 = 44 nM 
(Ohbayashi, H. 2005). Using electrospray ionization mass spectrometry, it 
was possible to identify the enzyme-inhibitor complex after 10 minutes of 
incubation with the enzyme, so its inhibition mechanism as reported in Fig. 22. 
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Fig. 22: Mechanism of action of Sivelestat 
 
It is commercialized as an injectable formulation, Elaspol® 100, for the 
treatment of the respiratory diseases ARDS and ALI, associated with systemic 
inflammatory response syndrome (SIRS) (Fujii, M. et al. 2010). However, its 
clinical efficacy is still not entirely clear: some studies have shown that 
Sivelestat can reduce mechanical ventilation, shorten stay in intensive care, 
and prolong survival of the patient, while others have failed in the same 
direction (Tamakuma, S. et al. 2004) (Aikawa, N. et al. 2011). However, this 
discrepancy in results may also be due to the different characteristics of 
patients treated with the drug, such as age, baseline respiratory condition and 
compromised non-pulmonary tissue (Zeiher, B. G. et al. 2004) (Tamakuma, 
S. et al. 2004). Sivelestat is also able to mitigate the cardiopulmonary bypass 
inflammatory response in pediatric surgery. Cardiopulmonary bypass (CPB) 
causes the activation of a systemic inflammatory response resulting in release 
of pro-inflammatory cytokines and growth factors. Neutrophil activation occurs 
due to the contact between the tissues and the newly installed surgical device 
(Inoue, N. et al. 2013), causing endothelial adhesion, massive release of pro-
inflammatory factors and acute tissue damage. Administration of Sivelestat 
sodium salt greatly attenuates systemic inflammatory response, decreasing 
levels of HNE and IL-8
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2. BACKGROUND AND AIMS OF THE WORK 
 
Our research group has been involved for many years in the design and 
synthesis of Human Neutrophil Elastase (HNE) inhibitors. Several nitrogen 
bicyclic scaffolds such as indazole (Crocetti, L. et al. 2011) (Crocetti, L. et al. 
2013), indole (Crocetti, L. et al. 2016) and cinnoline (Giovannoni, M. P. et al. 
2016) have been investigated. 
 
 
 
Among the various investigated nucleus, the N-benzoylindazole derivatives 
showed the best profile as for potency and selectivity. On the more active 
compounds, aqueous buffer stability studies were performed as well as 
inhibition test on other proteases to evaluate their selectivity and enzyme 
kinetic studies to define the mechanism of action. The results suggest that 
they work as pseudo-irreversible HNE inhibitors, which covalently attack the 
enzyme site but can be reversed by hydrolysis of the acyl-enzyme complex. 
In this class of compounds, we can highlight two fundamental requirements 
for the activity: the presence of the N-CO function at position 1, that undergoes 
the nucleophilic attack by Ser195, the amino acid of the catalytic triad 
responsible for the proteolytic action, and the presence of the N at position 2, 
that is involved in an important hydrogen bond with the enzyme pocket, thus 
favoring the correct anchorage of the molecules to the active site of the 
enzyme.  
Compounds L and EL17 are two representative terms and are very potent 
HNE inhibitors showing an IC50= 7 and 20 nM respectively.  
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Although compound L was the most potent compound of this series, EL17 
shows the best compromise among inhibitory activity, chemical stability and 
selectivity. For these reasons, it was also evaluated in vivo in the rat model of 
rheumatoid arthritis induced by Complete Freund’s Adjuvant (CFA) (Di Cesare 
Mannelli, L. et al. 2016). The Paw Pressure Test and the Incapacitance Test 
indicate that a single administration of EL17 significantly reduced CFA-
dependent hypersensitivity to mechanical noxious stimuli and the postural 
unbalance related to spontaneous pain. Additionally, the histological 
evaluation of the tibio-tarsal joint evidenced a significant prevention of articular 
derangement after EL17 treatment (30 mg/kg). The protective effects are 
directly correlated with a complete reversion of the plasmatic Neutrophil 
Elastase activity increase induced by CFA. 
On these basis, the research performed in the period as PhD student 
consisted in the design and synthesis of new potential HNE inhibitors, with 
two different aims: 
 
1- On one side, we focused on the synthesis of 7-azaindole derivatives, 
as isomers of the potent indazoles above described, where the 
nitrogen was formally shifted from position 2 to position 7. 
We have investigated the positions 1, 2 and 3, by introducing those 
substituents that in the series of indazoles gave the best results. Thus, 
at position 3, other than the carbethoxy and the carbonitrile, we 
inserted various groups with different chemical properties (halogens, 
  Background and aims of the work 
41 
 
heterocycles etc.) in order to understand the importance of this position 
in the interaction with the enzyme. We studied the affect on activity by 
moving the substituent from position 3 to position 2 and in addition we 
also synthesized a 2,3-disubstituted compound. On the other hand, at 
position 1 we introduced various substituted benzoyl fragments and 
different acyl groups, so keeping the N-CO function, fundamental for 
activity in the reference indazoles. 
 
 
 
2- On the other side, we moved our attention on the isoxazol-5(2H)-one 
nucleus, a small and flexible monocyclic scaffold; additionally we 
started to synthesize benzo[c]isoxazol-3(1H)-ones as elaboration of 
the monocyclic derivatives.  
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As regards the isoxazolone derivatives, the first approach was to synthesize 
various terms bearing the same groups and functions that in the other series 
of compounds previously investigated gave the best results. So we inserted 
at the nitrogen of position 2 benzoyl or acyl groups in order to reproduce the 
N-CO function, to understand if also for this series of compounds it is 
fundamental for the activity. For this purpose we also realized some terms 
lacking the N-CO group at position 2. The research has also provided the 
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introduction at positions 3 and 4 of a variety of substituents such as small 
alkyls and (substituted) phenyl rings. 
 
The biological evaluation of all new compounds was performed by Professor 
Quinn, University of Montana and consisted of HNE inhibition assays, studies 
of chemical stability in aqueous buffer, evaluation of the reversibility of HNE-
inhibitor complex over time and kinetic of HNE inhibition by a selected 
compound. 
 
Moreover, some preliminary molecular modeling studies were conducted by 
Dr. Andrei Khleibnikov on isoxazolones derivatives in order to start to 
investigate the interactions of new compounds with the target enzyme. 
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3. CHEMISTRY 
 
The synthetic routes affording all final 7-azaindoles are depicted in Schemes 
1-7, while the procedure affording the compounds with isoxazolones scaffold 
are reported in the Schemes 8-9. Some of these compounds have recently 
been published by our research group (Vergelli, C. et al. 2017). 
 
Scheme 1 shows the synthetic pathway followed to obtain the 7-azaindole 
derivatives bearing a carbonitrile or a carbethoxy group at position 3. On one 
side, the commercially available 7-azaindole-3-carboxylic acid 1 was 
transformed into the corresponding, not isolated, acid chloride which was 
subsequently reacted with an aqueous ammonia solution to give the amide 3 
(Carbone, A. et al. 2015); this last one, by dehydration with POCl3, was 
converted into the 7-azaindole-3-carbonitrile 4 (Bahekar, R. H. et al. 2007). 
On the other side, compound 1 was also transformed into the 3-carbethoxy 
derivative 6 (Jiang, J. H. et al. 2011) through a classic esterification reaction. 
On both compounds 4 and 6, the acylation at position 1 was carried out with 
the appropriate acyl or benzoyl chloride and triethylamine in anhydrous 
dichloromethane to give the final products 5a-i and 7a-e.  
 
In Scheme 2 is showed the synthetic route to obtain the 7-azaindoles 
substituted at position 3 respectively with halogens or with a nitro group. The 
insertion of the iodine (9a) (Baltus, C. B. et al. 2016) was performed with N-
iodosuccinimmide in anhydrous acetonitrile at high temperature. Instead, for 
the introduction of the bromine (9b) (Baltus, C. B. et al. 2016) or the chlorine 
(9c) (Minakata, S. et al. 1997), the halogenation reaction was carried out with 
N-bromosuccinimmide and N-chlorosuccinimmide at room temperature in 
anhydrous dichlorometane. The nitro group (9d) (Robinson, M. M. et al. 1959) 
was introduced with the classic nitration reaction in concentrate sulfuric acid 
and nitric acid at 0°C. Finally, the benzoylation to obtain the final compounds 
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10a-d was performed with m-toluoyl chloride and triethylamine in anhydrous 
dichlorometane.  
 
Scheme 3 reports the procedure followed to obtain the final compounds 15a-
e bearing at position 3 various different heterocycles such as pyridine, furan 
and thiophene or a 3-CN-phenyl ring. Starting from the commercially available 
7-azaindole 8, we first protected the nitrogen at position 1 with benzensulfonyl 
chloride thus obtaining compound 11 (Sandham, D. A. et al. 2009). After the 
iodination of position 3 (12) (Zhang, J. et al. 2011), a coupling reaction was 
carried out using the appropriate boronic acid and Tetrakis in toluene at high 
temperature (13a-e). Then we deprotected N-1 with tetrabutylammonium 
fluoride (TBAF) in dry THF (14a-e) (Lind, K. E. et al. 2008) (Ibrahim, P. N. et 
al. 2007) and we performed the benzoylation, following the procedure 
previously described, to obtain the final products 15a-e.  
 
The synthesis of compounds 18 and 21, substituted at position 3 with an 
oxadiazole ring as bioisoster of the carbethoxy group, is reported in Schemes 
4 and 5. By the treatment of the amide 3 (Scheme 4) (Carbone, A. et al. 2015) 
with N,N-dimethylacetamide dimethyl acetal in toluene we obtained 
compound 16, which in turn was treated with hydroxylamine hydrochloride to 
give the corresponding oxadiazole derivative 17. The final compound 18 was 
obtained through the benzoylation of N-1 following the same procedure above 
reported.  
 
Instead compound 21 (Scheme 5), even bearing an oxadiazole ring at 
position 3 but differently connected, was obtained starting from the 7-
azaindole-3-carbonitrile 4 (Bahekar, R. H. et al. 2007) which was converted 
into the intermediate 19 (Lape, H. E. et al. 1968) with hydroxylamine 
hydrochloride and sodium carbonate. The cyclization of compound 19 with 
dicyclohexylcarbodiimide and acetic acid afforded the 5-methyl-3-(1H-
pyrrolo[2,3-b]pyridine-3-yl)-1,2,4-oxadiazole 20, which was benzoylated at 
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position 1 with m-toluoyl chloride and triethylamine in anhydrous 
dichloromethane to obtain the final product 21.   
 
Scheme 6 shows the synthetic pathway affording the final compounds 26 and 
30. After the formylation of the 7-azaindole (8) at position 3 with 
hexamethylentetramine and acetic acid (22) (Singla, P. et al. 2016), we 
protected the nitrogen at position 1 (23) (Chavan, N. L. et al. 2010) and then 
we performed a reductive amination using aniline or N-methylaniline and 
NaBH(OAc)3 in dry dichloromethane, thus obtaining compounds 24a and 24b. 
Compound 24b (R=CH3) was directly deprotected at N1 and then subjected 
to the benzoylation obtaining the final compound 26. On the other hand, 
compound 24a (R=H) was further protected with allyl chloroformate furnishing 
compound 27. This intermediate was treated with TBAF to give compound 28, 
which was benzoylated (29), and finally, using Tetrakis and phenyl silane, the 
allhyl chloroformate was removed to obtain the final product 30.  
 
To obtain the 7-azaindole derivatives substituted at position 2 or disubstituted 
at position 2 and 3, we followed the procedure shown in Scheme 7. Starting 
from compound 11 (Sandham, D. A. et al. 2009), the introduction of the 
substituents at position 2 was carried out with lithium diisopropylamide (LDA) 
and the appropriate halogen derivative at -78°C (31a,b) (Sandham, D. A. et 
al. 2009) (Ahrendt, K. A. et al. 2009); then we removed the protection at 
position 1 following the same procedure described in the previous scheme 
and we obtain compounds 32a,b (Sandham, D. A. et al. 2009) (Baltus, C. B. 
et al. 2016). On compound 32a (R=CH3) we performed a formylation (33) 
(Bahekar, R. H. et al. 2007), according to the procedure reported in Scheme 
6, followed by the treatment with hydroxylamine hydrochloride and NaHCO3 
at high temperature which afforded the corresponding oxime 34 (Bahekar, R. 
H. et al. 2007). Dehydration with POCl3 of 34 furnished the 7-azaindole-2-
methyl-3-carbonitrile (35) (Bahekar, R. H. et al. 2007), which was finally 
benzoylated at position 1 with m-toluoyl chloride and triethylamine in 
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anhydrous dichloromethane (final compound 36). Instead, the 2-carbethoxy 
derivative 32b was as directly benzoylated at N-1 providing the final product 
37 and converted into the amide intermediate 38 (Jia, H. et al. 2014). This last 
one was then transformed into the 2-carbonitrile (39) which in turn was 
benzoylated to give the final product 40.  
 
Before moving on the description of the Scheme 8, in which are reported the 
procedures followed to obtain the final products with the isoxazolone scaffold, 
it is essential to mention that the isoxazolone nucleus shows three different 
tautomeric forms, depending on the solvent and the substituent at position 3 
and 4, as reported below (Laufer, S. A. et al. 2008).  
 
 
 
The NH-form is the most representative especially in polar solvents, but in the 
literature it is possible to find examples of alkylation and acylation reactions 
which afforded 2-N-CO-R and 5-O-CO-R derivatives, originating from the NH-
form and OH-form respectively (Frolund, B. et al. 2005). Taken into account 
this aspect, we performed the synthesis of our final compounds as reported in 
Scheme 8.  
The starting products to obtain the isoxalone scaffold are ketoesters 41a-m 
which were synthetized following the procedure reported in the literature 
(Beccalli, E. M. et al. 1984) (Kalaitzakis, D. et al. 2007) (Shneider, P. et al. 
2009) (Raeppel, F. et al. 2015) (Shu, Z. et al. 2011) if they are not 
commercially available. The isoxazolone nucleus, suitable substituted at 
position 3 and 4, was obtained or by treatment with hydroxylamine 
hydrochloride in ethanol and in the presence of piperidine (42a-g) (Krogsgaar-
Laersen, P. et al. 1973) (Sato, K. et al. 1986) (Yamaguchi, M. et al. 2009) 
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(Adembri, G. et al. 1965) (Jacobsen, N. et al. 1984), or by treatment with 
hydroxylamine hydrochloride in a mixture of methanol/water 1:1 at reflux (42h-
m) (Boulton, A. J. et al. 1961) (Beccalli, E. M. et al. 1987) (Beccalli, E. M. et 
al. 1984) (Maquestiau, A. et al. 1974) (Belzecki, C. et al. 1958) (Breslow, T. et 
al. 1965). The final compounds originating from the acylation and/or 
benzoylation on the isoxazolones 42a-m were grouped into two different 
series depending on the nature of the substituent at position 3 and 4: 
compounds of type 43 (R3, R4= H, alkyl) and compounds of type 45 (R3, R4 = 
H, alkyl, phenyl). This reaction was the limiting step of the synthesis and 
needed a lot of times and attempts to be optimized. At the beginning, the 
acylation was performed with the appropriate acyl chloride and potassium 
carbonate in tert-butanol at 80°C, but the yields were very low and the reaction 
mixture difficult to purify. Therefore, by varying the reaction conditions and 
investigating different solvents, bases and stoichiometric ratios, we found that 
the acylations carried out with the appropriate acyl or benzoyl chloride and 
natrium hydride in THF at room temperature gave the best yields. Thus, the 
final compounds of type 43 and 45 were obtained following these optimized 
conditions.  
In compound 43l and 43n, the replacement of the carbonyl group with a 
thiocarbonyl group with Lawesson’s reagent in toluene at high temperature 
afforded compounds 44a and 44b. Finally, reaction of 42a, 42f and 42g, with 
3-methylbenzyl chloride in anhydrous acetonitrile and potassium carbonate 
resulted in 46a-c. All acylation and alkylation reactions reported in Scheme 8 
led to an only one compound probably originating from the NH-form of the 
isoxazolone nucleus, according with the data reported in the literature. Only 
in the case of the treatment of 42g with m-toluoyl chloride, we observed the 
formation of a couple of compounds in very different ratio (95:5) but showing 
the same molecular weight, as demonstrated with mass spectrometry 
techniques. The main product has been completely characterized as 
compound 45b, while the other one was probably the isomer originating from 
the OH-form, but the obtained amount was too small to further investigation. 
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In order to univocally assign the structure to the final compounds 43a-s and 
45a-o, a crystallographic analysis was performed on products 43j and 45a. 
The results definitively confirm the structure reported in Scheme 8, thus 
originating from the acylation/benzoylation of the NH-form, in agreement with 
the literature (for Figures and Tables see Material and methods, 
Crystallographic Analysis).  
In the last scheme (Scheme 9), we reported the synthesis of bicyclic 
compounds with benzo[c]isoxazol-3(1H)-one structure. On the commercially 
available 2-nitrobenzoyl chloride 47, we performed an esterification with 
anhydrous methanol at room temperature obtaining the corresponding methyl 
ester 48 (Li, L. et al. 2014), which was cyclized with ammonium chloride and 
zinc in tetrahydrofuran and water to afford compound 49 (Wierenga, W. et al. 
1984). The final products 50a-c were obtained with the appropriate benzoyl or 
acyl chloride and potassium carbonate in tert-butanol. 
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SCHEME 1 
 
 
Reagents and conditions: 
a) SOCl2, Et3N, 0°C; reflux, 1h. 
b) NH4OH 33%, 0°C, 1h. 
c) POCl3, reflux, 1h. 
d) R1-COCl, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
e) EtOH abs, r.t., 16h.  
 
 
 
 
 
 
 
 
 
 
5 R1 
a m-CH3-Ph 
b p-CH3-Ph 
c cC3H5 
d cC5H9 
e cC6H11 
f m-CN-Ph 
g p-CN-Ph 
h m-CF3-Ph 
i p-CF3-Ph 
 
7 R1 
a m-CH3-Ph 
b p-CH3-Ph 
c cC3H5 
d m-CN-Ph 
e p-CN-Ph 
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SCHEME 2 
 
Reagents and conditions: 
a) (R3= I) NIS, dry MeCN, reflux, 3h. 
    (R3= Br, Cl) NBS or NCS, dry DCM, 0°C, 15 min; r.t., overnight. 
    (R3= NO2) H2SO4 conc., HNO3 (1:1) 0°C, 30 min. 
b) m-Toluoyl chloride, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
 
SCHEME 3 
 
 
Reagents and conditions 
a) Ph-SO2Cl, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
b) NIS, dry MeCN, reflux, 3h. 
c) R3-B(OH)2, Tetrakis, Na2CO3 2M, H2O, toluene, reflux, 4h. 
d) TBAF, dry THF, reflux, 3h. 
e) m-Toluoyl chloride, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
 
 
9,10 R3 
a I 
b Br 
c Cl 
d NO2 
 
 
13-15 R3 
a 3-CN-Ph 
b 3-pyridine 
c 2-furan 
d 3-furan 
e 3-thiophene 
 
 
Chemistry 
52 
 
SCHEME 4 
 
Reagents and conditions: 
a) N,N-DMA-DMA, dry DMF, reflux, 2h. 
b) NH2OH·HCl, glacial CH3COOH, NaOH 10%, dioxane, reflux, 5h. 
c) m-Toluoyl chloride, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
 
SCHEME 5 
 
Reagents and conditions: 
a) NH2OH·HCl, EtOH, 0°C; Na2CO3, H2O, reflux, 8h. 
b) DCC, glacial CH3COOH, dry DMF, 0°C, 2h; r.t., 2h. 
c) m-Toluoyl chloride, Et3N, dry DCM, 0°C, 2h; r.t., 2h.  
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SCHEME 6 
 
 
Reagents and conditions: 
a) HMTA, CH3COOH, reflux, 4h. 
b) Ph-SO2Cl, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
c) R-NH-Ph, glacial CH3COOH, dry DCM, r.t., 30 min; NaBH(OAc)3, r.t., overnight. 
d) TBAF, dry THF, reflux, 3h. 
e) m-Toluoyl chloride, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
f) Allyl chloroformate, NaN3, dioxane, H2O, r.t., 1h; Na2CO3 1%, overnight. 
g) Tetrakis, phenylsilane, dry DCM, r.t., 1h. 
 
 
 
 
 
24 R 
a H 
b CH3 
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SCHEME 7 
 
Reagents and conditions: 
a) LDA, dry THF, -78°C, 30 min; CH3-I (for 31a) or ClCOOEt (for 31b), r.t., 2h. 
b) TBAF, dry THF, reflux, 2h. 
c) HMTA, CH3COOH, reflux, 3h. 
d) NH2OH·HCl, H2O, 60°C, 30 min; NaHCO3, reflux, 4h. 
e) POCl3, reflux, 1h. 
f) m-Toluoyl chloride, Et3N, dry DCM, 0°C, 2h; r.t., 2h. 
g) NH4OH 33%, EtOH, 100°C, 8h. 
 
 
 
 
 
 
31, 32 R2 
a CH3 
b COOEt 
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SCHEME 8 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: 
a) (for 42a-g) NH2OH·HCl, piperidine, EtOH, reflux, 4-5h. 
    (for 42h-m) NH2OH·HCl, H2O/MeOH 1:1, 80°C, 1-4h. 
b) R2-COCl, NaH, dry THF, r.t., overnight. 
c) Lawesson’s reagent, toluene, reflux, 5h. 
d) 3-methylbenzyl chloride, K2CO3, dry MeCN, reflux, 2h. 
     
 
 
 
 
44 R2 
a cC3H5 
b m-CH3-Ph 
 
 
41, 42 R3 R4 
a CH3 CH3 
b CH3 C2H5 
c C2H5 CH3 
d COOEt CH3 
e C2H5 H 
f iC3H7 H 
g CH3 Ph 
h H Ph 
i Ph CH3 
j Ph H 
k Ph Ph 
l 4-NO2-Ph H 
m 4-NHCOCH3-Ph H 
 
46 R3 R4 
a CH3 CH3 
b iC3H7 H 
c CH3 Ph 
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43 R2 R3 R4 
a cC3H5 CH3 CH3 
b m-CH3-Ph CH3 CH3 
c cC3H5 CH3 C2H5 
d m-CH3-Ph CH3 C2H5 
e cC3H5 C2H5 CH3 
f m-CH3-Ph C2H5 CH3 
g cC3H5 COOEt CH3 
h m-CH3-Ph COOEt CH3 
i cC3H5 C2H5 H 
j m-CH3-Ph C2H5 H 
k C2H5 iC3H7 H 
l cC3H5 iC3H7 H 
m cC5H9 iC3H7 H 
n m-CH3-Ph iC3H7 H 
o p-CH3-Ph iC3H7 H 
p m-CN-Ph iC3H7 H 
q p-CN-Ph iC3H7 H 
r m-CF3-Ph iC3H7 H 
s p-CF3-Ph iC3H7 H 
 
45 R2 R3 R4 
a cC3H5 CH3 Ph 
b m-CH3-Ph CH3 Ph 
c m-CN-Ph CH3 Ph 
d m-CF3-Ph CH3 Ph 
e cC3H5 H Ph 
f m-CH3-Ph H Ph 
g cC3H5 Ph CH3 
h m-CH3-Ph Ph CH3 
i cC3H5 Ph H 
j m-CH3-Ph Ph H 
k cC3H5 Ph Ph 
l m-CH3-Ph Ph Ph 
m cC3H5 4-NO2-Ph H 
n m-CH3-Ph 4-NO2-Ph H 
o m-CH3-Ph 4-NHCOCH3-Ph H 
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SCHEME 9 
 
 
 
 
 
 
Reagents and conditions:  
a) dry MeOH, r.t., 2h. 
b) NH4Cl, Zn°, THF, H2O, r.t., 2h. 
c) R1-COCl, K2CO3, t-BuOH, 80°C, 2h. 
 
 
 
50 R1 
a C2H5 
b C4H9 
c m-CH3-Ph 
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4. RESULTS AND DISCUSSION 
4.1 Biological evaluation and structure activity relationships 
(SARs) 
All new products were tested as HNE inhibitors in the laboratory of Prof. 
Quinn, University of Montana. Experiments were conducted in triplicate using 
N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-cumarin (Calbiochem) as 
substrate for HNE. The results are reported in the Tables 1-6 and are 
compared with Sivelestat, the only HNE inhibitor commercially available and 
with compound L, a potent reference compound synthesized by us (see Aim 
of the work).  
Tables 1, 2 and 3 show activity values for compounds with 7-azaindole 
structure, isomers of the potent indazoles previously described (see Aim of 
the work). A look at the results indicates that this nucleus may be an 
appropriate scaffold for HNE inhibitors since the most part of the new 
synthetized compounds show an inhibitory activity in the 
micromolar/submicromolar range and some terms even exhibit an IC50 at 
nanomolar levels.  
Starting to analyze Table 1, the first observation is that both the 3-CN 
derivatives 5a and 5b, isomers of the powerful indazole L, are very potent 
inhibitors showing an IC50 = 15 and 14 nM respectively. This result indicates 
that the shift of the nitrogen from position 2 to position 7 doesn’t affect the 
inhibitory activity. The replacement of the methyl on the benzoyl fragment with 
other groups such as cyano (5f and 5g) or trifluoromethyl (5h and 5i), that in 
the literature are present in potent HNE inhibitors is not favorable for the 
activity as in meta and in para position. On the other hand, the insertion at 
position 1 of acyl groups (compounds 5c-e) gave good results only in the case 
of the cyclopropancarbonyl fragment resulting in compound 5c which showed 
IC50  = 87 nM. Going to the series of the 3-carbethoxy derivatives, although 
compounds 7a-c maintain good levels of inhibition (IC50 = 0.77 μM, 0.64 μM 
and 0.62 μM respectively), they are 10 fold less potent than the corresponding 
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3-CN derivatives 5a-c. The introduction of the CN group on the benzoyl 
fragment as in compounds 7d and 7e leads to a decrease of activity, 
analogously to the previously discussed series.  
Instead, analyzing the results shown in Table 2, it is possible to highlight that 
the shift of the carbonitrile or carbethoxy groups determines the total loss of 
activity (37) or a dramatic decrease of activity, as for compound 40 which 
shows an IC50 about two order of magnitude higher with respect to its 3-CN 
isomer. Also the introduction of a methyl group at position 2 of the potent 5a 
(compound 36) is detrimental for activity, affording a product with an IC50 = 
10.8 µM. 
From the above discussed data, it emerges that the methylbenzoyl group is 
the best substituent for position 1, as when the methyl is in meta and in para 
position.  So, also taking into account our previous results for the indazole 
series, we selected the m-methylbenzoyl fragment and keeping this group at 
position N-1, we modified the position 3 of the 7-azaindole nucleus by inserting 
a variety of substituents with different characteristics. The data are reported 
in Table 3.  As we can see, the performed modifications do not improve the 
HNE inhibitory activity since the most part of compounds work in the 
micromolar range. Only compounds 10d and 18 are potent HNE inhibitors with 
IC50 = 24 and 80 nM respectively. Indeed, compound 10d, substituted at 
position 3 with a NO2 groups, is a reaction intermediate since the NO2 group 
will be further processed (reduction and acetylation) to overcome the 
problems of toxicity linked to its metabolism. It was sent to the 
pharmacological experimentation, given the strong similarities between the 
NO2 and CN group, and the potent activity of 10d confirms that the presence 
of an electron-withdrawing group at position 3 is favorable for the activity. On 
the other hand, it is intriguing the different activity of the isomers 18 and 21, 
bearing at position 3 the same oxadiazole ring but differently connected. In 
fact, compound 21 is about 45 fold less potent then compound 18, suggesting 
a worse orientation and/or interaction at the level of the active site. This aspect 
is not easily understandable since the oxadiazole ring, isoster of the 
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carbethoxy group, appears to be able to freely rotate around the simple bond. 
The molecular modeling studies, provided for these compounds, will help us 
to clarify this apparent incongruity, as well as to understand the comparable 
activity of 7-azaindole derivatives with respect to the indazoles and hence the 
role of N-7 for the anchoring of this molecules to the enzyme pocket.  
The graphical summary of the preliminary structure activity relationships 
(SARs) of this series of compounds is reported below.  
 
 
 
The HNE inhibitory activity of compounds with isoxazolone scaffold is reported 
in the Tables 4 and 5. Following the same organization reported in Scheme 
8, the data of Table 4 refer to the isoxazolones alternatively substituted in 
positions 3 and 4 with small alkyl groups (43a-s), while Table 5 shows the 
results of compounds 45a-o, substituted at position 3 and/or 4 with a 
(substituted)phenyl ring. All the results demonstrated that also the isoxazolone 
nucleus is an appropriate scaffold for the synthesis of HNE inhibitors.  
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Going to specifically analyze the results and starting from Table 4, we can 
observe that the contemporary presence of small alkyl groups at position 3 
and 4 (43a-f) leads to compounds with an appreciable HNE inhibitory activity 
in the micromolar/submicromolar range; on the other hand the introduction at 
position 3 of a carbethoxy group (43g,h) give very different results, depending 
on the substituent at N-2 (43g IC50 = 440 nM, 43h IC50 = 39.7 µM). Instead, 
the elimination of the methyl group at position 4 (43i-s) gives compounds 
endowed with excellent inhibitory activity, indicating the importance of the 
unsubstitution of this position. This aspect can be highlighted comparing 
compounds 43i and 43j (IC50 = 96 and 43 nM respectively) with the 
corresponding 4-methyl derivatives 43e and 43f (IC50 = 2.2 and 1.8 μM 
respectively). Some other products of the 4-unsubstituted series, like 
compounds 43l, 43n, 43o and 43s are very potent HNE inhibitors exhibiting 
IC50 values in the nanomolar range (20-42 nM). At this regard, it is interesting 
to observe that the replacement of the methyl group at meta and para position 
of compounds 43n and 43o with a trifluoromethyl group (43r and 43s) does 
not modify the inhibitory activity when the substituent was in para position of 
the benzoyl group (i.e. compounds 43o and 43s with IC50 = 20 and 34 nM 
respectively), but results in a decrease of activity when the substituent was in 
meta position (43r, IC50 = 1.2 µM). These compounds display two carbonyl 
groups (2-N-CO and 5-CO) as possible point of attack for Ser195, the amino 
acid of the HNE catalytic site responsible for the nucleophilic attack and 
leading to the hydrolysis of the substrate. The evidence that all 2-N-
acyl/benzoyl derivatives are good HNE inhibitors suggests that the carbonyl 
group involved in the catalysis was the N-CO at position 2. The importance of 
this function seems to be confirmed by the complete inactivity of the 2-N-
benzyl derivatives 46a and 46b. Indeed this observation is consistent with our 
previous results for indazole derivatives (Crocetti, L. et al. 2011) (Crocetti, L. 
et al. 2013).  
On the other hand, informations about the importance of the endocyclic 
carbonyl group at position 5, which does not seem involved in the catalysis, 
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come from compounds 44a and 44b, the thioanalogues of the two potent 
compounds 43l and 43n. However, the low activity (44a, IC50 = 2.1 μM) or 
inactivity (44b) of these new products clearly suggest that the 5-CO group is 
important anyway for the interaction with the target. To assess if this low 
activity/inactivity was the result of increased bulkiness and/or decrease H-
binding acceptor efficacy of sulfur with respect to oxygen in the carbonyl 
groups or if it was related to other reasons, we performed molecular modeling 
studies (see Molecular Modeling section).  
The fundamental structure activity relationships of isoxazolones 43a-s are 
summarized below.  
 
 
 
In Table 5 are presented the results of isoxazolones bearing at positions 3 
and 4 at least one phenyl ring. Beginning the analysis of the data from 3-
methyl-4-phenylisoxazol-5(2H)-one derivatives (compounds 45a-d), the 
biological results suggest that also in this case, as in the series previously 
described, the best substituents at position N-2 are the m-methylbenzoyl or 
the cyclopropanecarbonyl fragment, as in compounds 45a and 45b which 
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show activity values in the nanomolar range (IC50 = 59 and 77 nM 
respectively). The replacement of the methyl on the benzoyl fragment at 
position 2 with other groups such as cyano (45c) or trifluoromethyl (45d), in 
any case is not favorable for the activity (IC50 = 6.3 μM and 0.20 μM 
respectively). Thus, keeping the m-methylbenzoyl and ciclopropanecarbonyl 
at position N-2, we further modified the positions 3 and 4 of the isoxazolone. 
Compounds 45e and 45f which are the 3-norderivatives of compounds 45a 
and 45b, are very potent HNE inhibitors with IC50 = 16 and 46 nM respectively. 
Instead, moving the phenyl from position 4 to position 3 we observe a 
decrease or a total collapse of the activity, as we can see in compounds 45g-
o. In particular, the insertion in para position on the phenyl ring of those 
substituents that in the previous series gave good results (such as nitro or 
acetamide) leads to compounds completely avoid of activity (45m-o). Similar 
results were obtained by introducing two phenyl rings at positions 3 and 4 at 
the same time (45k,l). Based on these results, we can affirm that the position 
4 of the isoxazolone scaffold bears bulky groups such a phenyl ring when 
position 3 is unsubstituted or substituted with a methyl group, while the same 
phenyl ring is never tolerate at position 3 independently from the substituent 
at position 4. Finally, as for compounds 46a,b of the above discussed series, 
the replacement of the benzoyl group at position 2 of compound 45b with a 
benzyl fragment (compound 46c) afforded a completely inactive product, in 
according with our previous affirmation.  
The graphical summary of SARs for compounds of type 45 is reported below.  
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At the end, the Table 6 shows the activity values of benzoisoxazolone 
derivatives 50a-c, which were designed and synthetized as elaboration of the 
isoxazolone scaffold and until now obtained. Only the m-methylbenzoyl 
derivative 50c has a remarkable activity with an IC50 of 638 nM, while the other 
compounds are less active (50a) or inactive (50b). This new series is under 
development. 
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Table 1: HNE inhibitory activity of 7-azaindole derivatives 5a-i and 7a-e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R1 IC50 (µM)a 
5a m-CH3-Ph 0.015 ± 0.004 
5b p-CH3-Ph 0.014 ± 0.004 
5c cC3H5 0.087 ± 0.021 
5d cC5H9 2.6 ± 0.21 
5e cC6H11 1.5 ± 0.32 
5f m-CN-Ph 19.1 ± 2.3 
5g p-CN-Ph 12.6 ± 2.5 
5h m-CF3-Ph 1.8 ± 0.24 
5i p-CF3-Ph 1.5 ± 0.23 
7a m-CH3-Ph 0.77 ± 0.15 
7b p-CH3-Ph 0.64 ± 0.12 
7c cC3H5 0.62 ± 0.14 
7d m-CN-Ph 11.5 ± 2.1 
7e p-CN-Ph 38.5 ± 4.8 
Sivelestat - 0.050 ± 0.020 
 
 
 
- 
 
 
0.007 ± 0.0015 
aIC50 values are presented as the mean ± SD of three independent experiments. 
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Table 2: HNE inhibitory activity of 7-azaindole derivatives 36, 37 and 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R2 R3 IC50 (µM)a 
36 CH3 CN 10.8 ± 2.2 
37 COOEt - NAb 
40 CN - 3.5 ± 1.2 
Sivelestat - - 0.050 ± 0.020 
aIC50 values are presented as the mean ± SD of three independent experiments.  
bNA: no inhibitory activity was found at the highest concentration of compound tested (50 µM). 
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Table 3: HNE inhibitory activity of 7-azaindole derivatives 10a-d, 15a-e, 18, 
21, 26 and 30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R3 IC50 (µM)a 
10a I 7.3 ± 2.6 
10b Br 11.9 ± 3.2 
10c Cl 28.5 ± 1.2 
10d NO2 0.024 ± 0.009 
15a 3-CN-Ph 6.7 ± 2.1 
15b 3-pyridine 6.0 ± 0.7 
15c 2-furan 44.8 ± 3.8 
15d 3-furan 42.6 ± 2.8 
15e 3-thiophene NAb 
18 3-methyl-1,2,4-oxadiazole 0.080 ± 0.020 
21 5-methyl-1,2,4-oxadiazole 3.6 ± 1.1 
26 CH2-N(CH3)-Ph 2.4 ± 0.46 
30 CH2-NH-Ph 1.8 ± 0.2 
Sivelestat - 0.050 ± 0.020 
aIC50 values are presented as the mean ± SD of three independent experiments. 
bNA: no inhibitory activity was found at the highest concentration of compound tested (50 µM). 
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Table 4: HNE inhibitory activity of isoxazolone derivatives 43a-s, 44a,b and 
46a,b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R2 R3 R4 IC50 (µM)a 
43a cC3H5 CH3 CH3 0.12 ± 0.023 
43b m-CH3-Ph CH3 CH3 10.9 ±1.2 
43c cC3H5 CH3 C2H5 0.13 ± 0.025 
43d m-CH3-Ph CH3 C2H5 0.094 ± 0.023 
43e cC3H5 C2H5 CH3 2.2 ± 0.28 
43f m-CH3-Ph C2H5 CH3 1.8 ± 0.32 
43g cC3H5 COOEt CH3 0.44 ± 0.14 
43h m-CH3-Ph COOEt CH3 39.7 ± 5.1 
43i cC3H5 C2H5 H 0.096 ± 0.022 
43j m-CH3-Ph C2H5 H 0.043 ± 0.011 
43k C2H5 iC3H7 H 1.1 ± 0.14 
43l cC3H5 iC3H7 H 0.034 ± 0.009 
43m cC5H9 iC3H7 H 0.56 ± 0.15 
43n m-CH3-Ph iC3H7 H 0.042 ± 0.011 
43o p-CH3-Ph iC3H7 H 0.020 ± 0.007 
43p m-CN-Ph iC3H7 H 6.5 ± 1.7 
43q p-CN-Ph iC3H7 H 18.2 ± 2.5 
43r m-CF3-Ph iC3H7 H 1.2 ± 0.22 
43s p-CF3-Ph iC3H7 H 0.034 ± 0.012 
44a cC3H5 - - 2.1 ± 0.31 
44b m-CH3-Ph - - NAb 
46a m-CH3-benzyl CH3 CH3 NAb 
46b m-CH3-benzyl iC3H7 H NAb 
Sivelestat - - - 0.050 ± 0.020 
aIC50 values are presented as the mean ± SD of three independent experiments. 
bNA: no inhibitory activity was found at the highest concentration of compound tested (50 µM). 
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Table 5: HNE inhibitory activity of isoxazolone derivatives 45a-o and 46c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R2 R3 R4 IC50 (µM)a 
45a cC3H5 CH3 Ph 0.059 ± 0.018 
45b m-CH3-Ph CH3 Ph 0.077 ± 0.027 
45c m-CN-Ph CH3 Ph 6.3 ± 1.4 
45d m-CF3-Ph CH3 Ph 0.20 ± 0.027 
45e cC3H5 H Ph 0.016 ± 0.005 
45f m-CH3-Ph H Ph 0.046 ± 0.012 
45g cC3H5 Ph CH3 1.1 ± 0.14 
45h m-CH3-Ph Ph CH3 13.6 ± 2.4 
45i cC3H5 Ph H 12.7 ± 2.7 
45j m-CH3-Ph Ph H 48.7 ± 3.3 
45k cC3H5 Ph Ph 17.2 ± 2.3 
45l m-CH3-Ph Ph Ph 10.1 ± 1.3 
45m cC3H5 4-NO2-Ph H NAb 
45n m-CH3-Ph 4-NO2-Ph H NAb 
45o m-CH3-Ph 4-NHCOCH3-Ph H 28.6 ± 3.3 
46c - - - NAb 
Sivelestat - - - 0.050 ± 0.020 
aIC50 values are presented as the mean ± SD of three independent experiments. 
bNA: no inhibitory activity was found at the highest concentration of compound tested (50 µM). 
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Table 6: HNE inhibitory activity of benzoisoxazolone derivatives 50a-c. 
 
 
 
 
 
 
 
 
 
 
 
4.2 Stability and kinetic features 
Some selected isoxazolones belonging to the first series (compounds of type 
43, substituted at position 3 and 4 with small alkyl group) were further 
evaluated for chemical stability in aqueous buffer using spectrophotometry to 
detect compounds hydrolysis. The compounds had t1/2 values from 3.1 to 19.3 
h for spontaneous hydrolysis (Table 7), indicating that these isoxazolones 
were more stable than our previously described HNE inhibitors with N-
benzoylindazole scaffolds (Crocetti, L. et al. 2011) (Crocetti, L. et al. 2013). 
 
 
 
 
 
 
 
 
Compound R1 IC50 (µM)a 
50a C2H5 25.1 ± 3.6 
50b C4H9 NAb 
50c m-CH3-Ph 0.638 ± 0.121 
Sivelestat - 0.050 ± 0.020 
aIC50 values are presented as the mean ± SD of three independent experiments. 
bNA: no inhibitory activity was found at the highest concentration of compound 
tested (50 µM) 
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Table 7: half-Life (t1/2) for the hydrolysis of selected isoxazolone derivatives 
in aqueous buffer in absence and in the presence of HNE. 
 
 
Compound 
 
max (nm)a 
t1/2 (h) 
spontaneous 
hydrolysis 
in the presence 
HNEb 
43d 290 7.7 3.5 
43i 275 19.3 4.0 
43j 285 5.3 2.1 
43l 275 19.3 4.3 
43n 285 6.2 2.6 
43o 290 8.9 3.4 
43s 285 3.1 0.9 
     aAbsorption maximum of the compounds for monitoring hydrolysis. bHydrolysis was monitored in the  
   presence of 400 mU/ml HNE.  
 
We also tested compound hydrolysis in the presence of HNE and found that 
the speed of hydrolysis gradually increased with increasing enzyme 
concentration. As an example, Fig. 23 shows dose-dependent hydrolysis of 
compound 43i over time. In the presence of 400 mU/ml HNE, the hydrolysis 
was 2.2-4.8-fold higher than for spontaneous hydrolysis (i.e., without HNE) 
(see Table 7).  
 
 
Fig. 23: analysis of compound 43i spontaneous hydrolysis. Compound 43i 
(80 µM) was incubated in 0.05 M phosphate buffer (pH 7.5, 25 oC) 
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supplemented with 0, 50, 200, and 400 µg/mL HNE, as indicated.  
Spontaneous hydrolysis was monitored by measuring changes in absorbance 
at 275 nm (absorption maximum of compound 43i) over time. The data are 
presented as the mean ± S.D. of triplicate samples from one experiment, 
which is representative of two independent experiments.  
 
We also evaluated reversibility of the HNE-inhibitor complex over time for 
most potent compounds. As shown in Fig. 24, HNE inhibition was maximal 
during the first 30 min for compounds 43n, 43d, 43l, 43i and 43j. However, 
inhibition by compound 43s was reversed after 10 min. The most stable 
inhibition was found for 43o, where inhibition of HNE activity was reversed 
only after 2h. 
 
 
Fig. 24: evaluation of HNE inhibition by selected isoxazolone derivatives. HNE 
was incubated with the indicated compounds at 5 μM concentrations, and 
kinetic curves monitoring substrate cleavage catalyzed by HNE are shown. 
Representative curves are from three independent experiments. 
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Compound 43o was the selected to perform additional kinetic experiments. 
As shown in Fig. 25, the representative double-reciprocal Lineweaver-Burk 
plot of fluorogenic substrate hydrolysis by HNE in the absence and presence 
of compound 43o indicates that this compound is a competitive HNE inhibitor. 
 
 
 
Fig. 25: kinetics of HNE inhibition by compound 43o. Representative double-
reciprocal Lineweaver-Burk plot from three independent experiments. 
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4.3 Molecular Modeling 
For some compounds with the isoxazolone scaffold, molecular modeling 
studies were conducted by Dr. Andrei Khlebnikov of the research group of 
Prof. Quinn. Molecular docking of derivatives 43l, 43n, 43o, 43q, 44a and 44b 
into the HNE binding site (1HNE entry of Protein Data Bank) was performed 
and the side chains of selected residues in HNE binding site were considered 
flexible, as described in our previous studies (Crocetti, L. et al. 2013) (Crocetti, 
L. et al. 2016).  
 
Table 8: biological activities, geometric parameters, and docking scores of the 
enzyme–inhibitor complexes predicted by molecular docking with MVD. 
 
Compound IC50 
(µM)a 
𝜶 d1 d2 d3 Lb Docking 
Score 
E 
(kcal/mol) 
43lс 0.034 85.2 2.903 2.763, 
3.967 
2.829 5.592 -58.9 
44a 2.1 139.6 4.148 2.379, 
3.611 
2.560 4.939 -44.0 
43n 0.042 81.6 3.861 2.399, 
3.627 
2.596 4.995 -34.2 
44b NA 148.3 4.659 2.750, 
3.962 
2.849 5.599 -21.1 
43oc 0.020 104.1 3.134 2.760, 
3.975 
2.819 5.579 -67.6 
43qс 18.2 89.4 4.500 3.130, 
4.319 
3.286 6.416 -58.4 
aHNE inhibitory activity. bThe length of the proton transfer channel was calculated as L = d3 + min(d2). 
cAccording to the docking results, a Michaelis complex with Ser195 is formed with participation of the ester 
carbonyl group. 
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According to the docking scores E of the poses (Table 8), isoxazolones are 
effectively anchored within HNE binding site. However, it is well known that 
catalytic activity of serine protease is related to synchronous proton transfer 
from serine via histidine to aspartate residues (Vergely, I. et al. 1996). In HNE, 
this catalytic triad corresponds to Ser195, His57 and Asp102 respectively. The 
length of the proton transfer channel is characterized by the magnitude of L 
(see Table 8). Additionally, effectiveness of HNE binding to a ligand depends 
on its ability to form a Michaelis complex between a carbonyl group of the 
ligand and an oxyanione hole centered at the hydroxyl oxygen atom of 
Ser195. Geometry which favours Michaelis complex formation corresponds to 
ligand orientation with angle α values from 80° to 120° and with shortened 
distance d1 (1.8-2.6 Å) (Vergely, I. et al. 1996) (Table 8). Although a low-
energy docking pose of each ligand is not completely identical to the Michaelis 
complex, they must have certain similarity. Hence, it is reasonable to use the 
geometry of the low-energy pose to evaluate the possibility of complex 
formation. Compounds 43l, 43n, 43o, 43q, 44a and 44b occupy an area in 
the HNE binding site in the vicinity of the terminal part of the co-crystallized 
peptide. As presented in Table 8, the sulfur-containing compounds 44a and 
44b had larger distances d1 (4.148 Å and 4.659 Å, respectively) than their 
counterparts 43l and 43n and they were characterized by an angle α that was 
not suitable for easy formation of a Michaelis complex (139.6° and 148.3°, 
respectively). The different orientation within the binding site of sulfur 
compounds, with respect to compounds containing the 5-carbonyl group could 
also be caused by higher values of C=S bond length and radius of the sulfur 
atom (Fig. 26). 
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Fig. 26: Docking poses of compounds 43n (blue) and 44b (red). The ovals 
represent respectively the C=S and C=O fragment of the two compounds, 
respectively.  Residues within 6 Å from the co-crystallized ligand are shown. 
 
From the docking studies, it is interesting to note that these isoxazolone 
compounds show involvement of the endocyclic carbonyl group in formation 
of a Michaelis adduct, but also the amide carbonyl group is important for 
proper anchoring of the ligands to the enzyme pocket.  For example, 
compounds 43o and 43q show values of angle α in the exact range (Table 8) 
and are located similarly in the HNE binding site to allow formation a Michaelis 
complex with the endocyclic carbonyl group.  In particular, inhibitor 43o, which 
has the best inhibitory activity (IC50 = 20 nM) forms a hydrogen bond between 
the oxygen of the 5-carbonyl group and the NH group of Ser195 that likely 
improves the enzyme-ligand orientation, in addition to the involvement of the 
5-carbonyl carbon atom and the Ser195 hydroxyl group, for the formation of 
Michaelis complex (Fig. 27). 
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Fig. 27: docking pose of compound 43o. Residues within 3Å of the pose are 
visible. The H-bond is shown by a light-blue dashed line. 
 
In compound 43q, the 5-carbonyl group (carbon atom) is located at a longer 
distance d1 from Ser195 than that of 43o (see Table 8). This is due to the H-
bond interaction of the oxygen atom of the 5-carbonyl group that involves the 
NH group of Gly193 instead of the NH group of Ser195. Moreover, for 
derivative 43q, the imidazole ring of His57 is rotated unfavorably, thus 
enhancing the length L of the proton transfer channel (Table 8). 
Consequently, the conditions for formation of a Michaelis complex are not as 
suitable and lead to reduced inhibitory activity (IC50 = 18.2 µM). Differences 
between 43o and 43q, which are p-tolyl- and p-cyanophenyl derivatives, 
respectively, could also likely be related to variations in hydrophobicity, 
polarity of substituents, and different orientation of flexible side chains in the 
ligand-enzyme complex. Thus, our docking studies indicate that the 2-amido 
carbonyl group also plays an important role in positioning the ligand within the 
binding site, although the attack of the Ser195 is directed at the endocyclic 
C=O group (5-carbonyl group).  
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The sum of non-bonding interaction energies between HNE and the two atoms 
of the amido carbonyl moiety of 43o equals -12.86 kcal/mol, which is even 
more negative than for the endocyclic carbonyl (-9.11 kcal/mol), indicating a 
strong interaction with the enzyme. Non-specific Van der Waals interaction by 
the tolyl ring and/or polar interactions by the 2-amido group are responsible 
for proper anchoring of 43o to the sub-pocket of the binding site surrounded 
by Cys191, Phe192, Phe215, Val216, and Cys220. Although 43q shows these 
non-specific interactions with the sub-pocket binding site, the different 
orientation in the enzyme pocket caused by the H-bond interaction of the 
oxygen atom of the 5-carbonyl group involving the NH Gly193 could explain 
the lower inhibitory activity compared to 43o. 
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5. CONCLUSIONS 
 
The work performed during this period as PhD student affords interesting 
results in the design and synthesis of two different classes of HNE inhibitors.  
 
 The first one, characterized by the 7-azaindole scaffold, includes some 
potent HNE inhibitors all showing at position 3 an electron withdrawing 
group, such as CN or NO2. This feature seems to be important for 
activity, as well as at position 1 the presence of the N-CO group that 
we believe to be the point of attack of Ser195. Furthermore, position 2 
should not be replaced.  
 
For this first series of compounds, designed as isomers of the potent 
indazoles previously reported by us, the results of the underway 
molecular modeling studies will be particularly important to understand 
the role of the nitrogen at position 7 in the anchoring of the molecules 
to the enzyme, as well as the importance of the substituents in the 
different positions. These information will be useful for the continuation 
of this project. 
 
 The second class consists of compounds with isoxazolone nucleus, 
another appropriate scaffold for the synthesis of HNE inhibitors. The 
most active compounds show IC50 = 20-80 nM. The best results were 
obtained when at position 3 is present an alkyl group (ethyl, isopropyl) 
and position 4 is unsubstituted (compound of type 43); alternatively 
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potent compounds were obtained when position 3 is unsubstituted or 
bearing a methyl group and at position 4 a phenyl ring is present 
(compounds of type 45).  
 
 
Since these compounds show two carbonyl groups as possible points of 
attack of the Ser195, molecular modeling studies were performed on products 
of type 43 (R3, R4 =H, alkyl) with the aim to clarify the interaction with the 
target. Docking studies show that the attack of the Ser195 is directed at the 
endocyclic C=O at position 5, but that also the 2-N-CO-R group is important 
for the anchoring to sub-pocket of the binding site surrounded by Cys191, 
Phe192, Phe215, Val216 and Cys220 through nonspecific van der Walls and 
polar interactions. These observations are in agreement with the inactivity of 
the 2-N-alkyl/aryl derivatives and of the thioanalogues. We are waiting for the 
results of docking studies on compounds of type 45 (bearing at position 4 a 
phenyl ring) whose activity seems in contrast with the results of the 4-
unsubstituted isoxazolones of type 43.  This apparent incongruity could be 
explained hypothesizing a π-π interaction of the phenyl ring with the enzyme. 
Studies of chemical stability in aqueous buffer indicate that the new 
isoxazolones are very stable with t1/2 values from 3.1 to 19.3 h. Experiments 
of reversibility of the HNE-inhibition complex over time for the most potent 
compounds, together with additional kinetic experiments indicate that this 
class of compounds work as competitive HNE inhibitors.  
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6. MATERIAL AND METHODS 
 
6.1 CHEMISTRY 
All melting points were determined on a Büchi apparatus (New Castle, DE) 
and are uncorrected. Extracts were dried over Na2SO4, and the solvents were 
removed under reduced pressure. Merck F-254 commercial plates (Merck, 
Durham, NC) were used for analytical TLC to follow the course of reactions. 
Silica gel 60 (Merck 70–230 mesh, Merck, Durham, NC) was used for column 
chromatography. 1H-NMR, 13C-NMR, HMBC and HSQC spectra were 
recorded on an Avance 400 instrument (Bruker Biospin Version 002 with SGU, 
Bruker Inc., Billerica, MA). Chemical shifts (δ) are reported in ppm to the 
nearest 0.01 ppm using the solvent as an internal standard. Coupling 
constants (J values) are given in Hz and were calculated using TopSpin 1.3 
software (Nicolet Instrument Corp., Madison, WI) and are rounded to the 
nearest 0.1 vHz. Mass spectra (m/z) were recorded on an ESI-TOF mass 
spectrometer (Brucker Micro TOF, Bruker Inc., Billerica, MA), and reported 
mass values are within the error limits of ±5 ppm mass units. Microanalyses 
indicated by the symbols of the elements or functions were performed with a 
Perkin–Elmer 260 elemental analyzer (PerkinElmer, Inc., Waltham, MA) for C, 
H, and N, and the results were within ±0.4% of the theoretical values, unless 
otherwise stated. Reagents and starting material were commercially available. 
 
General procedure for acylation or benzoylation at N-1 of the 7-azaindole 
derivatives. To a cooled (0°C) suspension of the appropriate substrate (0.56 
mmol) in anhydrous CH2Cl2 (2 mL), 0.72 mmol of Et3N and 1.67 mmol of the 
appropriate acyl or benzoyl chloride were added.  The mixture was stirred at 
0°C for 2h and then at room temperature for an additional 2h. The solvent was 
evaporated, cold water was added, and the mixture was neutralized with 0.5 
N NaOH. The reaction mixture was extracted with CH2Cl2 (3 x 15 mL), the 
solvent was dried over sodium sulfate and evaporated in vacuum. The final 
compounds were purified by crystallization from ethanol or by column 
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chromatography using cyclohexane/ethyl acetate or hexane/ethyl acetate as 
eluents in different ratio. 
 
1-(3-Methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5a) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5a was purified by crystallization 
(EtOH). 
Yield = 48%; mp = 127-129°C (EtOH). 1H-NMR (DMSO-d6) δ 2.36 (s, 3H, 
CH3), 7.40-7.46 (m, 2H, Ar), 7.53-7.58 (m, 2H, Ar), 7.63 (s, 1H, Ar), 8.24 (d, 
1H, Ar, J = 8.0 Hz), 8.36 (d, 1H, Ar, J = 4.8 Hz), 8.82 (s, 1H, Ar). 13C-NMR 
(DMSO-d6) δ 21.21 (CH3), 101.00 (C), 114.37 (C), 116.00 (CH), 120.89 (CH), 
128.31 (CH), 128.86 (CH), 129.03 (CH), 131.19 (CH), 132.76 (C), 135.04 
(CH), 138.53 (C), 146.55 (CH), 147.08 (C), 149.00 (C), 167.10 (C). IR = 1693 
cm-1 (C=O), 2229 cm-1 (CN). ESI-MS calcd. for C16H11N3O, 261.28; found: m/z 
262.09 [M+H]+. Anal. C16H11N3O (C, H, N). 
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1-(4-Methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5b) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5b was purified by crystallization 
(EtOH). 
Yield = 55%; mp = 146-149°C (EtOH). 1H-NMR (DMSO-d6) δ 2.41 (s, 3H, 
CH3), 7.35 (d, 2H, Ar, J = 8.0 Hz), 7.41-7.46 (m, 1H, Ar), 7.70 (d, 2H, Ar, J = 
8.0 Hz), 8.23 (dd, 1H, Ar, J = 1.4 Hz and J = 7.8 Hz ), 8.31-8.36 (m, 1H, Ar), 
8.84 (s, 1H, Ar). 13C-NMR (DMSO-d6) δ 21.80 (CH3), 101.00 (C), 115.05 (C), 
115.62 (CH), 121.21 (C), 123.85 (CH), 128.33 (CH), 129.52 (CH), 129.59 
(CH), 129.81 (CH), 129.86 (CH), 130.00 (C), 142.40 (CH), 144.25 (C), 146.66 
(C), 167.70 (C). IR = 1697 cm-1 (C=O), 2267 cm-1 (CN). ESI-MS calcd. for 
C16H11N3O, 261.28; found: m/z 262.09 [M+H]+. Anal. C16H11N3O (C, H, N). 
 
1-(Cyclopropanecarbonyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5c) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5c was purified by crystallization 
(EtOH).  
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Yield = 84%; mp = 142-145°C (EtOH). 1H-NMR (DMSO-d6) δ 1.23-1.29 (m, 
4H, 2 x CH2), 4.00-4.05 (m, 1H, CH), 7.49-7.54 (m, 1H, Ar), 8.24 (d, 1H, Ar, J 
= 7.6 Hz), 8.55 (d, 1H, Ar, J = 4.0 Hz), 8.89 (s, 1H, Ar). 13C-NMR (DMSO-d6) 
δ 12.60 (CH2), 15.24 (CH), 89.79 (C), 114.25 (C), 120.94 (CH), 121.67 (C), 
129.50 (CH), 135.26 (CH), 146.50 (CH), 146.64 (C), 172.69 (C).   IR = 1711 
cm-1 (C=O), 2226 cm-1 (CN). ESI-MS calcd. for C12H9N3O, 211.22; found: m/z 
212.08 [M+H]+. Anal. C12H9N3O (C, H, N). 
 
1-(Cyclopentanecarbonyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5d) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5d was purified by crystallization 
(EtOH).  
Yield = 39%; mp = 97-100°C (EtOH). 1H-NMR (DMSO-d6) δ 1.63-1.68 (m, 4H, 
2 x CH2), 1.81-1.86 (m, 2H, CH2), 1.99-2.04 (m, 2H, CH2), 4.61-4.66 (m, 1H, 
CH), 7.46-7.51 (m, 1H, Ar), 8.22 (d, 1H, Ar, J = 7.6 Hz), 8.56 (d, 1H, Ar, J = 
3.6 Hz), 8.92 (s, 1H, Ar). 13C-NMR (DMSO-d6) δ 26.28 (CH2), 29.98 (CH2), 
45.19 (CH), 89.95 (C), 114.26 (C), 120.80 (CH), 121.61 (C), 129.33 (CH), 
135.69 (CH), 146.64 (C), 146.70 (CH), 174.41 (C). IR = 1710 cm-1 (C=O), 
2230 cm-1 (CN). ESI-MS calcd. for C14H13N3O, 239.27; found: m/z 240.11 
[M+H]+. Anal. C14H13N3O (C, H, N). 
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1-(Cyclohexanecarbonyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5e) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5e was purified by crystallization 
(EtOH). 
Yield = 39%; mp = 172-175°C (EtOH). 1H-NMR (DMSO-d6) δ 1.22-1.28 (m, 
1H, CH), 1.34-1.50 (m, 4H, 2 x CH2), 1.65-1.70 (m, 1H, CH), 1.77-1.82 (m, 
2H, CH2), 1.95-2.00 (m, 2H, CH2), 4.23-4.28 (m, 1H, CH), 7.48 (dd, 1H, Ar, J 
= 4.8 Hz and J = 7.6 Hz), 8.22 (d, 1H, Ar, J = 8.0 Hz), 8.57 (d, 1H, Ar, J = 4.4 
Hz), 8.90 (s, 1H, Ar). 13C-NMR (DMSO-d6) δ 25.49 (CH2), 25.79 (CH2), 28.96 
(CH2), 43.95 (CH), 90.05 (C), 114.24 (C), 120.79 (CH), 121.55 (C), 129.34 
(CH), 135.53 (CH), 140.00 (C), 146.83 (CH), 174.26 (C). IR = 1711 cm-1 
(C=O), 2220 cm-1 (CN). ESI-MS calcd. for C15H15N3O, 253.30; found: m/z 
254.12 [M+H]+. Anal. C15H15N3O (C, H, N). 
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1-(3-Cyanobenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5f) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5f was purified by column 
chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
Yield = 10%; oil. 1H-NMR (CDCl3-d1) δ 7.35-7.40 (m, 1H, Ar), 7.66 (t, 1H, Ar, 
J = 7.6 Hz), 7.95 (d, 1H, Ar, J = 8.0 Hz), 8.03 (d, 1H, Ar, J = 8.0 Hz), 8.12 (s, 
1H, Ar), 8.13 (dd, 1H, Ar, J = 1.2 Hz and J = 8.0 Hz), 8.30 (d, 1H, Ar, J = 4.4 
Hz), 8.40 (s, 1H, Ar). 13C-NMR (CDCl3-d1) δ 101.02 (C), 113.15 (C), 115.54 
(C), 115.68 (CH), 118.61 (C), 121.20 (C), 123.86 (CH), 128.33 (CH), 129.97 
(CH), 131.22 (C), 133.10 (CH), 135.43 (CH), 138.05 (CH), 142.46 (CH), 
146.66 (C), 167.75 (C). ESI-MS calcd. for C16H8N4O, 272.26; found: m/z 
273.07 [M+H]+. Anal. C16H8N4O (C, H, N). 
 
1-(4-Cyanobenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (5g) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5g was purified by column 
chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
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Yield = 39%; oil. 1H-NMR (CDCl3-d1) δ 7.35-7.40 (m, 1H, Ar), 7.81 (d, 2H, Ar, 
J = 8.0 Hz), 7.89 (d, 2H, Ar, J = 8.0 Hz), 8.12 (dd, 1H, Ar, J = 1.2 Hz and J = 
7.6 Hz), 8.29 (d, 1H, Ar, J = 4.4 Hz), 8.39 (s, 1H, Ar). 13C-NMR (CDCl3-d1) δ 
92.41 (C), 112.95 (C), 116.95 (C), 117.68 (C), 117.75 (C), 120.74 (CH), 
121.13 (C), 129.03 (CH), 130.79 (CH), 132.01 (CH), 133.95 (CH), 136.34 
(CH), 146.55 (C), 165.36 (C). ESI-MS calcd. for C16H8N4O, 272.26; found: m/z 
273.07 [M+H]+. Anal. C16H8N4O (C, H, N). 
 
1-(3-(Trifluoromethyl)benzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
(5h) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5h was purified by crystallization 
(EtOH). 
Yield = 45%; mp = 155-157°C (EtOH). 1H-NMR (CDCl3-d1) δ 7.33-7.38 (m, 
1H, Ar), 7.67 (t, 1H, Ar, J = 8.0 Hz), 7.94 (d, 1H, Ar, J = 8.4 Hz), 8.00 (d, 1H, 
Ar, J = 7.6 Hz), 8.08 (s, 1H, Ar), 8.13 (dd, 1H, Ar, J = 1.6 Hz and J = 8.0 Hz), 
8.33 (dd, 1H, Ar,  J = 1.6 Hz and J = 4.8 Hz), 8.38 (s, 1H, Ar). 13C-NMR (CDCl3-
d1) δ 92.54 (C), 113.69 (C), 121.23 (CH), 121.71 (CH), 125.40 (C), 128.33 (C, 
q, J = 31.4 Hz), 128.37 (CH), 130.82 (C, q, J = 28.8 Hz), 131.32 (CH), 131.67 
(C), 133.67 (CH), 134.32 (CH), 134.86 (CH), 147.09 (CH), 147.19 (C), 166.10 
(C). ESI-MS calcd. for C16H8F3N3O, 315.25; found: m/z 316.07 [M+H]+. Anal. 
C16H8F3N3O (C, H, N). 
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1-(4-(Trifluoromethyl)benzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
(5i) 
 
 
 
Obtained from compound 4 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 5i was purified by crystallization 
(EtOH). 
Yield = 14%; mp = 120-123°C (EtOH). 1H-NMR (CDCl3-d1) δ 7.33-7.38 (m, 
1H, Ar), 7.78 (d, 2H, Ar, J = 8.4 Hz), 7.91 (d, 2H, Ar, J = 8.0 Hz), 8.12 (d, 2H, 
Ar, J = 7.6 Hz), 8.35 (s, 1H, Ar). 13C-NMR (CDCl3-d1) δ 101.15 (C), 115.65 (C), 
121.23 (C), 121.71 (CH), 125.67 (CH), 124.13 (C, q, J = 31.6 Hz), 128.37 
(CH), 130.82 (C, q, J = 28.8 Hz), 131.32 (CH), 133.67 (CH), 136.32 (C), 
142.10 (CH), 146.19 (C), 167.70 (C). ESI-MS calcd. for C16H8F3N3O, 315.25; 
found: m/z 316.07 [M+H]+. Anal. C16H8F3N3O (C, H, N). 
 
Ethyl 1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (7a) 
 
 
 
Obtained from compound 6 (Jiang, J. H. et al. 2011) following the general 
procedure reported at pag. 81. Compound 7a was purified by crystallization 
(EtOH). 
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Yield = 25%; mp = 92-95°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.42 (t, 3H, 
OCH2CH3, J = 7.0 Hz), 2.43 (s, 3H, CH3), 4.41 (q, 2H, OCH2CH3, J = 7.0 Hz), 
7.31 (t, 1H, Ar, J = 6.0 Hz), 7.39 (t, 1H, Ar, J = 7.2 Hz), 7.47 (d, 1H, Ar, J = 6.8 
Hz), 7.56 (d, 1H, Ar, J = 7.2 Hz), 7.66 (s, 1H, Ar), 8.30 (s,1H, Ar), 8.41 (s, 1H, 
Ar), 8.48 (d, 1H, Ar, J = 7.6 Hz). 13C-NMR (CDCl3-d1) δ 14.45 (CH3), 21.37 
(CH3), 60.69 (CH2), 110.81 (C), 120.13 (CH), 120.74 (C), 127.70 (CH), 128.31 
(CH), 130.60 (CH), 130.90 (CH), 132.80 (C), 133.20 (CH), 134.30 (CH), 
138.60 (C), 145.60 (CH), 148.40 (C), 163.70 (C), 167.60 (C). ESI-MS calcd. 
for C18H16N2O3, 308.33; found: m/z 309.12 [M+H]+. Anal. C18H16N2O3  (C, H, 
N). 
 
Ethyl 1-(4-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (7b) 
 
 
 
Obtained from compound 6 (Jiang, J. H. et al. 2011) following the general 
procedure reported at pag. 81. Compound 7b was purified by crystallization 
(EtOH). 
Yield = 30%; mp = 100-103°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.42 (t, 3H, 
OCH2CH3, J = 7.2 Hz), 2.47 (s, 3H, CH3), 4.41 (q, 2H, OCH2CH3, J = 7.2 Hz), 
7.30-7.35 (m, 3H, Ar), 7.73 (d, 2H, Ar, J = 8.4 Hz), 8.32 (s, 1H, Ar), 8.40 (dd, 
1H, Ar, J = 1.6 Hz and J = 4.8 Hz), 8.48 (dd, 1H, Ar, J = 1.6 Hz and J = 7.6 
Hz). 13C-NMR (CDCl3-d1) δ 14.40 (CH3), 24.30 (CH3), 60.90 (CH2), 101.00 (C), 
120.13 (CH), 120.74 (C), 126.00 (CH), 128.31 (CH), 130.62 (CH), 130.97 
(CH), 132.86 (C), 133.20 (CH), 134.38 (CH), 138.60 (C), 145.60 (CH), 148.49 
(C), 162.50 (C), 167.70 (C). ESI-MS calcd. for C18H16N2O3, 308.33; found: m/z 
309.12 [M+H]+. Anal. C18H16N2O3 (C, H, N). 
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Ethyl 1-(cyclopropanecarbonyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate 
(7c) 
 
 
 
Obtained from compound 6 (Jiang, J. H. et al. 2011) following the general 
procedure reported at pag. 81. Compound 7c was purified by crystallization 
(EtOH). 
Yield = 73%; mp = 77-80°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.23-1.28 (m, 2H, 
CH2), 1.39-1.44 (m, 5H, 3H OCH2CH3 + 2H CH2), 4.21-4.26 (m, 1H, CH), 4.40 
(q, 2H, OCH2CH3, J = 7.2 Hz), 7.29-7.34 (m, 1H, Ar), 8.42 (dd, 1H, Ar, J = 1.6 
Hz and J = 4.6 Hz), 8.48 (dd, 1H, Ar, J = 1.6 Hz and J = 7.6 Hz), 8.63 (s, 1H, 
Ar). 13C NMR (CDCl3-d1) δ 12.42 (CH2), 14.42 (CH3), 14.94 (CH), 60.61 (CH2), 
110.42 (C), 119.86 (CH), 121.59 (C), 130.69 (CH), 131.20 (CH), 144.64 (CH), 
149.00 (C), 164.00 (C), 173.69 (C). IR = 1701 cm-1 (C=O amide), 1718 cm-1 
(C=O ester). ESI-MS calcd. for C14H14N2O3, 258.27; found: m/z 259.10 
[M+H]+. Anal. C14H14N2O3 (C, H, N). 
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Ethyl 1-(3-cyanobenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (7d) 
 
 
 
Obtained from compound 6 (Jiang, J. H. et al. 2011) following the general 
procedure reported at pag. 81. Compound 7d was purified by column 
chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
Yield = 15%; oil. 1H-NMR (CDCl3-d1) δ 1.44 (t, 3H, OCH2CH3, J = 7.0 Hz), 4.44 
(q, 2H, OCH2CH3, J = 7.0 Hz), 7.28-7.33 (m, 1H, Ar), 7.64 (t, 1H, Ar, J = 8.0 
Hz), 7.93 (d, 1H, Ar, J = 7.6 Hz), 8.03 (d, 1H, Ar, J = 8.0 Hz), 8.09 (s, 1H, Ar), 
8.24 (dd, 1H, Ar, J = 1.2 Hz and J = 4.4 Hz), 8.48-8.53 (m, 2H, Ar). 13C-NMR 
(CDCl3-d1) δ 14.42 (CH3), 60.87 (CH2), 112.37 (C), 112.73 (C), 117.73 (C), 
120.48 (CH), 120.88 (C), 129.15 (CH), 130.87 (CH), 132.09 (CH), 134.04 
(CH), 134.32 (CH), 134.42 (C), 136.14 (CH), 145.26 (CH), 147.75 (C), 163.29 
(C), 165.62 (C). ESI-MS calcd. for C18H13N3O3, 319.31; found: m/z 320.10 
[M+H]+. Anal. C18H13N3O3 (C, H, N). 
 
 
 
 
 
 
 
 
 
 
 
Material and methods 
92 
 
Ethyl 1-(4-cyanobenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (7e) 
 
 
 
Obtained from compound 6 (Jiang, J. H. et al. 2011) following the general 
procedure reported at pag. 81. Compound 7e was purified by column 
chromatography using cyclohexane/ethyl acetate 1:1 as eluent.  
Yield = 30%; oil. 1H-NMR (CDCl3-d1) δ 1.43 (t, 3H, OCH2CH3, J = 7.2 Hz), 4.43 
(q, 2H, OCH2CH3, J = 7.2 Hz), 7.27-7.32 (m, 1H, Ar), 7.79 (d, 2H, Ar, J = 8.4 
Hz), 7.88 (d, 2H, Ar, J = 8.0 Hz), 8.23 (d, 1H, Ar, J = 4.4 Hz), 8.44-8.49 (m, 
2H, Ar). 13C-NMR (CDCl3-d1) δ14.41 (CH3), 60.87 (CH2), 112.38 (C), 116.46 
(C), 117.87 (C), 120.42 (CH), 120.84 (C), 130.62 (CH), 130.84 (CH), 131.98 
(CH), 137.12 (C), 142.28 (CH), 147.82 (C), 163.29 (C), 166.08 (C). ESI-MS 
calcd. for C18H13N3O3, 319.31; found: m/z 320.10 [M+H]+. Anal. C18H13N3O3 
(C, H, N). 
 
(3-Iodo-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (10a) 
 
 
 
Obtained from compound 9a (Baltus, C. B. et al. 2016) following the general 
procedure reported at pag. 81. Compound 10a was purified by column 
chromatography using cyclohexane/ethyl acetate 6:1 as eluent. 
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Yield = 47%; oil. 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, CH3), 7.26-7.31 (m, 1H, 
Ar), 7.37 (t, 1H, Ar, J = 7.6 Hz), 7.44 (d, 1H, Ar, J = 7.2 Hz), 7.55 (d, 1H, Ar, J 
= 7.6 Hz), 7.63 (s, 1H, Ar), 7.76 (dd, 1H, Ar, J = 1.6 Hz and J = 8.0 Hz), 7.82 
(s, 1H, Ar), 8.36 (d, 1H, Ar, J = 4.8 Hz). 13C-NMR (CDCl3-d1) δ 21.70 (CH3), 
95.64 (C), 119.46 (CH), 123.68 (C), 126.78 (CH), 127.46 (CH), 128.05 (CH), 
129.11 (CH), 131.72 (CH), 133.42 (C), 133.82 (CH), 138.36 (C), 143.70 (CH), 
146.31 (C), 167.55 (C). ESI-MS calcd. for C15H11IN2O, 362.17; found: m/z 
362.99 [M+H]+. Anal. C15H11IN2O (C, H, N). 
 
(3-Bromo-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (10b) 
 
 
 
Obtained from compound 9b (Baltus, C. B. et al. 2016) following the general 
procedure reported at pag. 81. Compound 10b was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
Yield = 25%; oil. 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, CH3), 7.24-7.29 (m, 1H, 
Ar), 7.37 (t, 1H, Ar, J = 7.6 Hz), 7.44 (d, 1H, Ar, J = 7.6 Hz), 7.55 (d, 1H, Ar, J 
= 7.6 Hz), 7.63 (s, 1H, Ar), 7.76 (s, 1H, Ar), 7.89 (dd, 1H, Ar, J = 1.6 Hz and J 
= 7.6 Hz), 8.38 (dd, 1H, Ar, J = 1.6 Hz and J = 4.8 Hz). 13C-NMR (CDCl3-d1) δ 
21.77 (CH3), 96.58 (C), 119.46 (CH), 122.68 (C), 126.78 (CH), 127.46 (CH), 
128.05 (CH), 129.11 (CH), 130.59 (CH), 133.42 (C), 133.82 (CH), 138.36 (C), 
145.77 (CH), 147.03 (C), 167.08 (C). ESI-MS calcd. for C15H11BrN2O, 315.16; 
found: m/z 317.01 [M+H]+. Anal. C15H11BrN2O (C, H, N). 
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(3-Chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (10c) 
 
 
 
Obtained from compound 9c (Minakata, S. et al. 1997) following the general 
procedure reported at pag. 81. Compound 10c was purified by column 
chromatography using cyclohexane/ethyl acetate 6:1 as eluent. 
Yield = 25%; oil. 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, CH3), 7.24-7.29 (m, 1H, 
Ar), 7.37 (t, 1H, Ar, J = 7.6 Hz), 7.44 (d, 1H, Ar, J = 7.2 Hz), 7.55 (d, 1H, Ar, J 
= 7.6 Hz), 7.62 (s, 1H, Ar), 7.69 (s, 1H, Ar), 7.94 (dd, 1H, Ar, J = 1.2 Hz and J 
= 6.4 Hz), 8.39 (d, 1H, Ar, J = 4.8 Hz). 13C-NMR (CDCl3-d1) δ 20.96 (CH3), 
101.05 (C), 115.68 (CH), 121.24 (C), 123.81 (CH), 128.10 (CH), 128.36 (CH), 
129.11 (CH), 130.17 (CH), 130.42 (C), 134.81 (CH), 138.95 (C), 142.46 (CH), 
146.63 (C), 167.76 (C). ESI-MS calcd. for C15H11ClN2O, 270.72; found: m/z 
272.05 [M+H]+. Anal. C15H11ClN2O (C, H, N). 
 
 
 
 
 
 
 
 
 
 
 
 
  Material and methods 
95 
 
(3-Nitro-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (10d) 
 
 
 
Obtained from compound 9d (Robinson, M. M. et al. 1959) following the 
general procedure reported at pag. 81. Compound 10d was purified by 
column chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 35%; oil. 1H-NMR (CDCl3-d1) δ 2.44 (s, 3H, CH3), 7.39-7.46 (m, 2H, 
Ar), 7.52 (d, 1H, Ar, J = 7.6 Hz), 7.59 (d, 1H, Ar, J = 8.0 Hz), 7.68 (s, 1H, Ar), 
8.47 (dd, 1H, Ar, J = 1.6 Hz and J = 4.8 Hz), 8.59-8.64 (m, 2H, Ar). 13C-NMR 
(CDCl3-d1) δ 21.62 (CH3), 113.61 (C), 115.68 (CH), 126.15 (CH), 128.05 (C), 
128.16 (CH), 128.30 (CH), 129.18 (CH), 130.16 (CH), 130.45 (C), 134.89 
(CH), 138.91 (C), 142.42 (CH), 148.76 (C), 167.73 (C). ESI-MS calcd. for 
C15H11N3O3, 281.27; found: m/z 282.08 [M+H]+. Anal. C15H11N3O3 (C, H, N). 
 
General procedure for compounds (13a-e). To a suspension of 
intermediate 12 (0.34 mmol) (Zhang, J. et al. 2011) in 3 mL of toluene, 0.051 
mmol of Tetrakis (catalytic amount), 3 mL of Na2CO3 2M solution and 0.68 
mmol of appropriate hetero(phenyl)-boronic acid were added. The mixture 
was stirred at reflux for 4h. After cooling, ice-cold water (20 mL) was added, 
the suspension was extracted with CH2Cl2 (3 x 15 mL), dried over sodium 
sulfate and the solvent was evaporated under vacuum to afford the 
compounds, which were purified by column chromatography using 
cyclohexane/ethyl acetate 3:1 (for 13a-d) or hexane/acetone 4:1 (for 13e) as 
eluent. 
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3-(1-(Phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzonitrile (13a) 
 
 
 
Yield = 74%; oil. 1H-NMR (CDCl3-d1) δ 7.25-7.30 (m, 1H, Ar), 7.51 (t, 2H, Ar, 
J = 8.0 Hz), 7.56-7.62 (m, 2H, Ar), 7.65 (d, 1H, Ar, J = 7.6 Hz), 7.82 (dd, 1H, 
Ar, J = 1.2 Hz and J = 6.4 Hz), 7.86 (s, 1H, Ar), 7.94 (s, 1H, Ar), 8.06 (dd, 1H, 
Ar, J = 1.2 Hz and J = 8.0 Hz), 8.26 (d, 2H, Ar, J = 7.2 Hz), 8.51 (dd, 1H, Ar, 
J = 1.2 Hz and J = 4.8 Hz). ESI-MS calcd. for C20H13N3O2S, 359.40; found: 
m/z 360.08 [M+H]+. Anal. C20H13N3O2S (C, H, N). 
 
1-(Phenylsulfonyl)-3-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine (13b) 
 
 
 
Yield = 88%; oil. 1H-NMR (CDCl3-d1) δ 7.25-7.30 (m, 1H, Ar), 7.40-7.46 (m, 
1H, Ar), 7.48-7.59 (m, 2H, Ar), 7.63-7.74 (m, 1H, Ar), 7.90 (dd, 1H, Ar, J = 1.6 
Hz and J = 8.0 Hz), 7.94 (s, 1H, Ar), 8.06 (d, 1H, Ar, J = 8.0 Hz), 8.19 (d, 2H, 
Ar, J = 8.4 Hz), 8.50 (d, 1H, Ar, J = 4.8 Hz), 8.61 (d, 1H, Ar, J = 4.8 Hz), 8.87 
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(s, 1H, Ar). ESI-MS calcd. for C18H13N3O2S, 335.38; found: m/z 336.08 [M+H]+. 
Anal. C18H13N3O2S (C, H, N). 
 
3-(Furan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (13c) 
 
 
 
Yield = 90%; oil. 1H-NMR (CDCl3-d1) δ 6.48-6.53 (m, 1H, Ar), 6.61 (d, 1H, Ar, 
J = 3.2 Hz), 7.22-7.27 (m, 1H, Ar), 7.43-7.49 (m, 3H, Ar), 7.55 (t, 1H, Ar, J = 
7.2 Hz), 7.99 (s, 1H, Ar), 8.16-8.21 (m, 3H, Ar), 8.46 (dd, 1H, Ar, J = 1.2 Hz 
and J = 4.8 Hz). ESI-MS calcd. for C17H12N2O3S, 324.35; found: m/z 325.06 
[M+H]+. Anal. C17H12N2O3S (C, H, N). 
 
3-(Furan-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (13d) 
 
 
 
Yield = 94%; mp = 137-140°C (EtOH). 1H-NMR (CDCl3-d1) δ 6.68 (s, 1H, Ar), 
7.21-7.26 (m, 1H, Ar), 7.47 (t, 2H, Ar, J = 7.6 Hz), 7.52-7.58 (m, 2H, Ar), 7.77 
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(s, 1H, Ar), 7.82 (s, 1H, Ar), 7.96 (dd, 1H, Ar, J = 1.2 Hz and J = 8.4 Hz), 8.21 
(d, 2H, Ar, J = 7.6 Hz), 8.46 (dd, 1H, Ar, J = 1.2 Hz and J = 4.8 Hz). ESI-MS 
calcd. for C17H12N2O3S, 324.35; found: m/z 325.06 [M+H]+. Anal. C17H12N2O3S 
(C, H, N). 
 
1-(Phenylsulfonyl)-3-(thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine (13e) 
 
 
 
Yield = 68%; mp = 164-167°C (EtOH). 1H-NMR (CDCl3-d1) δ 7.21-7.26 (m, 
1H, Ar), 7.35 (dd, 1H, Ar, J = 1.2 Hz and J = 7.6 Hz), 7.43-7.49 (m, 4H, Ar), 
7.57 (t, 1H, Ar, J = 7.6 Hz), 7.89 (s, 1H, Ar), 8.09 (dd, 1H, Ar, J = 1.2 Hz and 
J = 7.6 Hz), 8.22 (d, 2H, Ar, J = 7.6 Hz), 8.47 (dd, 1H, Ar, J = 1.2 Hz and J = 
4.8 Hz). ESI-MS calcd. for C17H12N2O2S2, 340.42; found: m/z 341.04 [M+H]+. 
Anal. C17H12N2O2S2 (C, H, N). 
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3-(1-(3-Methylbenzoyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzonitrile (15a) 
 
 
 
Obtained from compound 14a (Lind, K. E. et al. 2008) following the general 
procedure reported at pag. 81. Compound 15a was purified by column 
chromatography using cyclohexane/ethyl acetate 4:1 as eluent. 
Yield = 42%; oil. 1H-NMR (CDCl3-d1) δ 2.44 (s, 3H, CH3), 7.26-7.31 (m, 1H, 
Ar), 7.39 (t, 1H, Ar, J = 7.6 Hz), 7.46 (d, 1H, Ar, J = 7.6 Hz), 7.56-7.61 (m, 2H, 
Ar), 7.63-7.68 (m, 2H, Ar), 7.87 (d, 1H, Ar, J = 8.0 Hz), 7.90 (d, 2H, Ar, J = 5.6 
Hz), 8.14 (d, 1H, Ar, J = 7.6 Hz), 8.41 (d, 1H, Ar, J = 3.2 Hz). 13C-NMR (CDCl3-
d1) δ 21.40 (CH3), 113.36 (C), 118.09 (C), 118.52 (C), 119.40 (CH), 121.14 
(C), 125.07 (CH), 127.47 (CH), 128.12 (CH), 129.94 (CH), 130.67 (CH), 
130.82 (CH), 130.98 (CH), 131.76 (CH), 133.53 (C), 133.90 (CH), 134.52 (C), 
138.46 (C), 145.46 (CH), 148.76 (C), 167.77 (C). ESI-MS calcd. for 
C22H15N3O, 337.37; found: m/z 338.12 [M+H]+. Anal. C22H15N3O (C, H, N). 
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(3-(Pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (15b) 
 
 
 
Obtained from compound 14b (Ibrahim, P. N. et al. 2007) following the general 
procedure reported at pag. 81. Compound 15b was purified by column 
chromatography using cyclohexane/ethyl acetate 1:1 as eluent.  
Yield = 43%; oil. 1H-NMR (CDCl3-d1) δ 2.44 (s, 3H, CH3), 7.25-7.32 (m, 1H, 
Ar), 7.39 (t, 1H, Ar, J = 7.6 Hz), 7.44 (t, 2H, Ar, J = 7.6 Hz), 7.61 (d, 1H, Ar, J 
= 7.6 Hz), 7.69 (s, 1H, Ar), 7.91 (s, 1H, Ar), 7.97 (d, 1H, Ar, J = 8.0 Hz), 8.15 
(dd, 1H, Ar, J = 1.2 Hz and J = 8.0 Hz), 8.40 (d, 1H, Ar, J = 4.4 Hz), 8.63 (d, 
1H, Ar, J = 4.0 Hz), 8.87 (s, 1H, Ar). 13C-NMR (CDCl3-d1) δ 21.54 (CH3), 
116.71 (C), 119.51 (CH), 121.37 (C), 124.10 (CH), 124.96 (CH), 127.47 (CH), 
128.19 (CH), 128.33 (CH), 129.34 (C), 130.77 (CH), 132.90 (CH), 133.57 (C), 
133.86 (CH), 135.00 (CH), 138.30 (C), 145.48 (CH), 148.13 (CH), 148.92 (C), 
167.99 (C). ESI-MS calcd. for C20H15N3O, 313.35; found: m/z 314.12 [M+H]+. 
Anal. C20H15N3O (C, H, N). 
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(3-(Furan-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (15c) 
 
 
 
Obtained from compound 14c (Ibrahim, P. N. et al. 2007) following the general 
procedure reported at pag. 81. Compound 15c was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent.  
Yield = 61%; oil. 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, CH3), 6.51 (s, 1H, Ar), 6.64 
(d, 1H, Ar, J = 3.2 Hz), 7.24-7.29 (m, 1H, Ar), 7.36 (t, 1H, Ar, J = 7.6 Hz), 7.42 
(d, 1H, Ar, J = 7.6 Hz), 7.48 (s, 1H, Ar), 7.57 (d, 1H, Ar, J = 7.6 Hz), 7.65 (s, 
1H, Ar), 7.93 (s, 1H, Ar), 8.26 (d, 1H, Ar, J = 8.0 Hz), 8.39 (d, 1H, Ar, J = 4.8 
Hz). 13C-NMR (CDCl3-d1) δ 21.60 (CH3), 106.15 (CH), 111.01 (C), 111.47 
(CH), 119.37 (CH), 120.29 (C), 122.90 (CH), 127.36 (CH), 127.05 (CH), 
129.10 (CH), 130.66 (CH), 133.60 (CH), 133.83 (C), 138.29 (C), 141.83 (CH), 
145.31 (CH), 148.17 (C), 148.65 (C), 167.73 (C). ESI-MS calcd. for 
C19H14N2O2, 302.33; found: m/z 303.11 [M+H]+. Anal. C19H14N2O2 (C, H, N). 
 
 
 
 
 
 
 
 
 
Material and methods 
102 
 
(3-(Furan-3-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone (15d) 
 
 
 
Obtained from compound 14d (Ibrahim, P. N. et al. 2007) following the general 
procedure reported at pag. 81. Compound 15d was purified by column 
chromatography using hexane/acetone 4:1 as eluent. 
Yield = 31%; oil. 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, CH3), 6.69 (s, 1H, Ar), 
7.21-7.26 (m, 1H, Ar), 7.37 (t, 1H, Ar, J = 7.2 Hz), 7.43 (d, 1H, Ar, J = 7.6 Hz), 
7.53 (s, 1H, Ar), 7.57 (d, 1H, Ar, J = 7.6 Hz), 7.66 (s, 1H, Ar), 7.80 (s, 1H, Ar), 
7.83 (s, 1H, Ar), 8.04 (dd, 1H, Ar, J = 1.2 Hz and J = 8.0 Hz), 8.36 (d, 1H, Ar, 
J = 4.8 Hz). 13C-NMR (CDCl3-d1) δ 21.39 (CH3), 109.39 (CH), 111.72 (C), 
117.78 (C), 119.18 (CH), 121.79 (C), 123.75 (CH), 127.39 (CH), 127.94 (CH), 
128.41 (CH), 130.65 (CH), 133.63 (CH), 134.05 (C), 138.20 (C), 138.95 (CH), 
143.70 (CH), 145.10 (CH), 148.83 (C), 167.95 (C). ESI-MS calcd. for 
C19H14N2O2, 302.33; found: m/z 303.11 [M+H]+. Anal. C19H14N2O2 (C, H, N). 
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(3-(Thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-tolyl)methanone 
(15e) 
 
 
 
Obtained from compound 14e (Ibrahim, P. N. et al. 2007) following the general 
procedure reported at pag. 81. Compound 15e was purified by column 
chromatography using hexane/acetone 4:1 a eluent. 
Yield = 55%; oil. 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, CH3), 7.22-7.28 (m, 1H, 
Ar), 7.34-7.39 (m, 2H, Ar), 7.41-7.46 (m, 2H, Ar), 7.52 (s, 1H, Ar), 7.58 (d, 1H, 
Ar, J = 7.2 Hz), 7.67 (s, 1H, Ar), 7.84 (s, 1H, Ar), 8.17 (dd, 1H, Ar, J = 1.6 Hz 
and J = 8.0 Hz), 8.38 (dd, 1H, Ar, J = 1.6 Hz and J = 4.8 Hz). 13C-NMR (CDCl3-
d1) δ 21.54 (CH3), 115.54 (C), 119.29 (CH), 121.09 (CH), 121.88 (C), 124.05 
(CH), 126.53 (CH), 126.74 (CH), 127.48 (CH), 128.06 (CH), 128.59 (CH), 
130.70 (CH), 133.34 (C), 133.61 (CH), 133.98 (C), 138.26 (C), 145.02 (CH), 
148.77 (C), 167.94 (C). ESI-MS calcd. for C19H14N2OS, 318.39; found: m/z 
319.19 [M+H]+. Anal. C19H14N2OS (C, H, N). 
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(E)-N-(1-(dimethylamino)ethylidene)-1H-pyrrolo[2,3-b]pyridine-3-
carboxamide (16) 
 
 
 
To a suspension of 0.68 mmol of intermediate 3 (Carbone, A. et al. 2015) in 
anhydrous toluene (2 mL), 0.30 mL of dry DMF (catalytic amount) and 2.38 
mmol of N,N-dimethylacetamide dimethyl acetal were added. The mixture was 
stirred at reflux for 2h. After cooling, ice-cold water (20 mL) was added and 
the suspension was extracted with ethyl acetate (3 x 15 mL). Evaporation of 
solvent afforded the desired compound, which was purified by column 
chromatography using CH2Cl2/MeOH 95:5 as eluent.  
Yield = 38%; oil. 1H-NMR (CDCl3-d1) δ 2.34 (s, 3H, N=C-CH3), 3.10 (s, 3H, 
NCH3), 3.19 (s, 3H, NCH3), 7.16-7.21 (m, 1H, Ar), 8.10 (s, 1H, Ar), 8.33 (dd, 
1H, Ar, J = 1.2 Hz and J = 4.4 Hz), 8.65 (dd, 1H, Ar, J = 1.6 Hz and J = 8.0 
Hz), 12.04 (exch br s, 1H, NH). ESI-MS calcd. for C12H14N4O, 230.27; found: 
m/z 231.12 [M+H]+. Anal. C12H14N4O (C, H, N). 
 
3-Methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,2,4-oxadiazole (17) 
 
 
 
A mixture of 0.26 mmol of 16, 0.39 mmol of hydroxylamine hydrochloride, 1.2 
mL of glacial acetic acid, 0.25 mL of NaOH 10% in 1.5 mL of dioxane was 
heated at reflux under stirring for 5h. After cooling, ice-cold water (20 mL) was 
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added and the precipitate was recovered by vacuum filtration to obtain the 
pure compound.  
Yield = 57%; mp = 206-209°C (EtOH). 1H-NMR (DMSO-d6) δ 2.38 (s, 3H, 
CH3), 7.27-7.32 (m, 1H, Ar), 8.36-8.41 (m, 2H, Ar), 8.47 (s, 1H, Ar), 12.75 
(exch br s, 1H, NH). ESI-MS calcd. for C10H8N4O, 200.20; found: m/z 201.07 
[M+H]+. Anal. C10H8N4O  (C, H, N). 
 
(3-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-
tolyl)methanone (18) 
 
 
 
Obtained from compound 17 following the general procedure reported at pag. 
81. Compound 18 was purified by column chromatography using 
cyclohexane/ethyl acetate 4:1 as eluent. 
Yield = 42%; mp = 151-153°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.44 (s, 3H, m-
CH3-Ph), 2.49 (s, 3H, CH3), 7.36-7.42 (m, 2H, Ar), 7.49 (d, 1H, Ar, J = 7.6 Hz), 
7.60 (d, 1H, Ar, J = 7.6 Hz), 7.68 (s, 1H, Ar), 8.44 (s, 1H, Ar), 8.48 (dd, 1H, Ar, 
J = 1.6 Hz and J = 4.8 Hz), 8.61 (dd, 1H, Ar, J = 1.6 Hz and J = 7.6 Hz). 13C-
NMR (CDCl3-d1) δ 11.68 (CH3), 21.36 (CH3), 104.38 (C), 119.59 (C), 120.34 
(CH), 127.68 (CH), 128.39 (CH), 130.31 (CH), 130.53 (CH), 130.90 (CH), 
132.66 (C), 134.48 (CH), 138.67 (C), 146.26 (CH), 148.37 (C), 167.31 (C), 
167.57 (C), 171.04 (C). ESI-MS calcd. for C18H14N4O2, 318.33; found: m/z 
319.12 [M+H]+. Anal. C18H14N4O2 (C, H, N) 
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5-Methyl-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,2,4-oxadiazole (20) 
 
 
 
To a cooled (0°C) solution of 0.39 mmol of  glacial acetic acid in dry DMF (1 
mL), 0.58 mmol of N,N’-dicyclohexylcarbodiimide (DCC) was added. The 
mixture was stirred at 0°C for 1h, then 0.39 mmol of 19 (Lape, H. E. et al. 
1968) was added and the reaction was still kept under stirring at 0°C another 
hour and then at reflux for 6h. After cooling, ice-cold water (20 mL) was added, 
the precipitate was recovered by vacuum filtration and it was purified by 
column chromatography using CH2Cl2/MeOH 9:1 as eluent.  
Yield = 51%; mp = 194-197°C (EtOH). 1H-NMR (DMSO-d6) δ 2.62 (s, 3H, 
CH3), 7.21-7.26 (m, 1H, Ar), 8.15 (s, 1H, Ar), 8.30-8.35 (m, 2H, Ar), 12.38 
(exch br s, 1H, NH). ESI-MS calcd. for C10H8N4O, 200.20; found: m/z 201.07 
[M+H]+. Anal. C10H8N4O (C, H, N). 
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(3-(5-Methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-
tolyl)methanone (21) 
 
 
 
Obtained from compound 20 following the general procedure reported at pag. 
81. Compound 21 was purified by column chromatography using 
cyclohexane/ethyl acetate 4:1 as eluent. 
Yield = 47%; mp = 139-142°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.43 (s, 3H, m-
CH3-Ph), 2.66 (s, 3H, CH3), 7.33-7.41 (m, 2H, Ar), 7.46 (d, 1H, Ar, J = 7.2 Hz), 
7.59 (d, 1H, Ar, J = 7.6 Hz), 7.67 (s, 1H, Ar), 8.32 (s, 1H, Ar), 8.47 (d, 1H, Ar, 
J = 4.4 Hz), 8.57 (d, 1H, Ar, J = 8.0 Hz). 13C-NMR (CDCl3-d1) δ 12.22 (CH3), 
21.34 (CH3), 107.01 (C), 119.99 (CH), 120.23 (C), 127.50 (CH), 128.33 (CH), 
129.28 (CH), 130.77 (CH), 131.07 (CH), 133.10 (C), 134.09 (CH), 138.56 (C), 
145.69 (CH), 148.47 (C), 163.87 (C), 167.51 (C), 176.09 (C). ESI-MS calcd. 
for C18H14N4O2, 318.33; found: m/z 319.12 [M+H]+. Anal. C18H14N4O2 (C, H, 
N).  
 
General procedure for compounds (24a,b). To a solution of the 
intermediate 23 (0.98 mmol) (Chavan, N. L. et al. 2010) in anhydrous CH2Cl2 
(5 mL), 3.92 mmol of aniline or N-methylaniline, commercially available, and 
3.92 mmol of glacial acetic acid were added. The mixture was stirred at room 
temperature for 30 min, then 1.47 mmol of sodium triacetoxyborohydride was 
added and stirred at room temperature for 24h. Cyclohexane (20 mL) was 
added and the mixture was kept under stirring for 15-30 min. After evaporation 
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of solvent, the compounds 24a,b were purified by column chromatography 
using toluene/ethyl acetate 9:1 (for 24a) or cyclohexane/ethyl acetate 3:1 (for 
24b) as eluent. 
 
N-((1-(Phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)aniline (24a) 
 
 
 
Yield = 70%; oil. 1H-NMR (CDCl3-d1) δ 4.41 (s, 2H, CH2NH), 6.67 (d, 2H, Ar, 
J = 8.0 Hz), 6.77 (d, 1H, Ar, J = 7.2 Hz), 7.15-7.21 (m, 3H, Ar), 7.45 (t, 2H, Ar, 
J = 8.0 Hz), 7.55 (t, 1H, Ar, J = 7.2 Hz), 7.68 (s, 1H, Ar), 7.88 (d, 1H, Ar, J = 
7.6 Hz), 8.14 (d, 2H, Ar, J = 7.6 Hz), 8.43 (d, 1H, Ar, J = 4.4 Hz). ESI-MS 
calcd. for C20H17N3O2S, 363.44; found: m/z 364.11 [M+H]+. Anal. C20H17N3O2S 
(C, H, N). 
 
 
 
 
 
 
 
 
 
 
  Material and methods 
109 
 
N-methyl-N-((1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-
yl)methyl)aniline (24b) 
 
 
 
Yield = 65%; oil. 1H-NMR (CDCl3-d1) δ 2.93 (s, 3H, CH3N), 4.54 (s, 2H, CH2N), 
6.76-6.83 (m, 3H, Ar), 7.10-7.15 (m, 1H, Ar), 7.25 (t, 2H, Ar, J = 7.2 Hz), 7.45 
(t, 2H, Ar, J = 8.0 Hz), 7.51-7.57 (m, 2H, Ar), 7.73 (d, 1H, Ar, J = 7.6 Hz), 8.12 
(d, 2H, Ar, J = 8.0 Hz), 8.41 (dd, 1H, Ar, J = 1.2 Hz and J = 4.8 Hz). ESI-MS 
calcd. for C21H19N3O2S, 377.46; found: m/z 378.12 [M+H]+. Anal. C21H19N3O2S 
(C, H, N). 
 
N-((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-methylaniline (25) 
 
 
 
To a solution of intermediate 24b (0.29 mmol) in anhydrous THF (3 mL), 0.87 
mmol of TBAF was added and the mixture was stirred at reflux for 4h. After 
cooling, the solvent was evaporated and cold-ice water (20 mL) was added. 
The product was recovered by extraction with CH2Cl2 (3 x 15 mL). The solvent 
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was evaporated under vacuum to afford compound 25, which was purified by 
column chromatography using cyclohexane/ethyl acetate 1:3 as eluent. 
Yield = 44%; oil. 1H-NMR (CDCl3-d1) δ 2.94 (s, 3H, CH3N), 4.64 (s, 2H, CH2N), 
6.76 (t, 1H, Ar, J = 7.2 Hz), 6.88 (d, 2H, Ar, J = 8.4 Hz), 7.02-7.07 (m, 1H, Ar), 
7.19 (s, 1H, Ar), 7.25 (t, 2H, Ar, J = 7.6 Hz), 7.86 (d, 1H, Ar, J = 8.0 Hz), 8.28 
(d, 1H, Ar, J = 4.8 Hz), 9.93 (exch br s, 1H, NH). ESI-MS calcd. for C15H15N3, 
237.30; found: m/z 238.13 [M+H]+. Anal. C15H15N3 (C, H, N). 
 
(3-((Methyl(phenyl)amino)methyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-
tolyl)methanone (26) 
 
 
 
Obtained from compound 25 following the general procedure reported at pag. 
81. Compound 26 was purified by column chromatography using 
cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 65%; oil. 1H-NMR (CDCl3-d1) δ 2.39 (s, 3H, m-CH3-Ph), 2.96 (s, 3H, 
CH3N), 4.60 (s, 2H, CH2N), 6.79 (t, 1H, Ar, J = 6.8 Hz), 6.88 (d, 2H, Ar, J = 8.0 
Hz), 7.11-7.16 (m, 1H, Ar), 7.23-7.28 (m, 2H, Ar), 7.33 (t, 1H, Ar, J = 7.6 Hz), 
7.40 (d, 1H, Ar, J = 7.6 Hz), 7.48-7.53 (m, 2H, Ar), 7.59 (s, 1H, Ar), 7.82 (d, 
1H, Ar, J = 7.6 Hz), 8.34 (dd, 1H, Ar, J = 1.2 Hz and J = 4.4 Hz). 13C-NMR 
(CDCl3-d1) δ 21.35 (CH3), 38.28 (CH3), 49.14 (CH2), 113.68 (CH), 118.86 
(CH), 122.55 (C), 125.61 (CH), 127.07 (CH), 127.37 (CH), 127.97 (CH), 
128.02 (CH), 129.31 (CH), 130.64 (CH), 133.42 (CH), 133.92 (C), 138.12 (C), 
  Material and methods 
111 
 
144.89 (CH), 149.89 (C), 167.63 (C). ESI-MS calcd. for C23H21N3O, 355.43; 
found: m/z 356.17 [M+H]+. Anal. C23H21N3O (C, H, N). 
 
Allyl phenyl((1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-
yl)methyl)carbamate (27) 
 
 
 
To a suspension of 0.30 mmol of allyl chloroformate in 0.30 mL of dioxane, 
0.45 mmol of sodium azide in 0.30 mL of water was added and stirred at room 
temperature for 1h. Then, a solution of 24a (0.36 mmol) in 0.70 mL of Na2CO3 
1% and 0.70 mL of dioxane was added and the mixture was stirred at room 
temperature overnight. After addition of a little bit of water, the precipitate was 
recovered by vacuum filtration and crystallized from ethanol to obtain the 
desired compound.  
Yield = 83%; mp = 119-122°C (EtOH). 1H-NMR (DMSO-d6) δ 4.57 (d, 2H, 
CH2=CH, J = 4.8 Hz), 4.99 (s, 2H, CH2N), 5.06-5.11 (m, 2H, OCH2CH), 5.80-
5.88 (m, 1H, CH2=CH), 7.04 (d, 2H, Ar, J = 7.6 Hz), 7.20-7.28 (m, 4H, Ar), 
7.53-7.59 (m, 3H, Ar), 7.67 (t, 1H, Ar, J = 7.2 Hz), 7.86 (d, 3H, Ar, J = 7.6 Hz), 
8.32 (d, 1H, Ar, J = 3.6 Hz). ESI-MS calcd. for C24H21N3O4S, 447.51; found: 
m/z 448.13 [M+H]+. Anal. C24H21N3O4S (C, H, N).  
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Allyl ((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)(phenyl)carbamate (28) 
 
 
 
To a solution of intermediate 27 (0.30 mmol) in anhydrous THF (3 mL), 0.90 
mmol of TBAF was added and the mixture was stirred at reflux for 3h. After 
cooling, the solvent was evaporated and cold-ice water (20 mL) was added. 
The product was recovered by extraction with DCM (3 x 15 mL). The solvent 
was evaporated under vacuum to afford compound 28, which was purified by 
column chromatography using cyclohexane/ethyl acetate 1: 3 as eluent. 
Yield = 44%; oil. 1H-NMR (CDCl3-d1) δ 4.63 (d, 2H, CH2=CH, J = 4.8 Hz), 5.01 
(s, 2H, CH2N), 5.09-5.14 (m, 2H, OCH2CH), 5.85-5.90 (m, 1H, CH2=CH), 6.70-
6.76 (m, 1H, Ar), 7.01-7.10 (m, 3H, Ar), 7.15 (s, 1H, Ar), 7.18-7.28 (m, 3H, Ar), 
8.28-8.33 (m, 1H, Ar), 11.30 (exch br s, 1H, NH). ESI-MS calcd. for 
C18H17N3O2, 307.35; found: m/z 308.14 [M+H]+. Anal. C18H17N3O2 (C, H, N).  
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Allyl ((1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridin-3-
yl)methyl)(phenyl)carbamate (29) 
 
 
 
Obtained from compound 28 following the general procedure reported at pag. 
81. Compound 29 was purified by column chromatography using 
hexane/acetone 4:1 as eluent. 
Yield = 33%; oil. 1H-NMR (CDCl3-d1) δ 2.39 (s, 3H, m-CH3-Ph), 4.62 (d, 2H, 
CH2=CH, J = 4.4 Hz), 4.97 (s, 2H, CH2N), 5.10-5.15 (m, 2H, O-CH2-CH), 5.79-
5.84 (m, 1H, CH2=CH), 7.02 (d, 2H, Ar, J = 6.4 Hz), 7.14-7.19 (m, 1H, Ar), 
7.25-7.33 (m, 5H, Ar), 7.39 (t, 2H, Ar, J = 7.2 Hz), 7.52 (s, 1H, Ar), 7.90 (s, 
1H, Ar), 8.39 (dd, 1H, Ar, J = 1.2 Hz and J = 4.8 Hz). ESI-MS calcd. for 
C26H23N3O3, 425.48; found: m/z 426.18 [M+H]+. Anal. C26H23N3O3 (C, H, N). 
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(3-((Phenylamino)methyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(m-
tolyl)methanone (30) 
 
 
 
A mixture of 29 (0.05 mmol), phenylsilane (0.50 mmol) and Tetrakis (0.005 
mmol) in CH2Cl2 (3 mL) was stirred at room temperature for 1h. After dilution 
with ice-cold water (20 mL), the suspension was extracted with CH2Cl2 (3 x 15 
mL), dried over sodium sulfate, and the solvent was evaporated under vacuum 
to afford the final compound 30, which was purified by column 
chromatography using toluene/ethyl acetate 9:1 as eluent.  
Yield = 35%; oil. 1H-NMR (CDCl3-d1) δ 2.40 (s, 3H, m-CH3-Ph), 4.47 (s, 2H, 
CH2NH), 6.76 (d, 2H, Ar, J = 8.0 Hz), 6.81 (t, 1H, Ar, J = 7.6 Hz), 7.17-7.23 
(m, 2H, Ar), 7.34 (t, 2H, Ar, J = 7.6 Hz), 7.41 (d, 1H, Ar, J = 7.2 Hz), 7.52 (d, 
1H, Ar, J = 7.6 Hz), 7.59-7.64 (m, 2H, Ar), 7.97 (d, 1H, Ar, J = 7.6 Hz), 8.37 
(d, 1H, Ar, J = 4.0 Hz). 13C-NMR (CDCl3-d1) δ 21.03 (CH3), 39.47 (CH2), 
112.65 (C), 113.52 (CH), 113.59 (CH), 115.61 (CH), 120.22 (C), 120.87 (CH), 
122.53 (CH), 128.10 (CH), 128.34 (CH), 129.19 (CH), 129.56 (CH), 130.13 
(CH), 130.45 (C), 134.82 (CH), 138.90 (C), 142.44 (CH), 147.68 (C), 149.34 
(C), 167.72 (C). ESI-MS calcd. for C22H19N3O, 341.41; found: m/z 342.16 
[M+H]+. Anal. C22H19N3O (C, H, N). 
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Ethyl 1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (31b) 
 
 
 
To a cooled solution (-78°C) of lithium diisopropylamide (LDA 2.0 M in 
THF/epthane/ethyl benzene) (0.78 mmol) in 10 mL of THF, 0.39 mmol of 
intermediate 11 (Sandham, D. A. et al. 2009) was added. The mixture was 
stirred at -78°C for 30 minutes, then 0.78 mmol of ethyl chloroformate was 
added and the reaction is still kept under stirring at -78°C another hour, and 
then at room temperature for 2h. After diluition with ice-cold water (20 mL), 
the reaction mixture was extracted with CH2Cl2 (3 x 15 mL), washed with 
Brine, dried over sodium sulfate and evaporated under vacuum to afford 
compound 31b.  
Yield = 78%; oil. 1H-NMR (CDCl3-d1) δ 1.42 (t, 3H, OCH2CH3, J = 7.2 Hz), 4.44 
(q, 2H, OCH2CH3, J = 7.2 Hz), 7.02 (s, 1H, Ar), 7.20-7.25 (m, 1H, Ar), 7.53 (t, 
2H, Ar, J = 7.6 Hz), 7.60 (t, 1H, Ar, J = 7.6 Hz), 7.86 (dd, 1H, Ar, J = 8.0 Hz 
and J = 1.2 Hz), 8.41 (d, 2H, Ar, J = 7.6 Hz), 8.53-8.58 (m, 1H, Ar). ESI-MS 
calcd. for C16H14N2O4S, 330.36; found: m/z 331.07 [M+H]+. Anal. C16H14N2O4S 
(C, H, N). 
 
 
 
 
 
 
 
Material and methods 
116 
 
2-Methyl-1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
(36) 
 
 
Obtained from compound 35 (Bahekar, R. H. et al. 2007) following the general 
procedure reported at pag. 81. Compound 36 was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
Yield = 10%; oil. 1H-NMR (CDCl3-d1) δ 2.40 (s, 3H, m-CH3-Ph), 2.74 (s, 3H, 
CH3), 7.21-7.26 (m, 1H, Ar), 7.30-7.35 (m, 1H, Ar), 7.48 (d, 2H, Ar, J = 7.6 
Hz), 7.64 (s, 1H, Ar), 7.98 (d, 1H, Ar, J = 7.2 Hz), 8.19 (d, 1H, Ar, J = 4.0 Hz). 
13C-NMR (CDCl3-d1) δ 9.43 (CH3), 20.91 (CH3), 101.37 (C), 115.65 (CH), 
115.92 (C), 121.15 (CH), 128.10 (CH), 128.36 (CH), 129.14 (CH), 130.17 
(CH), 130.49 (CH), 134.86 (CH), 137.33 (C), 138.91 (C), 142.4 (CH), 146.36 
(C), 167.70 (C). ESI-MS calcd. for C17H13N3O, 275.30; found: m/z 276.11 
[M+H]+. Anal. C17H13N3O (C, H, N). 
 
Ethyl 1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (37) 
 
 
 
Obtained from compound 32b (Baltus, C. B. et al. 2016) following the general 
procedure reported at pag. 81. Compound 37 was purified by column 
chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
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Yield = 34%; oil. 1H-NMR (CDCl3-d1) δ 1.45 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.38 
(s, 3H, CH3-Ph), 4.21 (q, 2H, OCH2CH3, J = 7.2 Hz), 7.16-7.21 (m, 1H, Ar), 
7.29-7.34 (m, 1H, Ar), 7.42 (d, 1H, Ar, J = 7.6 Hz), 7.56 (d, 1H, Ar, J = 7.6 Hz), 
7.71 (s, 1H, Ar), 8.04 (d, 1H, Ar, J = 8.0 Hz), 8.41 (d, 1H, Ar, J = 4.4 Hz). 13C-
NMR (CDCl3-d1) δ 13.94 (CH3), 21.29 (CH3), 61.59 (CH2), 111.04 (CH), 
118.64 (CH), 119.46 (C), 127.93 (CH), 128.56 (CH), 130.65 (C), 131.02 (CH), 
131.18 (CH), 134.03 (C), 135.01 (CH), 138.61 (C), 147.70 (CH), 150.05 (C), 
160.65 (C), 169.00 (C). ESI-MS calcd. for C18H16N2O3, 308.34; found: m/z 
309.12 [M+H]+. Anal. C18H16N2O3 (C, H, N). 
 
1H-Pyrrolo[2,3-b]pyridine-2-carbonitrile (39) 
 
 
 
A mixture of intermediate 38 (0.68 mmol) (Jia, H. et al. 2014) and 4 mL of 
POCl3 was stirred at reflux for 1h. After cooling, ice-cold water (20 mL) was 
added, then the suspension was extracted with CH2Cl2 (3 X 15 mL), dried over 
sodium sulfate and the solvent was evaporated under vacuum to afford 
compound 39.  
Yield = 41%; oil. 1H-NMR (CDCl3-d1) δ 7.22-7.27 (m, 1H, Ar), 7.41 (s, 1H, Ar), 
8.18 (d, 1H, Ar, J = 7.2 Hz), 8.46 (d, 1H, Ar, J = 3.6 Hz), 8.70 (exch br s, 1H, 
NH). ESI-MS calcd. for C8H5N3, 143.15; found: m/z 144.05 [M+H]+. Anal. 
C8H5N3 (C, H, N). 
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1-(3-Methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile (40) 
 
 
 
Obtained from compound 39 following the general procedure reported at pag. 
81. Compound 40 was purified by column chromatography using 
cyclohexane/ethyl acetate 2:1 as eluent. 
Yield = 41%; oil. 1H-NMR (CDCl3-d1) δ 2.41 (s, 3H, CH3-Ph), 7.25-7.33 (m, 
1H, Ar), 7.34-7.40 (m, 2H, Ar), 7.48 (d, 1H, Ar, J = 7.6 Hz), 7.58 (d, 1H, Ar, J 
= 7.6 Hz) 7.69 (s, 1H, Ar), 8.03 (dd, 1H, Ar, J = 8.0 Hz and J = 1.2 Hz), 8.38 
(d, 1H, Ar, J = 3.6 Hz). 13C-NMR (CDCl3-d1) δ 21.53 (CH3), 110.31 (C), 112.22 
(C), 118.23 (CH), 119.60 (C), 120.03 (CH), 128.32 (CH), 128.59 (CH), 131.13 
(CH), 131.61 (CH), 132.56 (C), 135.23 (CH), 138.52 (C), 148.37 (CH), 166.85 
(C). ESI-MS calcd. for C16H11N3O, 261.28; found: m/z 262.09 [M+H]+. Anal. 
C16H11N3O (C, H, N). 
 
General procedure for acylation or benzoylation at N-2 of isoxazol-5(2H)-
one. To a suspension of the appropriate substrate of type 42 (0.86 mmol) in 
10 mL of anhydrous THF, 1.72 mmol of sodium hydride (60% dispersion in 
mineral oil) and 1.03 mmol of the appropriate acyl/aroyl chloride were added. 
The mixture was stirred at room temperature overnight. The solvent was 
concentrated under vacuum to obtain the final compounds 43a-s and 45a-o, 
which were purified by column chromatography using cyclohexane/ethyl 
acetate or toluene/ethyl acetate in different ratio as eluents. 
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2-(Cyclopropanecarbonyl)-3,4-dimethylisoxazol-5(2H)-one (43a) 
 
 
 
Obtained from compound 42a (Krogsgaar-Laersen, P. et al. 1973) following 
the general procedure reported at pag. 118. Compound 43a was purified by 
column chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
Yield = 32%; oil. 1H-NMR (CDCl3-d1) δ 1.02-1.07 (m, 2H, CH2 cC3H5), 1.12-
1.17 (m, 2H, CH2 cC3H5), 1.82 (s, 3H, C4-CH3), 2.34-2.40 (m, 1H, CH cC3H5), 
2.49 (s, 3H, C3-CH3). 13C-NMR (CDCl3-d1) δ 6.26 (CH3), 10.44 (CH2), 12.50 
(CH), 13.77 (CH3), 102.41 (C), 153.33 (C), 167.77 (C), 168.74 (C). ESI-MS 
calcd. for C9H11NO3, 181.19; found: m/z 182.08 [M+H]+. Anal. C9H11NO3 (C, 
H, N). 
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3,4-Dimethyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (43b) 
 
 
 
Obtained from compound 42a (Krogsgaar-Laersen, P. et al. 1973) following 
the general procedure reported at pag. 118. Compound 43b was purified by 
column chromatography using toluene/ethyl acetate 95:5 as eluent. 
Yield = 30%; oil. 1H-NMR (CDCl3-d1) δ 1.75 (s, 3H, C4-CH3), 2.05 (s, 3H, C3-
CH3), 2.41 (s, 3H, m-CH3-Ph), 7.35 (t, 1H, Ar, J = 8.0 Hz), 7.44 (d, 1H, Ar, J = 
7.6 Hz), 7.80-7.85 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 10.99 (CH3), 20.12 
(CH3), 21.23 (CH3), 29.70 (C), 127.38 (CH), 128.65 (CH), 130.68 (CH), 135.28 
(CH), 134.10 (C), 138.70 (C), 143.10 (C), 157.61 (C), 169.57 (C). ESI-MS 
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calcd. for C13H13NO3, 231.25; found: m/z 232.09 [M+H]+. Anal. C13H13NO3 (C, 
H, N).  
 
2-(Cyclopropanecarbonyl)-4-ethyl-3-methylisoxazol-5(2H)-one (43c) 
 
 
 
Obtained from compound 42b (Sato, K. et al. 1986) following the general 
procedure reported at pag. 118. Compound 43c was purified by column 
chromatography using cyclohexane/ethyl acetate 4:1 as eluent. 
Yield = 26%; oil. 1H-NMR (CDCl3-d1) δ 0.98-1.05 (m, 2H, CH2 cC3H5), 1.10 (t, 
3H, CH2CH3, J = 7.6 Hz), 1.13-1.18 (m, 2H, CH2 cC3H5), 2.26 (q, 2H, CH2CH3, 
J = 7.6 Hz), 2.34-2.40 (m, 1H, CH cC3H5), 2.50 (s, 3H, C3-CH3). 13C-NMR 
(CDCl3-d1) δ 10.96 (CH2), 13.09 (CH3), 13.58 (CH3), 14.06 (CH), 15.53 (CH2), 
108.58 (C), 153.56 (C), 167.87 (C), 169.34 (C). ESI-MS calcd. for C10H13NO3, 
195.22; found: m/z 196.09 [M+H]+. Anal. C10H13NO3 (C, H, N). 
 
4-Ethyl-3-methyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (43d) 
 
 
 
Obtained from compound 42b (Sato, K. et al. 1986) following the general 
procedure reported at pag. 118. Compound 43d was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
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Yield = 34%; oil. 1H-NMR (CDCl3-d1) δ 1.13 (t, 3H, CH2CH3, J = 7.6 Hz), 2.31 
(q, 2H, CH2CH3, J = 7.6 Hz), 2.39 (s, 3H, m-CH3-Ph), 2.61 (s, 3H, C3-CH3), 
7.30-7.37 (m, 2H, Ar), 7.61-7.66 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 12.99 
(CH3), 13.90 (CH3), 15.13 (CH2), 21.34 (CH3), 109.02 (C), 126.61 (CH), 127.70 
(CH), 129.75 (CH), 131.41 (C), 133.78 (CH), 138.18 (C), 154.31 (C), 163.72 
(C), 167.41 (C). ESI-MS calcd. for C14H15NO3, 245.27; found: m/z 246.11 
[M+H]+. Anal. C14H15NO3 (C, H, N). 
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2-(Cyclopropanecarbonyl)-3-ethyl-4-methylisoxazol-5(2H)-one (43e) 
 
 
 
Obtained from compound 42c, commercially available, following the general 
procedure reported at pag. 118. Compound 43e was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 54%; oil. 1H-NMR (CDCl3-d1) δ 0.97-1.05 (m, 2H, CH2 cC3H5), 1.13-
1.18 (m, 2H, CH2 cC3H5), 1.20 (t, 3H, CH2CH3, J = 7.2 Hz), 1.82 (s, 3H, CH3), 
2.34-2.40 (m, 1H, CH cC3H5), 2.90 (q, 2H, CH2CH3, J = 7.2 Hz). 13C-NMR 
(CDCl3-d1) δ 6.03 (CH3), 10.37 (CH2), 12.06 (CH3), 12.66 (CH), 20.74 (CH2), 
102.22 (C), 158.53 (C), 167.89 (C), 168.23 (C). ESI-MS calcd. for C10H13NO3, 
195.22; found: m/z 196.09 [M+H]+. Anal. C10H13NO3 (C, H, N).  
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3-Ethyl-4-methyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (43f) 
 
 
 
Obtained from compound 42c, commercially available, following the general 
procedure reported at pag. 118. Compound 43f was purified by column 
chromatography using toluene/ethyl acetate 95:5 as eluent. 
Yield = 10%; oil. 1H-NMR (CDCl3-d1) δ 1.30 (t, 3H, CH2CH3, J = 7.6 Hz), 1.85 
(s, 3H, CH3), 2.44 (s, 3H, CH3-Ph), 2.64 (q, 2H, CH2CH3, J = 7.6 Hz), 7.41 (t, 
1H, Ar, J = 7.6 Hz), 7.49 (d, 1H, Ar, J = 7.6 Hz), 7.96 (d, 2H, Ar, J = 7.6 Hz). 
13C-NMR (CDCl3-d1) δ 5.92 (CH3), 11.36 (CH3), 19.55 (CH2), 21.41 (CH3), 
97.56 (C), 127.03 (C), 127.96 (CH), 128.76 (CH), 131.21 (CH), 135.47 (CH), 
138.45 (C), 161.76 (C), 161.96 (C), 167.00 (C). ESI-MS calcd. for C14H15NO3, 
245.27; found: m/z 246.11 [M + H]+. Anal. C14H15NO3 (C, H, N).  
 
Ethyl 2-(cyclopropanecarbonyl)-4-methyl-5-oxo-2,5-dihydroisoxazole-3-
carboxylate (43g) 
 
 
 
Obtained from compound 42d (Adembri, G. et al. 1965) following the general 
procedure reported at pag. 118. Compound 43g was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 38%; oil. 1H-NMR (CDCl3-d1) δ 1.11-1.16 (m, 2H, CH2 cC3H5), 1.17-
1.23 (m, 2H, CH2 cC3H5), 1.35 (t, 3H, OCH2CH3, J = 7.2 Hz), 1.95 (s, 3H, CH3), 
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2.25-2.31 (m, 1H, CH cC3H5), 4.41 (q, 2H, OCH2CH3, J = 7.2 Hz). 13C-NMR 
(CDCl3-d1) δ 6.89 (CH), 10.91 (CH2), 12.40 (CH3), 13.88 (CH3), 63.22 (CH2), 
107.85 (C), 145.28 (C), 158.92 (C), 167.45 (C), 168.67 (C). ESI-MS calcd. for 
C11H13NO5, 239.22; found: m/z 240.08 [M+H]+. Anal. C11H13NO5 (C, H, N). 
 
Ethyl 4-methyl-2-(3-methylbenzoyl)-5-oxo-2,5-dihydroisoxazole-3-
carboxylate (43h) 
 
 
 
Obtained from compound 42d (Adembri, G. et al. 1965) following the general 
procedure reported at pag. 118. Compound 43h was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 21%; oil. 1H-NMR (CDCl3-d1) δ 1.42 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.08 
(s, 3H, CH3), 2.44 (s, 3H, CH3-Ph), 4.45 (q, 2H, OCH2CH3, J = 7.2 Hz), 7.42 
(t, 1H, Ar, J = 7.6 Hz), 7.51 (d, 1H, Ar, J = 7.6 Hz), 7.97 (d, 2H, Ar, J = 7.6 Hz) 
. 13C-NMR (CDCl3-d1) δ 6.68 (CH3), 14.16 (CH3), 21.26 (CH3), 62.03 (CH2), 
101.14 (C), 126.42 (C), 128.07 (CH), 128.90 (CH), 131.34 (CH), 135.89 (CH), 
138.81 (C), 156.61 (C), 160.17 (C), 161.66 (C), 163.86 (C). ESI-MS calcd. for 
C15H15NO5, 289.28; found: m/z 290.10 [M+H]+. Anal. C15H15NO5 (C, H, N). 
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2-(Cyclopropanecarbonyl)-3-ethylisoxazol-5(2H)-one (43i) 
 
 
 
Obtained from compound 42e (Yamaguchi, M. et al. 2009) following the 
general procedure reported at pag. 118. Compound 43i was purified by 
column chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
Yield = 47%; mp = 92-95°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.05-1.10 (m, 2H, 
CH2 cC3H5), 1.14-1.19 (m, 2H, CH2 cC3H5), 1.25 (t, 3H, CH2CH3, J = 7.4 Hz), 
2.36-2.42 (m, 1H, CH cC3H5), 2.95 (q, 2H, CH2CH3, J = 7.4 Hz), 5.32 (s, 1H, 
CH). 13C-NMR (CDCl3-d1) δ 10.83 (CH2), 11.33 (CH3), 12.69 (CH), 22.69 
(CH2), 92.92 (CH), 164.65 (C), 166.69 (C), 168.69 (C). ESI-MS calcd. for 
C9H11NO3, 181.19; found: m/z 182.08 [M + H]+. Anal. C9H11NO3 (C, H, N). 
 
3-Ethyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (43j) 
 
 
 
Obtained from compound 42e (Yamaguchi, M. et al. 2009) following the 
general procedure reported at pag. 118. Compound 43j was purified by 
column chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 48%; mp = 81-84°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.32 (t, 3H, CH2CH3, 
J = 7.4 Hz), 2.40 (s, 3H, CH3-Ph), 3.09 (q, 2H, CH2CH3, J = 7.4 Hz), 5.41 (s, 
1H, CH), 7.33-7.40 (m, 2H, Ar), 7.64-7.69 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 
11.49 (CH3), 21.36 (CH3), 23.07 (CH2), 93.81 (CH), 127.02 (CH), 128.28 (CH), 
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130.23 (CH), 131.04 (C), 134.05 (CH), 138.28 (C), 163.38 (C), 166.20 (C), 
166.66 (C). ESI-MS calcd. for C13H13NO3, 231.25; found: m/z 232.09 [M+H]+. 
Anal. C13H13NO3 (C, H, N). 
 
3-Isopropyl-2-propionylisoxazol-5(2H)-one (43k) 
 
 
 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43k was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 47%; mp = 93-95°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.15 (t, 3H, CH2CH3, 
J = 7.4 Hz), 1.23 (d, 6H, CH(CH3)2, J = 6.8 Hz), 2.72 (q, 2H, CH2CH3, J = 7.4 
Hz), 3.50-3.57 (m 1H, CH(CH3)2), 5.27 (s, 1H, CH). 13C-NMR (CDCl3-d1) δ 
7.73 (CH3), 21.08 (CH3), 28.10 (CH), 28.54 (CH2), 91.70 (CH), 166.50 (C), 
168.45 (C), 169.51 (C). ESI-MS calcd. for C9H13NO3, 183.20; found: m/z 
184.09 [M+H]+. Anal. C9H13NO3 (C, H, N). 
 
2-(Cyclopropanecarbonyl)-3-isopropylisoxazol-5(2H)-one (43l) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43l was purified by column 
chromatography using cyclohexane/ethyl acetate 4:1 as eluent. 
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Yield = 27%; mp = 55-57°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.07-1.12 (m, 2H, 
CH2 cC3H5), 1.16-1.21 (m, 2H, CH2 cC3H5), 1.26 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
2.38-2.45 (m, 1H, CH cC3H5), 3.54-3.61 (m 1H, CH(CH3)2), 5.33 (s, 1H, CH). 
13C-NMR (CDCl3-d1) δ 10.88 (CH2), 12.94 (CH), 21.17 (CH3), 28.18 (CH), 
91.72 (CH), 166.50 (C), 168.45 (C), 169.51 (C). ESI-MS calcd. for C10H13NO3, 
195.22; found: m/z 196.09 [M+H]+. Anal. C10H13NO3 (C, H, N). 
 
2-(Cyclopentanecarbonyl)-3-isopropylisoxazol-5(2H)-one (43m) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43m was purified by column 
chromatography using cyclohexane/ethyl acetate 4:1 as eluent.  
Yield = 23%; oil. 1H-NMR (CDCl3-d1) δ 1.26 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
1.63-1.74 (m, 4H, 2 x CH2 cC5H9), 1.82-1.87 (m, 2H, CH2 cC5H9), 1.97-2.02 
(m, 2H, CH2 cC5H9), 3.32-3.37 (m, 1H, CH cC5H9), 3.57-3.62 (m 1H, 
CH(CH3)2), 5.30 (s, 1H, CH). 13C-NMR (CDCl3-d1) δ 21.12 (CH3), 25.95 (CH2), 
28.17 (CH), 29.56 (CH2), 43.61 (CH), 91.66 (CH), 166.68 (C), 169.74 (C), 
170.93 (C). ESI-MS calcd. for C12H17NO3, 223.27; found: m/z 224.12 [M+H]+. 
Anal. C12H17NO3 (C, H, N). 
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3-Isopropyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (43n) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43n was purified by column 
chromatography using toluene/ethyl acetate 95:5 as eluent. 
Yield = 17%; oil. 1H-NMR (CDCl3-d1) δ 1.34 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
2.41 (s, 3H, CH3-Ph), 3.70-3.78 (m 1H, CH(CH3)2), 5.42 (s, 1H, CH), 7.33-7.41 
(m, 2H, Ar), 7.62-7.67 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 21.44 (CH3), 21.96 
(CH3), 28.50 (CH), 92.85 (CH), 127.15 (CH), 128.30 (CH), 130.23 (CH), 
131.38 (C), 134.08 (CH), 138.32 (C), 163.56 (C), 166.83 (C), 171.07 (C). ESI-
MS calcd. for C14H15NO3, 245.27; found: m/z 246.11 [M+H]+. Anal. C14H15NO3 
(C, H, N). 
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3-Isopropyl-2-(4-methylbenzoyl)isoxazol-5(2H)-one (43o) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43o was purified by column 
chromatography using toluene/ethyl acetate 95:5 as eluent. 
Yield = 45%; mp = 77-79°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.33 (d, 6H, 
CH(CH3)2, J = 7.0 Hz), 2.41 (s, 3H, CH3-Ph), 3.66-3.79 (m 1H, CH(CH3)2), 
5.40 (s, 1H, CH), 7.26 (d, 2H, Ar, J = 8.0 Hz), 7.78 (d, 2H, Ar, J = 8.0 Hz). 13C-
NMR (CDCl3-d1) δ 21.91 (CH3), 22.30 (CH3), 29.05 (CH), 93.10 (CH), 129.04 
(C), 129.66 (CH), 130.69 (CH), 144.82 (C), 163.72 (C), 167.36 (C), 171.67 
(C). ESI-MS calcd. for C14H15NO3, 245.27; found: m/z 246.11 [M + H]+. Anal. 
C14H15NO3 (C, H, N).  
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3-(3-Isopropyl-5-oxo-2,5-dihydroisoxazole-2-carbonyl)benzonitrile (43p) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43p was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 14%; oil. 1H-NMR (CDCl3-d1) δ 1.31 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
3.00-3.09 (m 1H, CH(CH3)2), 6.09 (s, 1H, CH), 7.70 (t, 1H, Ar, J = 8.0 Hz), 
7.96 (d, 1H, Ar, J = 8.0 Hz), 8.41 (d, 1H, Ar, J = 8.0 Hz), 8.46 (s, 1H, Ar). 13C-
NMR (CDCl3-d1) δ 21.92 (CH3), 28.09 (CH), 86.78 (CH), 114.41 (C), 117.84 
(C), 129.29 (C), 130.69 (CH), 134.65 (CH), 134.98 (CH), 138.19 (CH), 159.16 
(C), 164.82 (C), 172.17 (C). IR = 1600 cm-1 (C=O amide), 1777 cm-1 (C=O 
ester), 2235 cm-1 (CN). ESI-MS calcd. for C14H12N2O3, 256.26; found: m/z 
257.09 [M+H]+. Anal. C14H12N2O3 (C, H, N).  
 
4-(3-Isopropyl-5-oxo-2,5-dihydroisoxazole-2-carbonyl)benzonitrile (43q) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43q was purified by column 
chromatography using cyclohexane/ethyl acetate 3:1 as eluent. 
Yield = 38%; mp = 113-115°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.30 (d, 6H, 
CH(CH3)2, J = 7.2 Hz), 3.00-3.09 (m 1H, CH(CH3)2), 6.10 (s, 1H, CH), 7.84 (d, 
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2H, Ar, J = 8.4 Hz), 8.29 (d, 2H, Ar, J = 8.0 Hz). 13C-NMR (CDCl3-d1) δ 21.29 
(CH3), 27.48 (CH), 86.16 (CH), 117.46 (C), 118.11 (C), 131.03 (CH), 132.72 
(CH), 158.88 (C), 164.28 (C), 171.60 (C). ESI-MS calcd. for C14H12N2O3, 
256.26; found: m/z 257.09 [M+H]+. Anal. C14H12N2O3 (C, H, N). 
 
3-Isopropyl-2-(3-(trifluoromethyl)benzoyl)isoxazol-5(2H)-one (43r) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43r was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
Yield = 21%; oil. 1H-NMR (CDCl3-d1) δ 1.39 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
3.73-3.78 (m 1H, CH(CH3)2), 5.51 (s, 1H, CH), 7.66 (t, 1H, Ar, J = 7.6 Hz), 
7.87 (d, 1H, Ar, J = 8.0 Hz), 8.09 (d, 1H, Ar, J = 8.0 Hz), 8.14 (s, 1H, Ar). 13C-
NMR (CDCl3-d1) δ 21.83 (CH3), 29.12 (CH), 94.07 (CH), 127.33 (C), 129.64 
(CH), 130.20 (C), 131.93 (C), 132.87 (CH), 133.45 (CH), 162.29 (C), 166.72 
(C), 171.54 (C). ESI-MS calcd. for C14H12F3NO3, 299.25; found: m/z 300.08 
[M+H]+. Anal. C14H12F3NO3 (C, H, N).  
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3-Isopropyl-2-(4-(trifluoromethyl)benzoyl)isoxazol-5(2H)-one (43s) 
 
 
 
Obtained from compound 42f (Jacobsen, N. et al. 1984) following the general 
procedure reported at pag. 118. Compound 43s was purified by column 
chromatography using cyclohexane/ethyl acetate 2:1 as eluent. 
Yield = 16%; oil. 1H-NMR (CDCl3-d1) δ 1.36 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
3.69-3.77 (m 1H, CH(CH3)2), 5.47 (s, 1H, CH), 7.75 (d, 2H, Ar, J = 8.0 Hz), 
7.97 (d, 2H, Ar, J = 8.0 Hz). 13C-NMR (CDCl3-d1) δ 21.24 (CH3), 28.51 (CH), 
93.46 (CH), 125.40 (CH), 127.30 (C), 130.09 (CH), 130.20 (C), 134.72 (C), 
161.81 (C), 166.10 (C), 170.86 (C). ESI-MS calcd. for C14H12F3NO3, 299.25; 
found: m/z 300.08 [M+H]+. Anal. C14H12F3NO3 (C, H, N). 
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General procedure for compounds (44a,b). To a suspension of the 
appropriate substrate 43l or 43n (0.36 mmol) in 5 mL of anhydrous toluene, 
0.72 mmol of Lawesson’s reagent was added. The mixture was stirred at 
reflux for 6h. After cooling, the suspension was concentrated in vacuum, 
diluted with ice-cold water (10 mL) and extracted with ethyl acetate (3 x 15 
mL). The organic phase was dried over sodium sulfate and the solvent was 
evaporated to obtain the final compounds 44a,b, which were purified by 
column chromatography using cyclohexane/ethyl acetate in different ratio as 
eluent (5:1 for 44a and 3:1 for 44b). 
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Cyclopropyl-(3-isopropyl-5-thioxoisoxazol-2(5H)-yl)methanone (44a) 
 
 
 
Yield = 26%; oil. 1H-NMR (CDCl3-d1) δ 1.17-1.24 (m, 4H, 2 x CH2 cC3H5), 1.27 
(d, 6H, CH(CH3)2, J = 6.8 Hz), 2.55-2.61 (m, 1H, CH cC3H5), 3.54-3.61 (m 1H, 
CH(CH3)2), 6.12 (s, 1H, CH). 13C-NMR (CDCl3-d1) δ 10.88 (CH2), 14.76 (CH), 
21.15 (CH3), 35.40 (CH), 106.37 (CH), 166.84 (C), 169.52 (C), 171.69 (C). 
ESI-MS calcd. for C10H13NO2S, 211.28; found: m/z 212.07 [M+H]+. Anal. 
C10H13NO2S (C, H, N). 
 
(3-Isopropyl-5-thioxoisoxazol-2(5H)-yl)-(m-tolyl)methanone (44b) 
 
 
 
Yield = 40%; oil. 1H-NMR (CDCl3-d1) δ 1.32 (d, 6H, CH(CH3)2, J = 6.4 Hz), 
2.44 (s, 3H, CH3-Ph), 2.83-2.92 (m 1H, CH(CH3)2), 7.05 (s, 1H, CH), 7.36-7.41 
(m, 2H, Ar), 7.81-7.86 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 21.09 (CH3), 37.59 
(CH3), 108.44 (CH), 122.51 (CH), 124.40 (CH), 127.37 (CH), 129.54 (CH), 
131.38 (C), 134.14 (CH), 138.32 (C), 163.56 (C), 169.76 (C), 175.11 (C). ESI-
MS calcd. for C14H15NO2S, 261.34; found: m/z 262.09 [M+H]+. Anal. 
C14H15NO2S (C, H, N). 
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2-(Cyclopropanecarbonyl)-3-methyl-4-phenylisoxazol-5(2H)-one (45a) 
 
 
 
Obtained from compound 42g (Beccalli, E. M. et al. 1987) following the 
general procedure reported at pag. 118. Compound 45a was purified by 
column chromatography using toluene/ethyl acetate 95:5 as eluent. 
Yield = 63%; mp = 83-86°C (EtOH). 1H-NMR (DMSO-d6) δ 1.02-1.07 (m, 2H, 
CH2 cC3H5), 1.09-1.15 (m, 2H, CH2 cC3H5), 2.36-2.41 (m, 1H, CH cC3H5), 2.58 
(s, 3H, C3-CH3), 7.35-7.41 (m, 1H, Ar), 7.43-7.48 (m, 4H, Ar). 13C-NMR 
(DMSO-d6) δ 10.82 (CH2), 13.25 (CH3), 15.14 (CH), 106.28 (C), 128.25 (C), 
128.58 (CH), 129.10 (CH), 129.35 (CH), 154.69 (C), 166.05 (C), 169.02 (C). 
IR = 1695 cm-1 (CO amide), 1755 cm-1 (CO ester). ESI-MS calcd. for 
C14H13NO3, 243.26; found: m/z 244.09 [M+H]+. Anal. C14H13NO3 (C, H, N).  
 
3-Methyl-2-(3-methylbenzoyl)-4-phenylisoxazol-5(2H)-one (45b) 
 
 
 
Obtained from compound 42g (Beccalli, E. M. et al. 1987) following the 
general procedure reported at pag. 118. Compound 45b was purified by 
column chromatography using hexane/ethyl acetate 5:1 as eluent. 
Yield = 52%; mp = 85-88°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.43 (s, 3H, m-CH3-
Ph), 2.79 (s, 3H, C3-CH3), 7.35-7.40 (m, 3H, Ar), 7.43-7.51 (m, 4H, Ar), 7.70-
7.75 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 15.09 (CH3), 21.58 (CH3), 108.39 (C), 
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127.08 (CH), 127.62 (C), 128.28 (CH), 128.50 (CH), 128.81 (CH), 129.08 
(CH), 130.28 (CH), 131.14 (C), 134.07 (CH), 138.32 (C), 154.62 (C), 163.79 
(C), 165.90 (C). IR = 1690 cm-1 (CO amide), 1750 cm-1 (CO ester). ESI-MS 
calcd. for C18H15NO3, 293.32; found: m/z 294.11 [M+H]+. Anal. C18H15NO3 (C, 
H, N). 
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3-(3-Methyl-5-oxo-4-phenyl-2,5-dihydroisoxazole-2-
carbonyl)benzonitrile (45c) 
 
 
 
Obtained from compound 42g (Beccalli, E. M. et al. 1987) following the 
general procedure reported at pag. 118. Compound 45c was purified by 
column chromatography using hexane/ethyl acetate 5:2 as eluent. 
Yield = 10%; mp = 118-119°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.83 (s, 3H, C3-
CH3), 7.45-7.55 (m, 5H, Ar), 7.67 (t, 1H, Ar, J = 7.2 Hz), 7.89 (d, 1H, Ar, J = 
6.4 Hz), 8.16 (d, 1H, Ar, J = 7.6 Hz), 8.20 (s, 1H, Ar). 13C-NMR (CDCl3-d1) δ 
14.94 (CH3), 107.22 (C), 112.76 (C), 118.63 (C), 127.98 (CH), 128.67 (CH), 
128.91 (CH), 129.54 (CH), 130.71 (CH), 131.86 (CH), 134.54 (C), 134.95 (C), 
135.62 (CH), 139.52 (C), 157.64 (C), 165.87 (C). ESI-MS calcd. for 
C18H12N2O3, 304.30; found: m/z 305.09 [M+H]+. Anal. C18H12N2O3  (C, H, N). 
 
3-Methyl-4-phenyl-2-(3-(trifluoromethyl)benzoyl)isoxazol-5(2H)-one 
(45d) 
 
 
 
Obtained from compound 42g (Beccalli, E. M. et al. 1987) following the 
general procedure reported at pag. 118. Compound 45d was purified by 
column chromatography using hexane/ethyl acetate 5:2 as eluent. 
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Yield = 42%; mp = 96-97°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.85 (s, 3H, C3-
CH3), 7.40-7.45 (m, 1H, Ar), 7.48-7.54 (m, 4H, Ar), 7.69 (t, 1H, Ar, J = 8.0 Hz), 
7.90 (d, 1H, Ar, J = 7.8 Hz), 8.15 (d, 1H, Ar, J = 8.0 Hz), 8.20 (s, 1H, Ar). 13C-
NMR (CDCl3-d1) δ 15.61 (CH3), 109.53 (C), 125.39 (C), 127.34 (CH), 127.38 
(C), 127.84 (CH), 129.33 (CH), 129.49 (CH), 129.63 (CH), 129.71 (CH), 
130.28 (C), 131.69 (C), 132.75 (CH), 133.47 (CH), 154.88 (C), 162.74 (C), 
166.07 (C). 19F-NMR (CDCl3-d1) δ -62.82. IR = 1689 cm-1 (CO amide), 1738 
cm-1 (CO ester). ESI-MS calcd. for C18H12F3NO3, 347.29; found: m/z 348.08 
[M+H]+. Anal. C18H12F3NO3 (C, H, N).  
 
2-(Cyclopropanecarbonyl)-4-phenylisoxazol-5(2H)-one (45e) 
 
 
 
Obtained from compound 42h (Beccalli, E. M. et al. 1984) following the 
general procedure reported at pag. 118. Compound 45e was purified by 
column chromatography using cyclohexane/ethyl acetate 6:1 as eluent. 
Yield = 28%; mp = 171-172°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.15-1.20 (m, 
2H, CH2 cC3H5), 1.26-1.31 (m, 2H, CH2 cC3H5), 2.35-2.45 (m, 1H, CH cC3H5), 
7.36 (d, 2H, Ar, J = 6.0 Hz), 7.42 (t, 1H, Ar, J = 7.2 Hz), 7.78 (d, 2H, Ar, J = 
7.2 Hz), 8.72 (s, 1H, CH). 13C-NMR (CDCl3-d1) δ 11.21 (CH2), 11.82 (CH), 
108.14 (C), 125.82 (CH), 127.46 (C), 128.64 (CH), 128.95 (CH), 136.06 (CH), 
165.97 (C), 166.76 (C). ESI-MS calcd. for C13H11NO3, 229.24; found: m/z 
230.08 [M+H]+. Anal. C13H11NO3 (C, H, N).  
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2-(3-Methylbenzoyl)-4-phenylisoxazol-5(2H)-one (45f) 
 
 
 
Obtained from compound 42h (Beccalli, E. M. et al. 1984) following the 
general procedure reported at pag. 118. Compound 45f was purified by 
column chromatography using hexane/acetone 4:1 as eluent. 
Yield = 27%; mp = 119-120°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.45 (s, 3H, CH3), 
7.37-7.46 (m, 5H, Ar), 7.80-7.85 (m, 4H, Ar), 8.89 (s, 1H, CH). 13C-NMR 
(CDCl3-d1) δ 21.39 (CH3), 108.72 (C), 124.23 (C), 125.99 (CH), 126.92 (CH), 
127.31 (CH), 128.60 (CH), 128.83 (CH), 129.01 (CH), 129.27 (CH), 129.66 
(C), 130.55 (CH), 134.65 (CH), 138.09 (CH), 138.72 (C), 160.74 (C), 166.14 
(C). ESI-MS calcd. for C17H13NO3, 279.30; found: m/z 280.09 [M+H]+. Anal. 
C17H13NO3 (C, H, N).  
 
2-(Cyclopropanecarbonyl)-4-methyl-3-phenylisoxazol-5(2H)-one (45g) 
 
 
 
Obtained from compound 42i (Beccalli, E. M. et al. 1987) following the general 
procedure reported at pag. 118. Compound 45g was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent.  
Yield = 31%; oil. 1H-NMR (CDCl3-d1) δ 1.04-1.09 (m, 2H, CH2 cC3H5), 1.10-
1.15 (m, 2H, CH2 cC3H5), 1.86 (s, 3H, C4-CH3), 2.38-2.44 (m, 1H, CH cC3H5), 
7.36-7.41 (m, 2H, Ar), 7.43-7.48 (m, 3H, Ar). 13C-NMR (CDCl3-d1) δ 7.30 
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(CH3), 10.55 (CH2), 12.71 (CH), 104.82 (C), 127.78 (C), 128.21 (CH), 128.35 
(CH), 128.51 (CH), 130.44 (CH), 154.89 (C), 168.03 (C), 168.99 (C). ESI-MS 
calcd. for C14H13NO3, 243.26; found: m/z 244.09 [M+H]+. Anal. C14H13NO3 (C, 
H, N). 
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4-Methyl-2-(3-methylbenzoyl)-3-phenylisoxazol-5(2H)-one (45h) 
 
 
 
Obtained from compound 42i (Beccalli, E. M. et al. 1987) following the general 
procedure reported at pag. 118. Compound 45h was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
Yield = 27%; oil. 1H-NMR (CDCl3-d1) δ 1.96 (s, 3H, C4-CH3), 2.40 (s, 3H, m-
CH3-Ph), 7.32-7.40 (m, 2H, Ar), 7.44-7.50 (m, 5H, Ar), 7.70 (d, 2H, Ar, J = 6.8 
Hz). 13C-NMR (CDCl3-d1) δ 7.57 (CH3), 21.63 (CH3), 105.74 (C), 127.37 (CH), 
128.01 (CH), 128.33 (CH), 128.67 (CH), 128.82 (C), 130.51 (CH), 130.60 
(CH), 131.07 (C), 134.31 (CH), 138.46 (C), 156.85 (C), 165.24 (C), 169.02 
(C). ESI-MS calcd. for C18H15NO3, 293.32; found: m/z 294.11 [M+H]+. Anal. 
C18H15NO3 (C, H, N).  
 
2-(Cyclopropanecarbonyl)-3-phenylisoxazol-5(2H)-one (45i) 
 
 
 
Obtained from compound 42j (Maquestiau, A. et al. 1974) following the 
general procedure reported at pag. 118. Compound 45i was purified by 
column chromatography using cyclohexane/ethyl acetate 5:1 as eluent.  
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Yield = 57%; oil. 1H-NMR (CDCl3-d1) δ 1.10-1.16 (m, 2H, CH2 cC3H5), 1.23-
1.28 (m, 2H, CH2 cC3H5), 1.84-1.90 (m, 1H, CH cC3H5), 6.34 (s, 1H, CH), 7.42-
7.47 (m, 3H, Ar), 7.74-7.79 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 10.82 (CH2), 
12.71 (CH), 85.75 (CH), 126.55 (CH), 128.87 (CH), 129.27 (C), 130.26 (CH), 
164.15 (C), 165.51 (C), 168.48 (C). ESI-MS calcd. for C13H11NO3, 229.23; 
found: m/z 230.08 [M+H]+. Anal. C13H11NO3 (C, H, N). 
 
2-(3-Methylbenzoyl)-3-phenylisoxazol-5(2H)-one (45j) 
 
 
 
Obtained from compound 42j (Maquestiau, A. et al. 1974) following the 
general procedure reported at pag. 118. Compound 45j was purified by 
column chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
Yield = 72%; oil. 1H-NMR (CDCl3-d1) δ 2.46 (s, 3H, m-CH3-Ph), 6.54 (s, 1H, 
CH), 7.43-7.50 (m, 5H, Ar), 7.82-7.87 (m, 2H, Ar), 8.11-8.16 (m, 2H, Ar). 13C-
NMR (CDCl3-d1) δ 21.24 (CH3), 85.88 (CH), 126.76 (CH), 126.98 (C), 127.94 
(CH), 129.04 (CH), 129.18 (C), 130.38 (CH), 131.23 (CH), 135.69 (CH), 
139.06 (C), 160.47 (C), 164.26 (C), 165.70 (C). IR = 1600 cm-1 (CO amide), 
1757 cm-1 (CO ester). ESI-MS calcd. for C17H13NO3, 279.29; found: m/z 
280.09 [M + H]+. Anal. C17H13NO3 (C, H, N). 
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2-(Cyclopropanecarbonyl)-3,4-diphenylisoxazol-5(2H)-one (45k) 
 
 
 
Obtained from compound 42k (Breslow, T. et al. 1965) following the general 
procedure reported at pag. 118. Compound 45k was purified by column 
chromatography using cyclohexane/ethyl acetate 6:1 as eluent. 
Yield = 21%; mp = 100-103°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.06-1.11 (m, 
2H, CH2 cC3H5), 1.16-1.21 (m, 2H, CH2 cC3H5), 1.80-1.86 (m, 1H, CH cC3H5), 
7.17-7.22 (m, 2H, Ar), 7.31-7.40 (m, 5H, Ar), 7.39 (d, 1H, Ar, J = 7.2 Hz), 7.46 
(d, 2H, Ar, J = 7.6 Hz). 13C-NMR (CDCl3-d1) δ 10.39 (CH2), 12.51 (CH), 103.59 
(C), 128.03 (CH), 128.31 (CH), 128.37 (CH), 128.72 (CH), 129.16 (CH), 
129.84 (CH), 134.92 (C), 142.60 (C), 170.20 (C), 180.73 (C). ESI-MS calcd. 
for C19H15NO3, 305.33; found: m/z 306.11 [M+H]+. Anal. C19H15NO3 (C, H, N).  
 
2-(3-Methylbenzoyl)-3,4-diphenylisoxazol-5(2H)-one (45l) 
 
 
 
Obtained from compound 42k (Breslow, T. et al. 1965) following the general 
procedure reported at pag. 118. Compound 45l was purified by column 
chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
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Yield = 14%; mp = 160-163°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.42 (s, 3H, m-
CH3-Ph), 7.26-7.32 (m, 5H, Ar), 7.37-7.48 (m, 7H, Ar), 7.72-7.77 (m, 2H, Ar). 
13C-NMR (CDCl3-d1) δ 21.40 (CH3), 101.40 (C), 127.48 (CH), 128.31 (CH), 
128.46 (CH), 128.53 (CH), 128.83 (CH), 130.74 (CH), 132.49 (C), 132.63 (C), 
134.21 (C), 134.52 (CH), 138.50 (C), 142.65 (C), 157.66 (C), 165.80 (C). ESI-
MS calcd. for C23H17NO3, 355.39; found: m/z 356.12 [M+H]+. Anal. C23H17NO3  
(C, H, N).  
 
2-(Cyclopropanecarbonyl)-3-(4-nitrophenyl)isoxazol-5(2H)-one (45m) 
 
 
 
Obtained from compound 42l (Maquestiau, A. et al. 1974) following the 
general procedure reported at pag. 118. Compound 45m was purified by 
column chromatography using cyclohexane/ethyl acetate 4:1 as eluent. 
Yield = 23%; mp = 160-163°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.16-1.21 (m, 
2H, CH2 cC3H5), 1.27-1.32 (m, 2H, CH2 cC3H5), 1.87-1.94 (m, 1H, CH cC3H5), 
6.43 (s, 1H, CH), 7.96 (d, 2H, Ar, J = 8.8 Hz), 8.31 (d, 2H, Ar, J = 8.8 Hz). 13C-
NMR (CDCl3-d1) δ 10.55 (CH2), 12.71 (CH), 86.27 (CH), 121.42 (C), 124.67 
(CH), 127.37 (CH), 135.22 (C), 148.74 (C), 162.53 (C), 168.75 (C). ESI-MS 
calcd. for C13H10N2O5, 274.23; found: m/z 275.06 [M+H]+. Anal. C13H10N2O5  
(C, H, N). 
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2-(3-Methylbenzoyl)-3-(4-nitrophenyl)isoxazol-5(2H)-one (45n) 
 
 
 
Obtained from compound 42l (Maquestiau, A. et al. 1974) following the 
general procedure reported at pag. 118. Compound 45n was purified by 
column chromatography using cyclohexane/ethyl acetate 5:1 as eluent. 
Yield = 40%; mp = 177-180°C dec. (EtOH). 1H-NMR (DMSO-d6) δ 2.42 (s, 3H, 
m-CH3-Ph), 7.13 (s, 1H, CH), 7.54 (t, 1H, Ar, J = 7.6 Hz), 7.64 (d, 1H, Ar, J = 
7.6 Hz), 7.95-8.00 (m, 2H, Ar), 8.20 (d, 2H, Ar, J = 8.8 Hz), 8.36 (d, 2H, Ar, J 
= 8.8 Hz).  13C-NMR (DMSO-d6) δ 21.27 (CH3), 124.60 (CH), 125.76 (C), 
126.91 (CH), 127.99 (CH), 128.28 (CH), 128.91 (CH), 130.18 (CH), 131.20 
(C), 133.90 (CH), 136.50 (C), 138.35 (C), 148.54 (C), 160.45 (C), 167.84 (C). 
ESI-MS calcd. for C17H12N2O5, 324.29; found: m/z 325.08 [M+H]+. Anal. 
C17H12N2O5 (C, H, N). 
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N-(4-(2-(3-methylbenzoyl)-5-oxo-2,5-dihydroisoxazol-3-
yl)phenyl)acetamide (45o) 
 
 
 
Obtained from compound 42m (Belzecki, C. et al. 1958) following the general 
procedure reported at pag. 118. Compound 45o was purified by column 
chromatography using cyclohexane/ethyl acetate 1:1 as eluent. 
Yield = 21%; oil. 1H-NMR (CDCl3-d1) δ 2.20 (s, 3H, CH3CO), 2.45 (s, 3H, m-
CH3-Ph), 6.50 (s, 1H, CH), 7.42 (t, 1H, Ar, J = 7.8 Hz), 7.50 (d, 1H, Ar, J = 7.6 
Hz), 7.56 (exch br s, 1H, NH), 7.62 (d, 2H, Ar, J = 8.0 Hz), 7.76 (d, 2H, Ar, J 
= 8.4 Hz), 7.98-8.13 (m, 2H, Ar). 13C-NMR (CDCl3-d1) δ 21.30 (CH3), 24.81 
(CH3), 85.70 (C), 119.72 (CH), 127.45 (CH), 127.93 (CH), 128.88 (CH), 
129.65 (C), 131.17 (CH), 134.11 (C), 135.75 (CH), 138.99 (C), 139.73 (C), 
156.05 (C), 157.65 (C), 167.14 (C), 168.90 (C). ESI-MS calcd. for C19H16N2O4, 
336.34; found: m/z 337.11 [M+H]+. Anal. C19H16N2O4 (C, H, N). 
 
General procedure for compounds (46a-c). A mixture of the appropriate 
intermediates (42a, 42f, 42g) (0.63 mmol) (Krogsgaar-Laersen, P. et al. 1973) 
(Jacobsen, N. et al. 1984) (Beccalli, E. M. et al. 1987), K2CO3 (1.26 mmol), 
and 3-methyl benzyl chloride (0.95 mmol) in 2 mL of anhydrous acetonitrile 
was stirred at reflux for 2h. After cooling, the mixture was concentrated under 
vacuum, diluted with ice-cold water (10 mL), and extracted with ethyl acetate 
(3 x 15 mL). The organic phase was dried over sodium sulfate, and the solvent 
was evaporated under vacuum to obtain the final compounds 46a-c, which 
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were purified by column chromatography using cyclohexane/ethyl acetate in 
different ratio as eluent (1:1 for 46a, 2:1 for 46b and 46c). 
 
3,4-Dimethyl-2-(3-methylbenzyl)isoxazol-5(2H)-one (46a) 
 
 
 
Yield = 26%; mp = 80-83°C (EtOH). 1H-NMR (CDCl3-d1) δ 1.73 (s, 3H, C4-
CH3), 2.13 (s, 3H, C3-CH3), 2.32 (s, 3H, m-CH3-Ph), 4.59 (s, 2H, CH2), 7.03-
7.12 (m, 3H, Ar), 7.20 (t, 1H, Ar, J = 7.6 Hz). 13C-NMR (CDCl3-d1) δ 6.75 (CH3), 
11.30 (CH3), 29.70 (CH3), 55.18 (CH2), 100.16 (C), 125.42 (CH), 128.63 (CH), 
129.10 (CH), 129.19 (CH), 133.40 (C), 138.50 (C), 160.32 (C), 171.85 (C). 
ESI-MS calcd. for C13H15NO2, 217.26; found: m/z 218.11 [M+H]+. Anal. 
C13H15NO2 (C, H, N). 
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3-Isopropyl-2-(3-methylbenzyl)isoxazol-5(2H)-one (46b) 
 
 
 
Yield = 14%; oil. 1H-NMR (CDCl3-d1) δ 1.24 (d, 6H, CH(CH3)2, J = 6.8 Hz), 
2.33 (s, 3H, m-CH3-Ph), 2.73-2.79 (m, 1H, CH(CH3)2), 4.74 (s, 2H, CH2), 5.00 
(s, 1H, CH), 7.02-7.07 (m, 2H, Ar), 7.12 (d, 1H, Ar, J = 7.6 Hz), 7.22 (t, 1H, Ar, 
J = 7.4 Hz). 13C-NMR (CDCl3-d1) δ 21.41 (CH3), 21.60 (CH3), 26.58 (CH), 
56.00 (CH2), 81.50 (CH), 124.93 (CH), 129.40 (CH), 133.87 (CH), 138.22 (C), 
138.81 (CH), 141.50 (C), 171.51 (C), 174.09 (C). ESI-MS calcd. for 
C14H17NO2, 231.29; found: m/z 232.13 [M+H]+. Anal. C14H17NO2 (C, H, N). 
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3-Methyl-2-(3-methylbenzyl)-4-phenylisoxazol-5(2H)-one (46c) 
 
 
 
Yield = 57%; oil. 1H-NMR (CDCl3-d1) δ 2.35 (s, 6H, 2 x CH3), 4.79 (s, 2H, CH2), 
7.07-7.14 (m, 3H, Ar), 7.22-7.28 (m, 2H, Ar), 7.38 (t, 2H, Ar, J = 7.8 Hz), 7.45 
(d, 2H, Ar, J = 7.2 Hz). 13C-NMR (CDCl3-d1) δ 12.44 (CH3), 21.63 (CH3), 54.90 
(CH2), 103.58 (C), 125.16 (CH), 127.17 (CH), 128.21 (CH), 128.58 (CH), 
128.82 (CH), 128.90 (CH), 129.40 (CH), 129.77 (C), 133.45 (C), 138.75 (C), 
158.65 (C), 169.53 (C). ESI-MS calcd. for C18H17NO2, 279.33; found: m/z 
280.13 [M+H]+. Anal. C18H17NO2 (C, H, N). 
 
General procedure for compounds (50a-c). To suspension of the substrate 
49 (0.37 mmol) (Wierenga, W. et al. 1984) in tert-Butanol (3 mL), 0.41 mmol 
of K2CO3 and 0.74 mmol of the appropriate acyl chloride were added. The 
mixture was stirred at reflux for 3h. After evaporation of the solvent, the 
residue was mixed with ice-cold water (20 mL) and extracted with ethyl 
acetate (3 x 15 mL). The organic phase was dried over sodium sulfate, and 
the solvent was evaporated under vacuum to afford the final compounds 50a-
c, which were purified by column chromatography using cyclohexane/ethyl 
acetate (5:1) as eluent. 
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1-Propionylbenzo[c]isoxazol-3(1H)-one (50a) 
 
 
 
Yield = 10%; oil. 1H-NMR (CDCl3-d1) δ 1.28 (t, 3H, CH2CH3, J = 7.4 Hz), 2.83 
(q, 2H, CH2CH3, J = 7.2 Hz), 7.38 (t, 1H, Ar, J = 7.6 Hz), 7.78 (t, 1H, Ar, J = 
7.6 Hz), 7.89 (d, 1H, Ar, J = 8.0 Hz), 8.11 (d, 1H, Ar, J = 8.4 Hz). 13C-NMR 
(CDCl3-d1) δ 9.72 (CH3), 20.70 (CH2), 120.35 (CH), 122.50 (C), 124.09 (CH), 
130.31 (CH), 133.90 (CH), 142.44 (C), 166.02 (C), 172.05 (C). ESI-MS calcd. 
for C10H9NO3, 191.18; found: m/z 192.06 [M+H]+. Anal. C10H9NO3 (C, H, N). 
 
1-Pentanoylbenzo[c]isoxazol-3(1H)-one (50b) 
 
 
 
Yield = 12%; oil. 1H-NMR (CDCl3-d1) δ 0.87 (t, 3H, CH3CH2CH2CH2CO, J = 
6.8 Hz), 1.53-1.58 (m, 2H, CH3CH2CH2CH2CO), 1.98-2.03 (m, 2H, 
CH3CH2CH2CH2CO), 3.63 (t, 2H, CH3CH2CH2CH2CO, J = 6.8 Hz), 7.22 (d, 
1H, Ar, J = 8.4 Hz), 7.31 (t, 1H, Ar, J = 7.4 Hz), 7.68 (t, 1H, Ar, J = 7.6 Hz), 
7.86 (d, 1H, Ar, J = 7.6 Hz). 13C-NMR (CDCl3-d1) δ 13.10 (CH3), 22.15 (CH2), 
27.65 (CH2), 28.21 (CH2), 120.31 (CH), 122.49 (C), 124.00 (CH), 130.33 (CH), 
133.90 (CH), 142.41 (C), 165.31 (C), 172.22 (C). ESI-MS calcd. for 
C12H13NO3, 219.24; found: m/z 220.09 [M+H]+. Anal. C12H13NO3 (C, H, N). 
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1-(3-methylbenzoyl)benzo[c]isoxazol-3(1H)-one (50c) 
 
 
 
Yield = 53%; mp = 116-119°C (EtOH). 1H-NMR (CDCl3-d1) δ 2.44 (s, 3H, CH3), 
7.39-7.45 (m, 3H, Ar), 7.75-7.80 (m, 2H, Ar), 7.83 (t, 1H, Ar, J = 8.4 Hz), 7.92 
(d, 1H, Ar, J = 8.0 Hz), 8.22 (d, 1H, Ar, J = 8.4 Hz). 13C-NMR (CDCl3-d1) δ 
21.40 (CH3), 115.83 (CH), 117.51 (C), 125.60 (CH), 126.03 (CH), 126.87 
(CH), 128.34 (CH), 130.12 (CH), 133.40 (C), 133.81 (CH), 136.54 (CH), 
137.80 (C), 151.60 (C), 158.51 (C), 172.03 (C). ESI-MS calcd. for C15H11NO3, 
253.25; found: m/z 254.08 [M+H]+. Anal. C15H11NO3 (C, H, N). 
 
6.2 BIOLOGY 
6.2.1 HNE inhibition assay 
Compounds were dissolved in 100% DMSO at 5 mM stock concentrations. 
The final concentration of DMSO in the reactions was 1%, and this level of 
DMSO had no effect on enzyme activity. The HNE inhibition assay was 
performed in black flat-bottom 96-well microtiter plates. Briefly, a buffer 
solution containing 200 mM Tris–HCl, pH 7.5, 0.01% bovine serum albumin, 
0.05% Tween-20, and 20 mU/mL of HNE (Calbiochem) was added to wells 
containing different concentrations of each compound. The reaction was 
initiated by addition of 25 µM elastase substrate (N-methylsuccinyl-Ala-Ala-
Pro-Val-7-amino-4-methylcoumarin, Calbiochem) in a final reaction volume of 
100 µL/well. Kinetic measurements were obtained every 30 s for 10 min at 25 
°C using a Fluoroskan Ascent FL fluorescence microplate reader (Thermo 
Electron, MA) with excitation and emission wavelengths at 355 and 460 nm, 
respectively. For all compounds tested, the concentration of inhibitor that 
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caused 50% inhibition of the enzymatic reaction (IC50) was calculated by 
plotting % inhibition versus logarithm of inhibitor concentration (at least six 
points). The data are presented as the mean values of at least three 
independent experiments with relative standard deviations of <15%. 
 
6.2.2 Analysis for compounds stability 
Spontaneous hydrolysis of selected derivatives was evaluated at 25 °C in 
0.05 M phosphate buffer, pH 7.3. Kinetics of hydrolysis were monitored by 
measuring changes in absorbance spectra over time using a SpectraMax Plus 
microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). 
Absorbance (At) at the characteristic absorption maxima of each compound 
was measured at the indicated times until no further absorbance decreases 
occurred (A∞) (Forist, A. A. and Weber, D. J. 1973). Using these 
measurements, we created semi-logarithmic plots of log(At–A∞) versus time, 
and k′ values were determined from the slopes of these plots. Half-conversion 
times were calculated using t1/2 = 0.693/k′ (Crocetti, L. et al. 2011).  
 
6.3 MOLECULAR MODELING 
Initial structures of the compounds were generated with HyperChem 8.0 
(Shimadzu Corporation, Kyoto, Japan) and optimized by the semi-empirical 
PM3 method. Docking of the molecules was performed using Molegro Virtual 
Docker (CLC Bio, København, Denmark) (MVD), version 4.2.0 (CLC Bio, 
København, Denmark) (Crocetti, L. et al. 2013). The structure of HNE 
complexed with a peptide chloromethyl ketone inhibitor (Navia, M. A. et al. 
1989) was used for the docking study (1HNE entry of the Protein Data Bank). 
The search area for docking poses was defined as a sphere with a 10 Å radius 
centered at the nitrogen atom in the five-membered ring of the peptide 
chloromethyl ketone inhibitor. After removal of this peptide and co-crystallized 
water molecules from the program workspace, we set side chain flexibility for 
the 42 residues closest to the centre of the search area (Crocetti, L. et al. 
2013). Fifteen docking runs were performed for each compound, with full 
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flexibility of a ligand around all rotatable bonds and side chain flexibility of the 
above-mentioned residues of the enzyme. Parameters used within Docking 
Wizard of the Molegro program were as described in our previous work 
(Crocetti, L. et al. 2013).  The docking poses corresponding to the lowest-
energy binding mode of each inhibitor were evaluated for the ability to form a 
Michaelis complex between the hydroxyl group of Ser195 and the carbonyl 
group in the amido moiety of an inhibitor. For this purpose, values of d1 
[distance O(Ser195)·C between the Ser195 hydroxyl oxygen atom and the 
inhibitor carbonyl carbon atom closest to O(Ser195)] and α [angle 
O(Ser195)···C=O, where C=O is the carbonyl group of an inhibitor closest to 
O(Ser195)] were determined for each docked compound (Peters, M. B. and 
Merz, K. M. 2006). In addition, we estimated the possibility of proton transfer 
from Ser195 to Asp102 through His57 (the key catalytic triad of serine 
proteases) by calculating distances d2 between the NH hydrogen in His57 and 
carboxyl oxygen atoms in Asp102, as described in our previous work (Crocetti, 
L. et al. 2013). The distance between the hydroxyl proton in Ser195 and the 
pyridine-type nitrogen in His57 is also important for proton transfer. However, 
because of easy rotation of the hydroxyl about the C–O bond in Ser195, we 
measured distance d3 between the oxygen in Ser195 and the basic nitrogen 
atom in His57. The effective length L of the channel for proton transfer was 
calculated as L = d3 + min (d2). 
 
6.4 CRYSTALLOGRAPHIC ANALYSIS 
The data were collected at 100(2)K on Xcalibur3 CCD 4-circle diffractometer 
using a graphite monochromator, Mo Ka radiation. A reference frame was 
monitored every 50 frames to control the stability of the crystal, and the system 
revealed no intensity decay. The data set was corrected for Lorentz, 
polarization effects, and absorption corrections were performed by the 
ABSPACK (CrysAlis RED Oxford Diffraction) multi-scan procedure of the 
CrysAlis data reduction package. The structure was solved using the direct 
method with SUPERFLIP (Palatinus, L. and Chapuis, G. 2007) software, and 
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the refinement was carried out using the SHELXL-2013 (Sheldrick, G. M. 
1990) software package. All non-hydrogen atoms were located from the initial 
solution or from subsequent electron density difference maps during the initial 
course of the refinement. After locating the non-hydrogen atoms, the models 
were refined against F2, first using isotropic and finally anisotropic thermal 
displacement parameters. Hydrogen atoms have been introduced as “riding 
hydrogens”. Programs used in the crystallographic calculations included 
WinGX4 (Farrugia, L. J. 2012) and Mercury (Mercury CSD 3.6, Copyright 
CCDC 2001-2015) for graphics.  
 
 
Fig. 28: X-ray structure for compound 43j 
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Table 9:  Crystal data and structure refinement for 43j. 
Empirical formula                  C13 H13NO3 
Formula weight                     231.24 
Temperature                    298(2) K 
Wavelength                         1.54184Å 
Crystal system  Monoclinic 
Space group        P 21/c 
Unit cell dimensions               a = 9.7480(2) Å   alpha = 90°. 
                                         b = 14.0846(3) Å   beta = 91.372(2)°. 
                                         c = 8.10170(10) Å   gamma = 90°. 
Volume                             1112.02(4) Å3 
Z    4 
Calculated density              1.381 Mg/m3 
Absorption coefficient            0.814 mm-1 
F(000)                             488 
Crystal size                       0.35 x0.25x0.22mm 
Theta range for data collection 5.520 to 72.227 deg. 
Limiting indices                   -11<=h<=11, -16<=k<=16, -9<=l<=7 
Reflections collected / unique 6174 / 2114 [R(int) = 0.0276] 
Completeness to theta            70.000    98.9 % 
Refinement method                         Full-matrix least-squares on F2 
Data / restraints / parameters 2114 / 0 / 206 
Goodness-of-fit on F2                   1.100 
Final R indices [I>2sigma(I)]   R1 = 0.0386, wR2 = 0.0937 
R indices (all data)                      R1 = 0.0498, wR2 = 0.1017 
Largest diff. peak and hole               0.203 and -0.349 e.A- 
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Fig. 29: X-ray structure for compound 45a 
 
Table 10:  Crystal data and structure refinement for 45a. 
Empirical formula                  C14 H13 N O3 
Formula weight                     243.25 
Temperature                        298(2) K 
 Wavelength                         1.54184 Å 
Crystal system    Orthorhombic 
Space group           P 21 21 21 
Unit cell dimensions               a = 7.4305(2) Å   alpha = 90 deg. 
                                         b = 10.6042(3) Å    beta = 90 deg. 
                                         c = 15.1154(4) Å   gamma = 90 deg. 
Volume                          191.01(6) Å3      
Z     4 
Calculated density              1.357 Mg/m3 
Absorption coefficient            0.790 mm-1 
F(000)                             512 
Crystal size                       0.35 x 0.25 x 0.20 mm 
Theta range for data collection  5.855 to 71.849 deg. 
Limiting indices                   -4<=h<=8, -8<=k<=12, -18<=l<=18 
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Reflections collected / unique 4302 / 2073 [R(int) = 0.0361] 
Completeness to theta            70.000    97.7 % 
Refinement method                  Full-matrix least-squares on F2 
Data / restraints / parameters           2073 / 0 / 215 
Goodness-of-fit on F^2             1.184 
Final R indices [I>2sigma(I)]      R1 = 0.0392, wR2 = 0.0897 
R indices (all data)                           R1 = 0.0518, wR2 = 0.0976 
Absolute structure parameter   0.1(2) 
Largest diff. peak and hole        0.153 and -0.184 e. Å-3 
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1. INTRODUCTION 
 
1.1 Iron overload and iron chelators 
Iron is an essential metal in all living organisms, but it can become toxic when 
present in excess because there is no physiologic excretory pathway for this 
essential element. In the presence of molecular oxygen, “loosely-bound” iron 
undergoes to redox cycle between the two most stable oxidation states 
thereby generating oxygen-derived free radicals, such as the hydroxyl radical 
(Halliwell, B. et al. 1998). This last one is highly reactive and it is able to 
interact with most types of biological molecules including sugars, lipid, 
proteins and nucleic acids, resulting in peroxidative tissue damage. The 
uncontrolled production of these highly reactive species is undesirable, thus 
cells adopted a number of protective strategies to prevent their formation and 
following tissue damage. These cellular mechanisms include the efficient 
control of iron storage, transport and distribution (Crichton, R. R. 1991).  
In healthy individuals, iron levels are under extremely tight control and rarely 
iron-catalyzed free radical generating reactions occur (Zhou, T. et al. 2011). 
However, in some cases the iron status can change, either locally as in 
ischemic tissue, or systematically due to genetic hemochromatosis or 
transfusion-induced iron overload (e.g. β-thalassemia major and sickle cell 
anemia). In patients affected by β-thalassemia major, regular blood 
transfusions lead to elevated body iron levels due to inability to excrete iron. 
Each unit of blood (400 mL) contains approximately 250 mg of iron and thus 
if received more than twice per annum, the patient will begin to rapidly 
accumulate iron. Excess of iron is mainly located in the liver and the spleen 
but its levels gradually increase in the heart and endocrine tissue over a period 
of years (Ma, Y. et al. 2012). In these cases, the elevated levels of iron 
ultimately lead to free radical-mediated tissue damage and eventually death 
(Brittenham, G. M. 1991). Although excess of iron can be removed by 
venesection where an adequate erythropoietic reserve exists, iron chelation 
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is the only effective way to relieve iron overload in transfusion-dependent 
patients. In this view, the design of an orally active iron chelator has been a 
major research objective resulting in the development of a large number of 
iron chelators (Hider, R. C. and Zhou, T. 2005). In the design of iron chelators 
for clinical applications, it is necessary to evaluate the efficacy of the iron 
chelator by measuring the amount of iron eliminated during use of the chelator 
and comparing that with the amount of iron input. However, efficacy 
assessment may be somewhat more complicated, because one is concerned 
not only in achieving a negative iron balance, but also in minimizing iron-
induced organ toxicity. Since some chelators may be more effective in 
removing iron from some tissues/organs than others, in part based upon their 
ability to access these sites, organ-specific iron removal is another key factor 
in the assessment of efficacy (Galanello, R. 2007). In addition to the efficacy, 
other important parameters that must be considered in the design of an ideal 
iron chelator are metal selectivity and affinity, kinetic stability of the complex, 
iron-binding capacity, bioavailability and toxicity (Zhou, T. et al. 2011).  
Many examples of iron chelators are reported in the literature and numerous 
compound are currently approved for clinical use in the treatment of the 
pathologies characterized by iron overload. Below are reported two important 
examples of compounds that have been commonly used in therapy as iron 
chelators: Desferrioxamine and Deferiprone (Ma, Y. et al. 2012). 
 
Desferrioxamine (DFO) (Fig. 1) is a natural hexadentate chelator produced by 
the microorganism Streptomyces pilosus. It is used to treat diseases 
characterized by iron overload and it shows a high lipophilicity, being able to 
interact with iron in the hepatocytes both at the intracellular and extracellular 
levels; it promotes iron excretion through the urinary tract and bile ducts and 
it shows a good selectivity for Iron(III). Despite this, Desferrioxamine is not 
considered a good therapeutic agent due to oral inefficiency and rapid kidney 
clearance (plasma half-life 5-10 minutes) (Summers, M. R. et al. 1979), 
allowing only parenteral administration, typically as an 8- to 12-hour nightly 
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infusion for 5–7 nights a week (Pippard, M. J. et al. 1978). Although, DFO 
showed a safe drug for the treatment of elevated iron burden in the body, 
intensive therapy in young patients with lower body iron stores may results in 
serious neurotoxicity and additional adverse effects (Porter, J. B. et al. 1989) 
(Olivieri, N. F. et al. 1986).  
 
 
Fig. 1: Desferrioxamine 
 
Deferiprone (DFP, Ferriprox™, Kelfer™) (Fig. 2) belong to a series of 
hydroxypyridinone-based iron chelators synthesized in the early 80s in the 
laboratory of Professor R. Hider in London (Dobbin, P. S. et al. 1993). DFP 
was licensed for use in India in 1994 and in Europe in 1999, receiving full 
marketing authorization in 2002 and FDA approval in 2011. 
 
 
Fig. 2: Deferiprone 
 
A particularly important feature of Deferiprone is the ability to penetrate into 
the cells, and form a neutral complex by coordinating iron, which is also able 
to permeate cell membranes. Thus, iron can be readily removed from iron-
loaded cells including those of cardiac tissue (Fig. 3) (Glickstein, H. et al. 
2006) (Ma, Y. et al. 2012). This ability extends to clinical applications (Pennel, 
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D. J. et al. 2006) (Hershko, C. et al. 2004), where it has been directly 
demonstrated that Deferiprone therapy is associated with significantly greater 
cardiac protection than Desferrioxamine in patients with thalassemia major 
(Borgna-Pignatti, C. et al. 2006) (Pepe, A. et al. 2011). DFP is rapidly and 
completely absorbed after oral administration, with a plasma peak level 
typically occurring about 1 hour after administration. In addition, DFP is rapidly 
eliminated from the body (i.e. half-life of about 2 hours) due to hepatic 
biotransformation, with glucuronidation accounting for almost all the 
metabolism (i.e. about 90% of the drug is excreted in the urine as the 
glucuronide). Long-term therapy with Deferiprone is associated with the 
occurrence of transient gastrointestinal symptoms (GI) such as nausea, 
vomiting, and abdominal pain, which are the most frequently reported adverse 
symptoms for DFP (Galanello, R. 2007), although also a low incidence of 
reversible agranulocytosis has been occasionally found (Ceci, A. et al. 2002).  
 
 
Fig. 3: Schematic representation of the Deferiprone penetration [LH]0 
through the plasma membrane 
 
1.2 Prostate cancer and gallium chelators 
Prostate cancer is the most common malignancy in men and a major cause 
of cancer death. It is classified as an adenocarcinoma that begins when 
normal semen-secreting prostate gland cells mutate into cancer cells. Aside 
from age and race, the only established risk factor for prostate cancer is a 
family history of the disease. The risk for first-degree relatives of men with 
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prostate cancer is about twice that for men in the general population (Goldgar, 
D. E. et al. 1994) (Schaid, D. J. 2004). This familial risk is more than four times 
higher than in the general population for first-degree relatives of men with 
prostate cancer diagnosed younger than 60 years (Johns, L. E. and Houlston, 
R. S. 2003). Its incidence differs between countries due to coverage of 
prostate-specific antigen (PSA) screening, but in both populations with and 
without PSA screening, prostate cancer is the cause of 1–2% of death in men 
(Cancer Research UK, 2011). It was estimated that in 2012 there would be 
241,740 new cases of prostate cancer diagnosed in the United States and that 
28,170 men would die of the disease. When detected early, and when disease 
is only localized in the prostate gland, the 5-years survival rate is nearly 100%. 
However, once the cancer has spread beyond the prostate, survival rates fall 
dramatically. Hence, the primary clinical goal is to define the anatomic extent 
of the tumor and to distinguish patients with organ-confined, locally invasive, 
or metastatic disease. As accurate detection is critical to determining 
appropriate patient management, it follows that sensitive and specific 
localization of disease should be a vital component of staging (American 
Cancer Society, 2012). 
In this view, effective diagnosis and treatment response in prostate cancer are 
major challenges commonly faced by oncologists and radiologists, since both 
PSA level determination and radiological imaging have limitations with respect 
to diagnosis, staging, and prognosis, showing high false positives during 
screening in relation to benign prostatic hyperplasia and prostatitis (Chappell, 
B. and Mc Loughlin, J. 2005).  
Positron emission tomography (PET) is a whole body diagnostic three-
dimensional molecular imaging modality used in nuclear medicine that detects 
radiation arising from the decay of unstable positron-emitting radioisotopes 
(Cusnir, R. et al. 2017). With the advent of PET, several radiotracers such as 
11C-Acetate, 18F-Choline, and 11C-Choline have been used for prostate cancer 
imaging. 11C acetate is not a sensitive marker for detection of prostate cancer, 
due to the age that causes physiological accumulation of 11C-Acetate and 
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therefore careful interpretation of images is necessary (Kato, T. et al. 2002). 
Moreover, 11C-Acetate uptake is also present in other tissues such as liver, 
cardiac and bladder, thereby being nonspecific for prostate cancer (Kallur, K. 
G. et al. 2017).  
Additionally, PSA values show a lot of inter and intra-individual variations with 
time due to manipulations of the prostate and they are less reliable as a 
standalone marker. For all these reasons, it was necessary to identify more 
robust surface biomarkers in prostate cancer. One of these molecules is 
Prostate-Specific Membrane Antigen (PSMA) also known as folate hydrolase 
I or glutamate carboxypeptidase I. PSMA is a cell surface protein with a 
significantly increased expression in prostate cancer cells when compared to 
other PSMA-expressing tissues such as kidney, proximal small intestine or 
salivary glands (Sweat, S. D. et al. 1998) (Mannweiler, S. et al. 2009) 
(Schuhmacher, J. and Maier-Borst, W. 1981). An additional advantage of 
PSMA detection is the transmembrane location with a large extracellular 
domain that allows for internalization of the receptor after ligand binding, 
providing an accurate target for prostate carcinoma specific imaging and 
therapy (Ghosh, A. and Heston, W. D. 2004). Consequently, there is a need 
for the development of high-resolution PET imaging methods using the 
extracellular domain of PSMA (Afshar-Oromieh, A. et al. 2013). Recently, 
methods have been developed to label PSMA ligands with 68Ga, 99mTc, 
123/124/131I enabling their use for PET imaging, more scintigraphy options and 
radio ligand therapy (Hillier, S. M. et al. 2009) (Eder, M. et al. 2012). Earlier 
observations with 68Ga-PSMA suggests that this novel tracer can detect 
prostate carcinoma relapses and metastases with high contrast by targeting 
the extracellular domain of PSMA (Afshar-Oromieh, A. et al. 2013). 
In this context, hexadentate tris(3,4-hydroxypyridinone) ligands (THP) that 
show complex high affinities for oxophilic trivalent metal ions (e.g. Fe3+)  
demonstrated to be good candidate for the development of 68Ga3+ bifunctional 
chelators, the positron emitting radio metal which is clinically used for 
molecular imaging in positron emission tomography (PET). THP-peptide bio-
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conjugates rapidly and quantitatively complex 68Ga3+ at room temperature, 
neutral pH and micromolar concentrations of ligand, making them amenable 
to kit-based radio synthesis of 68Ga-PET radiopharmaceuticals. 68Ga-labelled 
THP-peptides accumulate at target tissue in vivo, and are excreted largely via 
a renal pathway, providing high quality PET images (Cusnir, R. et al. 2017).  
 
 
The research group of Professor R. Hider at King’s College London, where I 
performed my PhD visiting period, has been involved for many years in the 
design and synthesis of new metal chelators (e.g. Deferiprone, the small-
molecule iron chelator reported above). More recently, a new research project 
has been started by the group focused on the development of peptide-based 
ligands for both iron and gallium.  
In this context, my project focused on the solid-phase synthesis of tripeptide 
(Lys-Lys-Lys) and tetrapeptide (Lys-Lys-Lys-Lys) derivatives bearing 3,4-
dihydroxy picolinic acid and the 3-(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-
yl)propionic acid (as chelating groups) on the amino groups of the side chains 
. All final compounds will be tested in the near future as iron and gallium 
chelators for biological and clinical applications. In particular, as regard the 
iron chelators, all the final products will be subjected to spectrophotometric 
titration in order to determine the pka values and the affinity costants for 
iron(III). These compounds will also be tested in cell culture, in order to 
investigate their ability to remove iron from cells.  
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2. CHEMISTRY 
 
The synthetic pathway followed to obtain the final compounds 12a,b and 
20a,b are reported in the Schemes 1 and 2. 
 
Scheme 1 
 
Reagents and conditions:  
a) Fmoc-Lys-Mtt, ethyl (hydroxyimino)cyanoacetate, DIC, dry DMF. 
b) Piperidine-DMF (2:8, v/v). 
c) TFA (2% v/v), TIPS (2% v/v), DCM (96% v/v). 
d) R-COOH, PyOxP, DIPEA, dry DMF. 
e) (CH3CO)2O, DIPEA. 
f) TFA (90% v/v), phenol (5% w/v), TIPS (5% v/v), H2O (5% v/v). 
g) BCl3, dry DCM. 
 
 
 
  Chemistry 
191 
 
Scheme 2 
 
 
Reagents and conditions:  
a) Fmoc-Lys-Mtt, ethyl (hydroxyimino)cyanoacetate, DIC, dry DMF. 
b) Piperidine-DMF (2:8, v/v). 
c) TFA (2% v/v), TIPS (2% v/v), DCM (96% v/v). 
d) R-COOH, PyOxP, DIPEA, dry DMF. 
e) (CH3CO)2O, DIPEA. 
f) TFA (90% v/v), phenol (5% w/v), TIPS (5% v/v), H2O (5% v/v). 
g) BCl3, dry DCM. 
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a 
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For solid-phase synthesis we used NovaPeg Rink Amide Resin, consisting of 
only PEG units. This unique composition confers excellent swelling and 
mechanical properties on the polymer. Furthermore, in contrast to polystyrene 
and other commonly used supports, NovaPeg resin appears not to suffer from 
osmotic shock when solvent is exchanged from hydrophobic to hydrophilic 
and it shows an excellent chemical stability, particularly towards strong acids 
and bases (Garcia-Martin, F. et al. 2006). The Fmoc/Mtt solid-phase strategy 
involved the use of the base labile Fmoc protecting group for α-amino 
protection and Mtt protecting groups for side chain ε-amino protection of 
Lysine. Mtt-based protecting groups are highly convenient because they are 
removed with 2% of TFA in dichloromethane, being stable to piperidine used 
to remove the Fmoc group (Palomo, J. M. 2014). The amino acid couplings 
(compounds 2, 4, 6 and 14) were performed using DIPEA as a base, DIC to 
activate the carboxylic groups and ethyl (hydroxyimino)cyanoacetate as an 
agent to minimize epimerization.  
The picryl sulfonic acid test for detection of primary amines was performed 
after each coupling to confirm the coupling completion (Cayot, P. et al. 1997). 
When the test was negative (absence of free amines) the Fmoc group was 
removed with piperidine-DMF (2:8 v/v) and we coupled the next amino acid. 
Once the Mtt protecting peptides were obtained (compounds 6 and 14) we 
remove the protecting groups using 2% of TFA in dichloromethane 
(compounds 7 and 15) and we performed the coupling with two different 
chelating groups (3,4-dihydroxy picolinic acid and the 3-(3-hydroxy-2-methyl-
4-oxopyridin-1(4H)-yl)propionic acid) (Gaeta A. et al. 2011) (Dobbin, P. S. et 
al. 1993). These coupling reactions (for compounds 8a, 8b, 16a and 16b) 
were carried out using the appropriate acid, PyOxP and DIPEA.  
PyOxP (O-[(1-cyano-2-ethoxy-2-oxoethylidene) amino]-oxytri(pyrrolidin-1-
yl)phosphonium hexafluoro phosphate) is a new coupling reagent that 
exhibited higher capacity to suppress racemization in various peptide models 
and enhanced solubility in DMF and DCM than benzotriazole-based reagents 
(Subiròs-Funosas, R. et al. 2010). This is the most difficult step of the 
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synthesis because we had to be sure that the coupling had occurred on all the 
amino groups. Therefore, we worked with particular reaction conditions 
modulating the stoichiometric ratios and the reaction times depending on 
whether the coupling was carried out on the tripeptide or the tetrapeptide. Also 
in this case, after the coupling, we performed the picryl sulfonic acid test as 
previously described. After the last Fmoc removal (compounds 9a, 9b, 17a 
and 17b), we performed the acetic capping using acetic anhydride and DIPEA 
in large excess and we obtained compounds 10a, 10b, 18a and 18b. 
Washings after every coupling and every deprotection were performed with 
DMF, methanol and dichloromethane. Then we carried out the cleavage from 
the resin with TFA in presence of phenol (5% w/v), water (5% v/v) and 
triisopropylsilane (5% v/v) as scavengers (compound 11a, 11b, 19a and 19c). 
The last step of the synthesis was performed in solution using BCl3 in dry 
dichloromethane at room temperature, in order to remove benzyl protections 
on OH groups and obtain the final compounds 12a, 12b, 20a and 20b. 
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3. MATERIAL AND METHODS 
 
1H-NMR, 13C-NMR, COSY and HSQC spectra were recorded on an Avance 
400 instrument (Bruker AscendTM 400). Chemical shifts (δ) are reported in 
ppm to the nearest 0.01 ppm using the solvent as an internal standard. 
Coupling constants (J values) are given in Hz (rounded to the nearest 0.1 Hz) 
and were calculated using TopSpin 3.5 pI software (Nicolet Instrument Corp., 
Madison, WI) . HPLC-DAD: HP 1050 series equipped with quaternary pump, 
auto-sampler, diode array detector (DAD) and Kontron DEG 104 degasser. 
Mass spectra were recorded on Agilent 1100 series coupled to LCQDECAXP 
(from Thermo Finnigan) and reported mass values are within the error limits 
of ±5 ppm mass unists. Preparative HPLC was performed on MicromassXQ 
(Waters). A C8 Kinetex® column (Phenomenex Inc.) 100×2.1 mm i.d., particle 
size 5 μm was used for analytical characterizations. HPLC mobile phases A 
and B consisted of 0.1% v/v TFA in water and acetonitrile, respectively. The 
gradient was 0% B ramping to 90% B within 30 minute. The flow rate was set 
at 0.2 mL/min and the injection volume was 5-20 μL. 
 
H-Lys-(Mtt)-NovaPeg resin (2) 
NovaPeg Rink amide resin (2.0 g equivalent to a loading of 0.98 mmol) was 
placed in a 60.0 mL polypropylene syringe fitted with a polyethylene filter disk 
and it was conditioned with DMF for 30 minutes. A solution of Fmoc-Lys-Mtt-
OH (1.84 g, 2.94 mmol, 3.0 eq), ethyl (hydroxyimino)cyanoacetate (0.42 g, 
2.94 mmol, 3.0 eq) and N,N′-diisopropylcarbodiimide (DIC, 0.43 mL, 2.94 
mmol, 3.0 eq) in dry DMF was added. After stirring overnight, the resin was 
washed with DMF (3 x 0.5 min), MeOH (3 x 0.5 min), DCM (3 x 0.5 min) and 
subsequently treated with acetic anhydride and DIPEA for 30 minutes. 
Thereafter the resin was washed again (DMF/MeOH/DCM) and finally dried 
under vacuum to perform the picryl sulfonic acid test (Cayot, P. et al. 1997) 
that resulted negative (no free amine). The Fmoc group was removed as 
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indicated in the following General procedure for Fmoc-removal producing 
resin-bound compound 3.  
 
General procedure for Fmoc-removal: the Fmoc protecting-group was 
removed with piperidine/DMF (2:8 v/v) (3 x 20 min). Washing between 
deprotection, coupling and again deprotection steps was performed with 
DMF (3 X 0.5 min), MeOH (3 x 0.5 min), DCM (3 x 0.5 min) using 20 mL 
solvent/resin each time.  
 
General procedure for compounds 4, 6 and 13:  Fmoc-Lys-Mtt-OH (1.22 g, 
1.96 mmol, 2.0 eq), ethyl (hydroxyimino)cyanoacetate (0.28 g, 1.96 mmol, 2.0 
eq) and N,N′-diisopropylcarbodiimide (DIC, 0.30 mL, 1.96 mmol, 2.0 eq) in dry 
DMF were added to the appropriate substrate. After one night, the picryl 
sulfonic acid test (Cayot, P. et al. 1997) was negative for all the couplings. 
Then, the peptidyl-resin was subjected to Fmoc-removal and washing 
treatment as described in the General procedure for Fmoc-removal previously 
described.  
 
General procedures for cleavage from the resin: the peptidyl-resin was 
treated with TFA (90% v/v) for 2 hours at room temperature in the presence 
of phenol (5% w/v), water (5% v/v), water (5% v/v) and TIPS (2% v/v) as 
scavengers. The filtrate was collected and the resin washed with TFA. The 
solution was concentrated to <0.5 mL at 40°C under a gentle stream of 
nitrogen. Ice-cold diethyl ether was added to precipitate the compound. The 
suspension was centrifuged and the supernatant removed. The precipitate 
was washed with diethyl ether and finally dried in the desiccator under 
vacuum. 
 
H-Lys-(Mtt)-Lys-(Mtt)-Lys-(Mtt)-NovaPeg Resin (6) 
A small aliquot of the peptidyl-resin was subjected to the “small cleavage” 
following the general procedure for cleavage from the resin as reported above. 
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During the “small cleavage” for the check of the tripeptide 6 we also lost the 
acid labile Mtt protecting-group. The HPLC-DAD analysis (tR = 10.02 min) of 
the crude showed a purity of >90%.  LC-MS: calcd. for C33H49N7O5, 623.4 
Found: m/z 624.4 [M+H]+, 312.7 [M+2H]2+. 
 
H-Lys-(Mtt)-Lys-(Mtt)-Lys-(Mtt)-Lys-(Mtt)-NovaPeg Resin (13) 
A small aliquot of the peptidyl-resin was subjected to the “small cleavage” 
following the general procedure for cleavage from the resin as above reported. 
During the “small cleavage” for the check of the tetrapeptide 13 we also lost 
the acid labile Mtt protecting-group. The HPLC-DAD analysis (tR = 9.85 min) 
of the crude showed a purity of >90%. (LC-MS): calcd. For C39H61N9O6, 751.5. 
Found: m/z 752.5 [M+H]+, 376.7 [M+2H]2+. 
 
General procedure for Mtt removal (compounds 7 and 15): the Mtt 
protecting group was removed using TFA (2% v/v), TIPS (2% v/v) as 
scavenger and DCM (96% v/v) (5 x 15 min). Washing after deprotection was 
performed with DMF (3 x 0.5 min), MeOH (3 x 0.5 min), DCM (3 x 0.5 min) 
using 20 mL solvent/resin each time.  
 
General procedure for compounds 9a and 9b: the appropriate acid (2.94 
mmol, 6.0 eq) and PyOxP (0.775 g, 2.94 mmol, 6.0 eq) (Subiròs-Funosas, R. 
et al. 2010) were dissolved in DMF dry and then DIPEA (0.51 mL, 5.88 mmol, 
12.0 eq) was added. The mixture was added to the peptidyl-resin 7 (0.49 
mmol). After three days of coupling, the picryl sulfonic acid test (Cayot, P. et 
al. 1997) was negative for both compounds 8a and 8b. Then, the peptidyl-
resin was subjected to Fmoc-removal and washing treatment as described in 
the General procedure for Fmoc-removal reported above.  
 
Compound 9a 
A small aliquot of the peptidyl-resin was subjected to the “small cleavage” 
following the General procedure for cleavage from the resin as above 
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reported. (LC-MS): calcd. For C78H84N10O12, 1353.6. Found: m/z 1354.4 
[M+H]+, 677.8 [M+2H]2+, 452.2 [M+3H]3+. 
 
Compound 9b 
A small aliquot of the peptidyl-resin was subjected to the “small cleavage” 
following the General procedure for cleavage from the resin as above 
reported. (LC-MS): calcd. For C66H84N10O12, 1208.6. Found: m/z 1209.5 
[M+H]+, 605.7 [M+2H]2+, 404.3 [M+3H]3+. 
 
General procedure for compound 17a and 17b: the appropriate acid (3.92 
mmol, 8.0 eq) and PyOxP (1.034 g, 3.92 mmol, 8.0 eq) (Subiròs-Funosas, R. 
et al. 2010) were dissolved in DMF dry and then DIPEA (0.68 mL, 7.84 mmol, 
16.0 eq) was added. The mixture was added to the peptidyl-resin 15 (0.49 
mmol). After four days of coupling, the picryl sulfonic acid test (Cayot, P. et al. 
1997) was negative for both compounds 16a and 16b. Then, the peptidyl-resin 
was subjected to Fmoc-removal and washing treatment as described in the 
General procedure for Fmoc-removal reported above.  
 
Compound 17a 
A small aliquot of the peptidyl-resin was subjected to the “small cleavage” 
following the General procedure for cleavage from the resin as reported 
above. (LC-MS): calcd. For C104H111N13O16, 1797.8. Found: m/z 899.5 
[M+2H]2+, 600.3 [M+3H]3+. 
 
Compound 17b 
A small aliquot of the peptidyl-resin was subjected to the “small cleavage” 
following the General procedure for cleavage from the resin as reported 
above. (LC-MS): calcd. For C88H111N13O16, 1605.8 Found: m/z 803.5 [M+2H]2+, 
536.3 [M+3H]3+. 
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General procedure for “acetic capping” (compound 10a, 10b, 18a and 
18b): the appropriate peptidyl-resin was treated with acetic anhydride (10.0 
eq) and DIPEA (20.0 eq). After stirring for 50 minutes, the resin was washed 
with DMF/MeOH/DCM and finally dried under vacuum to perform the picryl 
sulfonic acid test (Cayot, P. et al. 1997) that resulted negative (no free amine). 
After the acetic capping, the peptidyl-resins were subjected to the cleavage 
from the resin following the General procedure for cleavage from the resin as 
reported above, obtaining respectively compounds 11a, 11b, 19a and 19b. 
 
General procedure to obtain compounds 12a, 12b, 20a and 20b: the 
appropriate substrate was dissolved in dry DCM under N2 and the solution 
was cooled at 0°C. Then, a large excess of BCl3 (i.e. 1 M solution of BCl3 in 
anhydrous dichloromethane, ca. 3 mL of solution for 10 mg of substrate) was 
added and the reaction mixture was stirred at room temperature overnight. 
After quenching with MeOH, the solvent was evaporated and ice-cold diethyl 
ether was added to precipitate the compound. The suspension was 
centrifuged and the supernatant removed. The precipitate was washed with 
diethyl ether and finally dried in the desiccator under vacuum. After 
preparative HPLC purification, the residues were lyophilized and the final 
products were obtained as white solids.  
 
Compound 12a 
Yield: 10%; 1H-NMR (MeOH-d4) δ 1.20-1.39 (m, 8H, 4 x CH2, side chain), 1.59-
1.77 (m, 10H, 5 x CH2, side chain), 1.93 (s, 3H, NHCOCH3), 3.37-3.45 (m, 6H, 
3 x NHCH2), 4.21-4.27 (m, 3H, 3 x NHCHCH2), 7.27 (d, 3H, Ar, J = 8.0 Hz), 
8.11 (d, 3H, Ar, J = 8.0 Hz). 13C-NMR (MeOH-d4) δ 20.74 (CH3), 22.71 (CH2), 
28.35 (CH2), 39.61 (CH2), 47.93 (CH), 112.39 (CH), 127.68 (C), 135.56 (CH), 
145.58 (C), 158.85 (C), 162.82 (C). The HPLC-DAD analysis (tR = 8.13 min) 
showed a purity of 90%. (LC-MS): calcd. For C38H50N10O13, 854.4 Found: m/z 
855.3 [M+H]+, 428.3 [M+2H]2+. 
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Compound 12b 
Yield: 22%; 1H-NMR (MeOH-d4) δ 1.07-1.22 (m, 10H, 5 x CH2, side chain), 
1.46-1.55 (m, 8H, 4 x CH2, side chain), 1.89 (s, 3H, NHCOCH3), 2.33 (s, 9H, 
3 x CH3-C), 2.57-2.63 (m, 6H, 3 x NCH2CH2CO), 2.85-3.04 (m, 6H, 3 x 
NHCH2), 3.99-4.07 (m, 1H, NHCHCH2), 4.08-4.13 (m, 2H, 2 x NHCHCH2), 
4.26-4.35 (m, 6H, 3 x NCH2CH2CO), 6.46-6.51 (m, 3H, Ar), 7.48-7.54 (m, 3H, 
Ar). 13C-NMR (MeOH-d4) δ 11.40 (CH3), 21.19 (CH3), 22.25 (CH2), 27.83 
(CH2), 30.69 (CH2), 36.27 (CH2), 38.99 (CH2), 50.77 (CH2), 50.96 (CH2), 53.14 
(CH), 53.38 (CH), 53.80 (CH), 112.15 (CH), 138.82 (CH), 144.39 (C), 167.48 
(C), 172.04 (C), 174.13 (C). The HPLC-DAD analysis (tR = 7.49 min) showed 
a purity of 91%. (LC-MS): calcd. For C47H68N10O13, 980.5 Found: m/z 981.5 
[M+H]+, 491.4 [M+2H]2+, 328.1 [M+3H]3+. 
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Compound 20a 
Yield: 10%; 1H-NMR (MeOH-d4) δ 1.35-1.52 (m, 8H, 4 x CH2, side chain), 1.64-
1.78 (m, 10H, 5 x CH2, side chain), 1.84-1.97 (m, 6H, 3 x CH2, side chain), 
2.02 (s, 3H, NHCOCH3), 3.45-3.56 (m, 8H, 4 x NHCH2), 4.28-4.39 (m, 4H, 4 x 
NHCHCH2), 7.34-7.42 (m, 4H, Ar), 8.19-8.28 (m, 4H, Ar). 13C-NMR (MeOH-
d4) δ 21.07 (CH3), 22.70 (CH2), 28.36 (CH2), 30.98 (CH2), 39.64 (CH2), 49.96 
(CH), 112.39 (CH), 135.58 (CH), 142.22 (C), 158.55 (C), 162.80 (C). The 
HPLC-DAD analysis (tR = 8.26 min) showed a purity of 91%. MS (LC-MS): 
calcd. For C50H65N13O17, 1119.5 Found: m/z 1120.4 [M+H]+, 560.9 [M+2H]2+. 
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Compound 20b 
Yield: 21%; 1H-NMR (MeOH-d4) δ 1.08-1.47 (m, 16H, 8 X CH2, side chain), 
1.59-1.82 (m, 8H, 4 X CH2, side chain), 1.98 (s, 3H, NHCOCH3), 2.46 (s, 12H, 
4 X CH3-C), 2.93-3.26 (m, 8H, 4 X NCH2CH2CO), 3.28-3.37 (m, 8H, 4 X 
NHCH2), 4.21-4.44 (m, 12H, 4 X NHCHCH2, 4 X NCH2CH2CO), 6.37-6.45 (m, 
4H, Ar), 7.53-7.60 (m, 4H, Ar). 13C-NMR (MeOH-d4) δ 10.43 (CH3), 20.37 
(CH3), 22.88 (CH2), 22.99 (CH2), 23.11 (CH2), 28.36 (CH2), 28.68 (CH2), 31.46 
(CH2), 31.63 (CH2), 49.66 (CH2), 50.06 (CH2), 52.92 (CH), 58.33 (CH), 53.62 
(CH), 111.57 (CH), 131.70 (C), 137.72 (CH), 145.81 (C), 169.06 (C), 170.20 
(C), 171.91 (C), 172.82 (C), 173.00 (C), 173.18 (C), 175.40 (C). The HPLC-
DAD analysis (tR = 8.07 min) showed a purity of 90%. (LC-MS): calcd. For 
C62H89N13O17, 1287.6 Found: m/z 1288.6 [M+H]+, 645.1 [M+2H]2+, 430.6 
[M+3H]3+. 
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